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A database consisting of information on human WD40 domains was compiled from literature 
sources. Data collected included information on function, structure, links to disease and 
information on molecules known to bind to WD40 domain containing proteins. Curation of 
the data collected suggested that 21% of WD40 domain containing proteins are linked to 
cancer, and that only 6% had known small molecule binders. From the database a shortlist of 
WD40 domain containing proteins that were considered of interest as research targets was 
produced. It was determined that WD40 Domain Containing Protein 5 (WDR5) was a 
potential cancer target open to several targeting methods. 
WDR5 normally plays a structural roll in the formation of a complex containing WDR5, 
RbBP5, ASH2L, and DPY-30. This complex is required for methylation of H3K4, when MLL1 
joins the complex it is able to methylate H3K4me2. It was also recently determined that WDR5 
complexes with MYC, another protein with roles in transcriptional control. Both MLL1 and 
MYC are known to be prominent cancer targets. 
His-tagged WDR5 was successfully expressed in BL21 (DE3) cell line and purified by a 2 step 
method. First the protein was purified via His tag - Ni-NTA agarose affinity chromatography, 
the eluted protein was then further purified via Size Exclusion Chromatography.  
The first approach targeting WDR5 consisted of a combination of an in-silico approach and a 
small molecule binder screen. Two in-silico methods, Q-mol and USRCAT, were used to 
determine small molecules that would potentially bind to WDR5. From this suggested set, 81 
compounds were screened against WDR5. Thermal denaturation fluorescence (TDF) was 
chosen as assay technique. A single compound increased the thermal stability of WDR5 in 
repeated experiments. This compound, NCI292249, was further characterised in microdialysis 
experiments where it was determined to have a low affinity of 564 µM to WDR5. 
In a second approach, in order to target the MYC-WDR5 interaction, a series of truncated 
peptides derived from the WDR5 binding motif from MYC were produced testing a variation 
of the One-Bead One-Compound (OBOC) synthesis method derived in this work. These 
peptide fragments were synthesised using Fmoc solid phase peptide synthesis on TentaGel 
micobeads experimenting with the SOBOC technique (Scanning OBOC) adapted to produce 
all possible fragments of a peptide in parallel. The peptide fragments were fluorescently 
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labelled with tetramethylrhodamine and screened against 6XHis-WDR5 isolated on Ni-NTA 
functionalised agarose beads. The peptide fragments were ranked based on their affinity to 
the WDR5-coated micro-beads assayed by Confocal Scanning (CONA).  The highest affinity 
peptide found in the CONA screen was further tested for WDR5 binding in solution by 
fluorescence anisotropy which resulted in an affinity of 96 µM to WDR5. This 7-mer truncate 
of the MYC peptide was used as input for an in-silico method of peptide optimisation named 
MorPH. MorPH is a technique developed in the Auer Lab in which amino acids in a peptide 
are systematically replaced by all commercially available non-natural amino acids in a 
sequential manner. Each of ~ 1000 modified peptidomimetics are docked in-silico to the target 
structure. The suggestions from MorPH for the MYC peptide truncate were analysed and the 
potential replacements discussed in order to plan a possible future synthesis. 
The MorPH technique was tested experimentally in this thesis in a second example, targeting 
of Survivin. Survivin is followed as cancer target in the Auer lab and it is found in significantly 
high concentrations in cancer cell lines and in stem cells. Increased Survivin expression has 
also been linked to a poor prognosis and reduced patient survivability in the clinic. Several 
suggestions resulting from the MorPH in-silico screen were synthesised and screened against 
Survivin. The best-in-series peptide was shown to have a Kd of 2.5 µM, with significantly 
increased plasma stability. 
Several chemical tools were developed and characterised for use with on-bead synthesis 
methods. A contribution was made to a novel synthetic method for isomerically pure 
rhodamine dyes and their functionalisation[1] (Tetramethylrhodamine was azide-
functionalised for use in peptide labelling, based on the azide-alkyne Huisgen cycloaddition 
reaction). The Auer lab synthesises many of its compounds and libraries using solid phase 
synthesis techniques. Several compounds exist in literature for the linking of chemicals to a 
solid-support, all of which are stable to different chemistries and require different conditions 
to cleave the reaction product from the solid phase. The use of methionine as a linker is 
described in literature as being highly specific in its cleavage conditions. A series of literature 
cleavage conditions were tested, the method that offered the highest purity was selected to be 
improved through further testing. The improved cleavage method was then characterised by 
cleaving the 20 natural amino acids from the methionine linker. In this experiment it was 
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determined that all amino acids tolerated the new conditions with the exception of 
methionine, cysteine and tryptophan, which were expected to react poorly to the harsh 
conditions. This verified that methionine was a suitable alternative to current lab standards 
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2.1. Protein-Protein Interactions 
The cellular pathways of the human body are a complicated interconnected series of 
interactions, balancing one another in an effort to maintain function. Enzymes are proteins 
that bind and interact with ligands, processing them into a new product or products. 
However, many biological processes are carried out by more complicated structures, formed 
of several proteins. These large protein structures are known as protein complexes. These 
protein complexes are held together by protein-protein interactions (PPIs), their formation 
dependant on the affinity of the interactions and local cellular concentrations. As these 
molecular machines are made of several proteins, as opposed to enzymes that are often single 
unit, there is the possibility of inhibition of these complexes through the targeting of the 
interactions that allow for the formation of the complex. While this is a reasonable assumption 
to be made the practice has proven difficult. PPIs have been shown to be difficult to target, 
interaction interfaces tend to be large, flat surfaces with few charged residues or pockets that 
could hold a small molecule inhibitor.1 This is in contrast to enzymes that have represented 
the collection of targets focussed upon by research for decades, which typically have a well-
defined active site/cofactor site. In more recent years it has been determined that PPIs tend to 
be modulated by interaction hotspots.2 These interaction hotspots are small patches of 
residues that contribute significantly more to the interaction than the other residues in the 
interaction interface.  
The field of PPI targeting has seen significant growth in the last decade or so, arguably starting 
in 2004 with the discovery that the small molecule Nutlin and its derivatives modulate the 
activity of the P53 pathway via binding to MDM2, an inhibitor of P53.3 To date around 50 PPIs 
having been successfully targeted, both for inhibition and for stabilisation.4 Information on 
these successfully targeted interactions is maintained in online databases such as TIMBAL4 
and 2P2I.5 According to TIMBAL 49 PPIs have been targeted with small molecules for 
modulation. 9 of these examples have been found to stabilise PPIs interactions. Lipinski 
famously outlined guidelines for the characteristics of a drug-like chemical structure.6 
However, the structures determined to bind to PPI interfaces tend to be larger than 400 
Daltons, more hydrophobic and with a larger number of hydrogen bonds.4, 5, 7 As classical 
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methods of targeting proteins are biased towards Lipinskis guidelines and the current state of 
PPI targeting small molecules break many of these guidelines it could be interpreted that one 
of the challenges of targeting PPIs is due to the requirement of shifting the rules of small 
molecule discovery.  
Despite impressive steps in the improvement of targeting PPIs human PPI networks are vast, 
therefore there are many therapeutically interesting interactions and protein complexes that, 
as of yet, have not been successfully targeted. Many of these protein complexes are formed 
around PPI scaffold proteins. Scaffold proteins serve as a core around which large complexes 
can assemble, an example of a protein domain that behaves as a scaffold for complexation is 
the WD40 domain.  
2.2. WD40 Domains 
WD40 domains are large, made up of several repeated units named WD40 repeat domains. 
The repeat domains are around 40 amino acid residues in length and often terminate in a 
tryptophan-aspartic acid sequence, hence the name WD40. A single WD40 domain will 
generally have 5-7 WD40 repeat domains.8 Structurally, WD40 domains resemble a propeller, 
with the repeat domains forming the blades of the propeller. Within these propeller structures 





Figure 1 - Example WD40 domain structure. A) The protein chain is coloured from blue to red. The folding of 
the domain is highly compact with distinct "blades". B) The same structure with the surface shown. Oxygen is 
shown in red, nitrogen is shown in blue. 
Despite having common structures WD40 domains are each highly specific towards their own 
series of binding partners. These interactions generally occur on the smaller top interface of 
the WD40 domain with the bottom interface having fewer associated interactions and the 
sides fewer still.8 Despite the stereotypes of PPI interfaces previously described in this chapter 
(primarily that the interfaces are flat), the top face of WD40 domains tend to resemble a 
binding pocket. WD40 domains are remarkably prevalent within the human proteome, 
preliminary searches into WD40 domains and their interactions revealed that WD40 domains 
appear in around 1 % of all proteins in the human proteome.8 Being as prominent as they are 
the domains appear in a broad variety of different proteins and pathways, covering an equally 
broad variety of functions. WD40 domain containing proteins have roles in cell signalling, cell 




Databases have become a valuable source of information for researchers in a great many 
fields. In the field of biological sciences the range of databases covers information on 
structures, expression levels, and general summaries of protein function. These databases 
were utilised in a broad literature search at the beginning of this research project in an effort 
to better understand the nature of WD40 domains and their potential as research targets. In 
order to better investigate the interactions and cellular roles of hundreds of proteins the 
information found was initially catalogued as a spreadsheet in Microsoft Excel. Overtime this 
spreadsheet grew to incorporate information from other databases such as NCI databases10 
and ChEMBL databases11 and itself was compiled into a database for ease of use. The 
information gathered was then used to determine human WD40 domain containing proteins 
of possible interest for further research. In order to better determine possible targets for 
further research a set of criteria were defined that would guide the decision making process. 
It was determined that the biology of the target proteins should be well understood, that 
inhibition of the interactions of the target would lead to a predictable effect. The target should 
have 3D structural data available for the application of in-silico methods, preferably data 
where a structure obtained through co-crystallisation with a known binding partner reveals 
the binding site. The structural information would allow for the application of structure based 
ligand screening methods. Finally for the application of ligand-based screening methods the 
structures of known binders to the target WD40 domain are required. These criteria were 
applied and a small number of potentially interesting WD40 domain containing targets were 
determined. 
2.4. WD40 Repeat Domain Containing Protein 5  
Of the potential targets identified WD40 repeat domain containing protein 5 (WDR5) met all 
criteria. WDR5 is known to form complexes with cancer related proteins, has 3D structural 
information available, and has been targeted for chemical intervention before, providing a 
selection of known binders. WDR5 also had the added advantage of being well documented 
as being expressible in bacterial cell lines, as opposed to other potential targets of interest that 
required more complex cell lines. WDR5 is made up of 334 amino acids, forming 7 WD40 
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repeat domains. WDR5 is a protein comprised of only a WD40 domain, its only function is to 
behave as a scaffold for complexes to form around. This makes WDR5 an excellent example 
of a prototypical PPI scaffold protein. WDR5 is found at the core of several different 
complexes, the most notable complexes are the methyltransferase complexes that are formed 
around this core subunit. The methyltransefase group of complexes all contain ASH2L, 
RBBP5, WDR5, DPY30 plus an additional specific methyltransferase subunit, for example for 
the methylation of H3K4. One of the binding partners to WDR5 in this complex, mixed lineage 
leukaemia 1 protein (MLL1), has been associated with a variety of leukaemias through its 
mutations. Another WDR5 interacting protein is MYC, a prominent cancer target, it was 
recently shown that this interaction is required to drive tumorigenesis.12 Structural 
information available on WDR5 includes a variety of apo structures and structures with small 
molecules and peptides based on biological partners. These structures were used as input for 
structure-based in-silico docking experiments to determine possible novel binders to WDR5. 
Structures of WDR5 and its interaction partners showed the interaction between MLL1 and 
the top interface of WDR5, while this fulfilled an important criterion for future experiments 
over the course of this research project further structural information regarding the bottom 
interface of WDR5 and the WDR5-MYC interaction was published. This bottom interface 
interaction would go on to become the subject of a peptide fragment based interaction 
characterisation, as opposed to the better characterised top interface. The top interface of 
WDR5 has been a subject of interest for 2 research groups that began publishing their findings 
soon after the start of this research project. The two groups had each determined their own 
series of high affinity binders to the top interface of WDR5. These ligands would go on to be 
used for our own ligand-based in-silico screening in an effort to determine novel binders to 







2.5. In-silico Methods for the Determination of Novel Small 
Molecule Ligands to WDR5, Screened Via Label Free 
Affinity Methods 
Having decided on WDR5 as a target, in-silico methods were applied towards the 
development of a novel chemical probe for the modulation of WDR5. Ligand-based methods 
were applied using the structures of known binders to WDR5 as input. Ligand-based methods 
are widely used for the discovery of novel ligands to protein targets, their advantage being 
that there is no requirement for a target structure for docking studies. The lack of structural 
docking studies also makes the methods less computationally intensive. Many ligand-based 
methods are available, however molecular similarity was selected as it has been reported to 
have a relatively high success rate compared to structure-based methods and due to the 
experience that the Auer lab has with molecular similarity methods, specifically USRCAT. 
The structural information gathered on WDR5 was used as input for structure-based in-silico 
screening, with collaboration partner Anton Cheltsov using the Q-mol software package of 
his own design.13 The small molecule suggestions from both USRCAT and Q-mol were tested 
using label-free affinity detection methods. For the targeting of PPIs enzymatic assays are not 
an option, due to the lack of activity in the absence of a complete complex. Fluorescence 
techniques are popular for the detection and characterisation of affinity, such as fluorescence 
anisotropy, however for the screening of the suggestions label-free methods were better 
suited. Label-free methods allow researchers to move directly from suggestions to the 
screening phase without the need for costly or potentially time consuming labelling step, it 
also removes the chance of the label moiety interfering with an assay. As there are a variety 
of in-silico techniques for the identification of novel ligands for proteins, so too is there a 
variety of label-free techniques available for the screening of these potential binders. Methods 
such as isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR) are 
powerful techniques for the characterisation of binding interactions. Thermal shift analysis is 
an exceptionally low cost screening method, compared to many other label-free screening 
methods, which utilises a quantitative real-time PCR machine and allows for screening in a 
96 well format. The method determines the temperature at which a protein denatures, upon 
incubation with a ligand the stability of the ligand will increase, reflected as an increase in 
19 
 
thermal stability and an increase in the temperature of denaturation. Any compounds found 
to increase the thermal stability of the target protein require a second assay to verify that the 
potential binder is truly active. Microdialysis was selected as the second label-free method. 
Microdialysis has a distinct advantage as an assay technique, as the results can be used to 
determine if the test compound is precipitating under the assay conditions or binding to the 
assay vessel walls.  
2.6. The MYC-WDR5 Interaction 
The second method of targeting WDR5 was to use structural information that illustrated the 
MYC-WDR5 interaction12. As briefly mentioned above, MYC binds to the bottom interface of 
WDR5. MYC proteins have been linked to a variety of different cancers, however the 
interaction between a MYC protein and WDR5 is required for MYC to bind to chromatin12. 
The bottom interface of WDR5 is also involved in binding interactions with KANSL2 and 
RBBP5, interactions required for the formation of methyltransferase protein complexes14. As 
these interactions occupy the same space on the bottom of WDR5 they cannot occur in parallel. 
This suggests that MYC does not bind with WDR5 in the context of a methyltransferase or 
NSL complex. MYC proteins are over expressed in a large number of different malignancies. 
MYC forms a complex with MAX to form a DNA binding domain that is able to regulate the 
transcription of target genes. It was recently determined that WDR5 is also required for the 
targeting of these genes. Wang et al12 determined that MYC binds directly to WDR5 and that 
this complex binds to chromatin. 80 % of genomic sites occupied by MYC were also occupied 
by WDR5. Mutations in MYC that inhibited the ability of MYC to bind to WDR5 were found 
to have no effect on binding to DNA. However, binding to chromatin was negatively affected 
and its tumorigenic potential was attenuated in mice. There are a few different possible 
conclusions on the nature of the MYC-WDR5 interaction that could be drawn from the results 
of this investigation. Current research suggests that modulation of the behaviour of MYC 
could be possible through the targeting of the MYC-WDR5 interaction. Although MYC has 
existed as a cancer target for years15 targeting the protein has proven to be difficult as both 
MYC and its known binding partner MAX are unstructured in solution.16 The current state of 
the art in MYC inhibition are BET bromodomain inhibitors that instead target the expression 
of MYC, however the effectiveness is limited by MYC expression being driven by a number 
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of different proteins.15 The binding of MYC to WDR5 does not appear to alter the structure of 
WDR5 on binding.16 This could indicate that the targeting of the two interfaces of WDR5 is 
mutually exclusive, requiring that targeting of the two interfaces be carried out 
independently.  
2.7. Targeting the MYC-WDR5 interaction 
An alanine scan from literature suggested that the central 4 residues “IDVV” contributed 
significantly more to the interaction than other residues, making this area a hotspot.12 To better 
evaluate the nature of the interaction it was decided that a series of truncates of this known 
binder should be synthesised and screened against WDR5. However rather than simply 
producing single peptides built around the central IDVV sequence a method was trialled 
whereby all possible truncates of a certain size range are synthesised in parallel. The basic 
method is inspired by one-bead one-compound library synthesis and deconvolution methods. 
One Bead, One Compound (OBOC) library synthesis produces its library products with only 
a single compound occurring an each bead. For the purposes of deconvolution throughout 
the synthesis of an OBOC library a sample of resin can be removed from each precursor sub-
library after each coupling reaction. In the final library sub-libraries are separated based on 
the last coupling reaction carried out on the resin. These sub-libraries can then be screened in 
an on-bead format, using confocal nanoscanning (CONA) with fluorescently labelled protein. 
In peptide synthesis these precursor sub-libraries are N-terminal truncates, meaning that 
isolation of N-terminal truncates over the course of a peptide synthesis is a simple matter of 
removing resin after each coupling step. By synthesising a series of C-terminal truncates in 
parallel and removing N-terminal truncates as the synthesis progresses all truncates can be 
isolated easily. Having established the synthesis method of the peptide fragments, a screening 
method needed to be established. A two colour CONA screen with His-tagged protein 
isolated on Ni-NTA agarose resin was planned, whereby hit peptides could be ranked based 
on the relative fluorescence intensities of the labelled peptide and protein on bead. Further 
characterisation of peptides of interest was to be carried out using fluorescence anisotropy. 
To compliment this investigation in-silico studies were also carried out using structural based 
methods, Fast Rigid Exhaustive Docking (FRED, OpenEye Scientific Software) and hotpoint.17 
FRED is a part of the OEDocking suite and was used to dock fragments of the MYC peptide 
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to its interaction site on WDR5 to evaluate the contributions of individual residues to the 
MYC-WDR5 interaction. Hotpoint is an online server that analyses the change in potential 
and solvent accessibility of binding pocket to determine potential hotspots on either side of 
the PPI. The information provided from this research provides valuable guidance in the 
development of a novel binders based on the WDR5 interaction sequence of the MYC peptide.  
The Auer lab has a unique method for the development of peptidomimetics, utilising in-house 
proprietary software, MorPH. 
2.8. MorPH – An In-silico Tool for Optimising Known 
Peptide Binders and Protein-Protein Interactions 
The MorPH software uses structural information of peptide-protein or protein-protein 
interactions as input, systematically replacing the amino acid residues of each position with a 
selection of building blocks that are suitable for solid phase synthesis methods. These 
replacements are incorporated into the structure of the peptide and the modified peptide 
docked to the target protein and scored. This produces a list of suggestions for replacements 
for each position, ranked by the docking scoring function. In order to test the method the 
protein Survivin was used as an example target. Survivin is not a WD40 domain containing 
protein, however it has been a target of interest for the Auer lab for several years. Survivin is 
a part of the chromosomal passenger complex (CPC), along with Aurora B kinase, Borealin 
and inner centromere protein. The CPC is responsible for the proper localisation of 
microtubules to kinetochores during mitosis. Survivin also inhibits apoptosis in healthy cells 
by binding to caspases 3 and 7 with nanomolar affinity.18 The cellular concentration of 
Survivin is highly regulated. Usually Survivin is found to be in a very low abundance, except 
in the G2M phase of the cell cycle there is a significant increase in cellular concentrations. 
Survivin is found to be in significantly higher concentrations in many cancer cell lines, 
particularly in lung and breast cancer cell lines.19-21 Higher levels of Survivin expression are 
also linked to reduced patient survivability in the clinic.19, 20 The compilation of these factors 
has made Survivin an important cancer target. Survivin and its interactions have been the 
subject of extensive investigation. These investigations have led to the development of binders 
to Survivin which were determined to increase cell death and delay the cell cycle in cellular 
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assays. Shugoshin 1 (hSgo1) is known to bind to histone H2A when the histone is 
phosphorylated by the kinase Bub1, in turn hSgo1 is known to bind to Borealin. Interestingly 
a fragment of hSgo1, a peptide with the sequence AKER, was found to also bind to Survivin 
in a co-crystallisation experiment.22 This sequence, AKER, was used as a starting point for a 
MorPH investigation targeting Survivin. A series of recommendations for the targeting of 
Survivin had already been developed by the Auer lab by the time this thesis had begun. In 
this prior work the best-in-class peptides representing the best replacements for each position 
were determined. In the following work described in this thesis these best-in-class peptides 
were synthesised for further characterisation, including plasma stability analysis and 
fluorescence anisotropy. For the purpose of targeting WDR5 MorPH software was applied to 
the MYC-WDR5 structure. The output from this was reviewed position by position, creating 
a list of possible replacements for targeting the bottom interface of WDR5 that could be 
incorporated into a future synthesis to develop novel binders to targeting the MYC-WDR5 
interaction. 
2.9. An Introduction to Solid Phase Peptide Synthesis 
The Auer lab uses on-bead synthesis methods for many of its projects. In this thesis solid phase 
peptide synthesis was used to produce labelled peptides. Both using more classical methods 
for the synthesis of labelled Survivin MorPH peptides and via the scanning one-bead one-
compound library production method, for the probing of the MYC-WDR5 interface. Solid 
phase peptide synthesis was first developed in 1963 by Robert Merrifield,23 in the decades that 
followed the method evolved and improved into a technique that sees wide application in the 
synthesis of peptides and peptidomimetics. Solid phase synthesis uses polymer beads made 
of a semi-porous resin with many repeated functional groups throughout the polymer, to 
these functional groups a solid phase linker is attached. The linker acts as a chemical 
attachment point between solid phase and the reaction products. To this linker products are 
synthesised through the iterative process of coupling N-Fmoc protected amino acid building 
block, then deprotecting the newly attached building block ready for the attachment of the 
next. The coupling reaction can be broken down into two steps. The first step is the activation 




hexafluorophosphate (HATU) is the most frequently used coupling reagent used in this thesis. 
The carboxylic acid is converted into an OAt-active ester through incubation with HATU. 
After the formation of this ester the activated amino acid is added to resin holding the N-
deprotected peptide, where the free N-terminus attacks the carbonyl carbon in a nucleophilic 
substitution reaction Figure 2. 
 
 
Figure 2 - The amide coupling mechanism using HATU as the coupling reagent. 
Following the coupling of an amino acid building block the Fmoc protecting group is 
removed. The Fmoc protecting group has a short half-life in the presence of a secondary 
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amine, in the case of piperidine the halflife has been determined to be 6 seconds in a 20 % 
solution.24 In this work 20 % piperidine in dimethylformaldehyde (DMF) was used as the 
Fmoc deprotection reagent of choice for peptide synthesis Figure 3. 
 
Figure 3 - Deprotection of an Fmoc protected amine using piperidine. 
Both the coupling and deprotection reaction are carried out on the immobilised reagent or 
product, leaving the unreacted reagents and side products in the solution. This is the great 
advantage of solid phase synthesis; purification is a simple matter of thoroughly washing the 
resin with a suitable solvent. These two reactions make for a versatile core from which a great 




Tetramethylrhodamine (TMR) is a commonly used fluorescent label by the Auer lab, often 
used in conjunction with solid phase techniques to produce TMR labelled peptides. Due to 
the frequency of its use it is necessary to synthesise the label in-house, often in the scale of 
grams. Previously published synthetic routes to TMR and other rhodamine cored labels 
would frequently produce mixed isomers that would prove difficult to separate.25 Gemma 
Mudd et al. determined that an alternative synthetic route was possible that produced single 
isomer rhodamine cored labels, forgoing the difficult and often low-yielding purification 
process.26 As a part of this work other researchers in the Auer lab with chemistry training 
verified that the method was reproducible on a variety of scales. One of the more frequent 
applications of TMR in the Auer lab is in the labelling of peptides via the Huigen azide-alkyne 
click reaction.27 In this generic method an azide-functionalised fluorescent label is attached to 
a peptide immobilised on solid phase that has been functionalised with an alkyne group. In 
order to carry out this reaction the TMR synthesised using the novel synthetic route must be 
azide functionalised. Fortunately the 5 or 6 position carboxylic acid on the pendent ring can 
be coupled with no significant impact of the fluorescence of the dye. Coupling reagents 
HATU, DIC, PyBop, EDC and TSTU were trialled in a series of time course experiments in 
order to determine optimal conditions for the formation of an amide coupling reaction with 
3-azidopropylamine. The best method would be employed as the standard synthesis method 
to produce all azide-functionalised TMR used in this thesis and in the experiments of other 




2.11. Methionine Linker 
For the development of chemical libraries for on-bead screening the linker used must be 
highly specific, it must be inert to all reactions required to produce and deprotect the library 
of compounds but must also be able to release the synthesis products from the solid phase 
under conditions that are inert to the products of the synthesis. In other words the method of 
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library synthesis and the method of cleavage must be sufficiently different from one another 
to ensure no premature cleavage or side reactions occur. A number of solid phase linkers that 
meet this criteria are known as safety catch linkers. These linkers equire a 2 step cleavage or 
the inclusion of a reagent will not be used under any normal synthesis conditions. At the time 
this research was carried out the lab standard safety catch linker required an 11 step synthesis 
and gives a final yield of 22 %. The time and reagent cost of such a synthesis makes the linker 
less appealing for frequent use. A search of the literature revealed that methionine had 
previously been used as a linker for the solid phase synthesis of libraries.28 Cyanogen bromide 
(CNBr) is known to react with methionine residues in proteins, causing the cleavage of the 
peptide bond at the C-terminus of the methionine residue.29 It is reasonable to expect that labs 
that frequently carry out peptide synthesis will often have a complete selection of all 20 
natural amino acids as N-Fmoc protected building blocks. The application of the Fmoc-
methionine building block as a linker is a significantly faster and cheaper option compared to 
the in house synthesis of a safety catch linker. In order to validate the use of methionine as a 
solid phase linker a series of experiments were carried out to verify the best cleavage methods 
for the linker. These methods would evaluate the reaction time, yield and purity. The purity 
of the reaction would be further characterised through the testing of all 20 natural amino acids 









2.12. Summary of Thesis Work 
 
Figure 4 - Chart showing illustrating the outline of work carried out during this thesis. 
The work carried out in this thesis begins with the development of a WD40 domain containing 
protein database, from this database a list of potential protein targets was defined. Of these 
targets WDR5 was judged to be most auspicious and selected as the target protein to focus on 
in this work. In order to find small molecule inhibitors for WDR5 two routes were taken. The 
first used in-silico methods to identify small molecules with the potential to bind to WDR5. 
These small molecules were screened using the label-free affinity methods thermal shift 
analysis and microdialysis to identify WDR5 binders. The second route focused on the WDR5-
MYC interaction interface, evaluating the contributions of residues to the interaction and 
creating a possible starting point for the development of a peptide inhibitor of the WDR5-
MYC interaction. A library of peptide truncates was synthesised and a sample of these 
truncates were screened against WDR5. In parallel with this in-silico techniques were utilised 
to evaluate the contributions of individual residues to the PPI to determine possible hotspot 
residues. Finally MorPH software was utilised using the WDR5-MYC structural information 
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from literature as input. The suggestions from MorPH were evaluated and a short list of 

























3. The Gathering of Information on WD40 Domains 
and a Review of Literature 
3.1. Introduction 
WD40 domains are amongst the most prominent within the human proteome, appearing in 
1% of all human proteins8 and are involved in a variety of pathways and cellular processes 
including apoptosis, the cell cycle and cell signalling. In turn this makes it possible to create a 
connection between a WD40 domain containing protein, sometimes several, and a variety of 
disease states. The current literature on WD40 domains reflects this hypothesis, indicating 
WD40 domain containing proteins linked to cancer developmental disorders, neurological 
disorders and others.30  To better understand WD40 domains and their roles in both health 
and disease, a data gathering effort was undertaken and a database generated for the 
evaluation of WD40 domains as drug targets. As a part of this work a review of the current 
literature binders to WD40 domains and methods used to find these binders is described in 
this chapter. 
3.2. Aims 
Aims of this section of work were as follows; i) To gather and curate data on WD40 domain 
containing proteins. ii) To assemble the data into a digestible format for future reading and 
ease of use. Data gathered should be as complete as possible, including information of protein 
structure, known binders and relevant biological information, referring to literature 
references where applicable. iii) From the gathered and curated information a list of WD40 
domain containing proteins of interest was to be determined. These proteins would fulfil 
criteria such as having a perceived possible therapeutic value, having 3D structural data 
available, known protein-protein interaction partners and known binders. 
3.3. Results 
The Universal Protein Resource (UniProt) database (uniprot.org)10 was searched for all 
proteins tagged as WD40 domain containing. The UniProt Knowledgebase contains 
information on all known proteins from a variety of organisms. The database has unique 
identifiers for each protein and includes information such as alternative names, sequences and 
some biological information10. Records for these proteins were exported and used as a list of 
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WD40 domain containing proteins. Proteins from this list were then searched for in literature 
to determine their roles in pathways and disease states. Through searching however, it was 
determined that a number of proteins flagged as containing WD40 domains may have been 
falsely flagged. In total 311 proteins were listed as WD40 domain containing, 283 were 
confirmed to have WD40 domains as labelled domains within their sequences10. The list of 
confirmed WD40 domain containing proteins was used as a starting point for the search for 
further information. Searching other databases using the list of names and identifiers that was 
taken from the Uniprot knowledgebase10 significantly increased the rate at which information 
could be gathered from other sources. Biogrid (Biogrid.org)31 is a repository for biological 
interaction datasets. The database contains information on thousands of interactions between 
proteins in a variety of organisms. The information provided includes interaction partners 
and the method used to determine their interaction. The Biogrid database was used to 
determine interaction partners of all WD40 domains that were suggested by the UniProt 
database. The European Bioinformatics Institute (EBI) ChEMBL database 
(ebi.ac.uk/chembl/)11 was searched for binders to the list of WD40 domain containing proteins. 
The ChEMBL database contains information on the results of the screening of compounds 
against proteins and protein complexes. The information includes structural information on 
the binding compound, the affinity and the method in which the interaction was measured. 
Searching this database provided a list 1747 binders for 17 WD40 domain containing proteins 
and protein complexes. These binders are further discussed in the database summary below. 
Reactome (reactome.org)32, another EBI database, uses visual tools to illustrate the links 
between proteins within pathways and the links between pathways. Using the Uniprot 
identifiers of the confirmed WD40 domain containing proteins led to 138 WD40 domain 
containing proteins being described across 475 pathways.  However, many pathways entered 
into the Reactome database overlap, possibly increasing the number significantly. 
3.4. Discussion 
The original intention of the WD40 domain containing protein database was to catalogue all 
human WD40 domain containing proteins and all relevant information about them. This 
catalogue was then to be used to determine which WD40 domain proteins could be considered 
high priority for finding hits due to valuable information being available; for example, known 
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binders or structural data, and information on disease states that are linked to these proteins. 
It was determined during the course of information gathering that many WD40 domain 
containing proteins, such as CDC20, WDR5 and LRRK2 have been reported as valuable targets 
in literature with strong links to disease.  As these proteins are more closely associated with 
disease, there was also more data available with more research carried out. It could be argued 
that proteins such as WDR5 and LRRK2 were highly cited and had more reported binders 
than others due to their links with disease. This investigation into the literature showed which 
WD40 domain containing proteins were of the centre of larger research efforts. Similarly it 
shows which WD40 domain containing proteins have been the subject of less research. Many 
WD40 domain proteins in the database are missing information due to a lack of published 
literature on their function. 
3.4.1. Database Summary 
The CTB-WD40 database contains entries for 283 proteins as listed in the UniProt database as 
being flagged as WD40 domain containing. Of these 278 are confirmed to contain a WD40 
domain. Of these confirmed WD40 domain containing proteins, 59 (21%) are, as of writing, 
linked to cancer according to literature with the most common cancer type being colorectal 
cancer. 16 (6%) are linked to neurological disorders such as Parkinson’s disease and 
Alzheimer’s disease. There is a total number of 2664 unique binders with an affinity of < 100 
µM for 17 entities as determined from the ChEMBL database and by literature searches. The 
total number of binders to WD40 domains is significantly inflated by 3 entries. Of these WD40 
domains it was determined there was a subset that were of particular interest for studies. 
These WD40 domain containing proteins generally had significantly more information 
available. 3D structural information and affinity information on binders were key datapoints 







3.4.2. WD40 domain containing pathways 
Data from Reactome gathered by searching for the Uniprot identifiers of WD40 domains. The 
search returned 475 different named pathways containing varying numbers of WD40 domain 
containing proteins. Tables 1 and 2 describe in which pathways WD40 domain containing 
proteins are most highly concentrated and which pathways the most WD40 domains reside 
in. 














Signal Transduction 38 2569 0.245 
Immune System 33 2302 0.220 
Metabolism 16 2113 0.202 
Gene Expression 50 1790 0.171 
Innate Immune System 9 1429 0.137 
Metabolism of proteins 33 1399 0.134 
Signaling by GPCR 6 1326 0.127 
Disease 12 1110 0.106 
Adaptive Immune System 21 1072 0.102 
Developmental Biology 11 1061 0.101 
GPCR downstream signaling 5 1003 0.096 
Generic Transcription Pathway 10 894 0.085 
Post-translational protein modification 17 866 0.083 
Vesicle-mediated transport 14 795 0.076 
Metabolism of lipids and lipoproteins 5 793 0.076 
Cytokine Signaling in Immune system 9 740 0.071 
Transmembrane transport of small 
molecules 10 680 0.065 
Cell Cycle 21 603 0.058 
Membrane Trafficking 14 602 0.058 
Hemostasis 9 601 0.057 
Table 2 below is also the results of a Reactome database search for WD40 domain containing 
proteins, but sorted by total number of WD40 domains rather than ratio of WD40 domain 




















Gene Expression 50 1790 0.171 
Signal Transduction 38 2569 0.245 
Metabolism of proteins 33 1399 0.134 
Immune System 33 2302 0.220 
Cell Cycle 21 603 0.058 
Adaptive Immune System 21 1072 0.102 
Cellular responses to stress 19 420 0.040 
Class I MHC mediated antigen processing & presentation 18 437 0.042 
Cell Cycle, Mitotic 18 498 0.048 
Post-translational protein modification 17 866 0.083 
Antigen processing: Ubiquitination & Proteasome 
degradation 16 306 0.029 
Metabolism 16 2113 0.202 
Major pathway of rRNA processing in the nucleolus and 
cytosol 15 172 0.016 
rRNA processing in the nucleus and cytosol 15 183 0.017 
rRNA processing 15 193 0.018 
Processing of Capped Intron-Containing Pre-mRNA 14 236 0.023 
Organelle biogenesis and maintenance 14 350 0.033 
Membrane Trafficking 14 602 0.058 
Vesicle-mediated transport 14 795 0.076 
Chaperonin-mediated protein folding 13 95 0.009 
The pathways listed must be interpreted with the caveat that many pathways overlap or even 
in some cases contain other pathways that may be listed. For example, the immune system 
appears four times in table 1 and twice in table 2. Searching within the immune system 
pathway and checking the roles of WD40 domain containing proteins appearing within shows 
that many are connected to cell cycle regulation and gene expression. While it is of course true 
that these proteins play an important role in the immune system, their role would normally 
be defined as what their specific pathway is, e.g. cell cycle regulation and gene expression. 
Table 1 and Table 2 show that WD40 domains appear in proteins in a wide variety of human 
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cell pathways.  It is valuable to have this information available to better understand the role 
of a WD40 domain containing protein and to better assess its suitability as the subject of 
further investigation.  
As this compiled data can be used to determine WD40 domain targets so too can it be used to 
determine which WD40 domain containing proteins should be avoided. Taking an example 
at random, the protein WDR83 acts as a scaffold for several different complexes, including 
complexes in the MAPK and ERK pathway,33 a highly validated cancer related pathway34. 
However WDR83 is also known to be linked to insulin signalling.32 This example 
demonstrates that the database allows researchers interested in a specific WD40 domain 
containing protein can check for effects outside of the desired pathway. As WD40 domains 
are often a scaffold to several complexes it could be thought that some WD40 domains could 
be found in many different biological pathways. Using the results from the Reactome database 
and checking the occurrences of the different WD40 domain containing proteins in each 
different pathway reveals that the proteins are almost exclusively involved in interactions in 
specific pathways. Several pathways related to cancer were investigated using information 
gathered from Reactome and literature to determine pathways of interest that contain WD40 
domains and to assess the role of WD40 domain containing proteins within these pathways. 
3.4.3. WD40 domains in cancer pathways 
Several different pathways that are linked to cancer were investigated possible pathways that 
could be investigated to find WD40 domain containing proteins of interest. In this section 
several examples of cancer pathways that contain WD40 domain containing proteins are 
described. The NOTCH pathway is associated with numerous functions including 
maintaining stem cell populations, cell fate, promoting cell survival and inhibiting apoptosis. 
The NOTCH pathway has been targeted due to its connections to cancer, most famously by 
the targeting of gamma secretase as NOTCH activation depends largely on gamma secretase 
activity.35 Several WD40 domain containing proteins appear within the NOTCH pathway11. 
Mutations in the WD40 domain containing protein FBXW7-binding pocket of Fbw27/Sel-10 
E3 ubiquitin ligase can lead to Notch pathway activation. The effects of modulation of FBXW7 
are likely to be complicated however, as FBXW7 is the substrate recognition subunit of an E3 
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ubiquitin ligase that interacts with a variety of different phosphorylated proteins36 there is 
likely to be other pathways affected. 
Another notable cancer related pathway is the PI3K/AKT1/mTOR pathway, specifically the 
constitutive signalling of AKT1E17K in cancer, featuring the WD40 domain protein LST8 (target 
of rapamycin complex subunit LST8). LST8 is a subunit of both MTORC1 and MTORC2. 
MTORC2 phosphorylates AKT1. AKT1 is a kinase and is activated in the event of this 
phosphorylation. In turn AKT1 phosphorylates several cellular proteins involved in cell cycle 
entry and cell survival. Several small molecules have been developed to inhibit the activities 
of different proteins in the pathway, however the inhibition of other proteins is seen to be less 
effective when the E17K mutation of AKT1 is present. While LST8 has value as a potential 
target for future research, other WD40 domain containing proteins were determined have 
more favourable qualities as a starting point as LST8 lacks known binders. 
17 WD40 domain containing proteins appear in pathways linked to control of the cell cycle. 
Control of the mitotic cell cycle is a complicated, highly regulated series of interactions 
involving hundreds of proteins. Research into the roles of different proteins as a part of the 
cell cycle is at the heart of many cancer research efforts. The role of WD40 domains in cell 
cycle regulation is varied, with many different WD40 domain containing proteins appearing 
in complexes promoting or inhibiting the advance of the cell cycle. CDH1 and CDC20 act as 
substrate recognition subunits of the anaphase promoting complex (APC). The APC 
ubiquitinates key targets such as securing and the S and M cyclins to tag them for degradation. 
The degradation of these targets promotes the transition of the cell cycle from metaphase to 
anaphase. For the purposes of cell cycle regulation, the WD40 domain containing protein 
BUB3 exists as part of a complex with BUB1. The BUB1/BUB3 complex binds to and 
phosphorylates free CDC20, inhibiting its ability to form the APC.  
3.4.4. Known Binders to WD40 domain containing proteins 
The ChEMBL database11 (version 19) was searched for WD40 domain containing proteins and 
protein complexes. The data set was supplemented with data found in the literature, returning 
a total of 23 entries with 4,335 total binders. A large portion of these reported binders however, 
have very low affinities. By applying a cut off of a minimum KD of 100 µM the dataset is 
reduced to 2,664 binders for 17 WD40 domain containing targets (Table 3, following page). 
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The dataset is clearly skewed towards a few targets with a very high number of reported 
binders, Leucine rich repeat kinase (LRRK2) and homeodomain-interacting kinase 2 (HIPK2) 
making up half of all reported binders (45% of the unfiltered dataset, 53% with the 100 µM 
filter). With the 100 µM filter in place HIPK2 and LRRK2 have 828 and 596 unique compounds 
respectively. Both of these high-hit rate WD40 domain containing proteins are kinases. 
Kinases represent a prominent cancer target with 25 drugs in use against cancers and many 
more in different stages of clinical trials.37 HIPK2 is a kinase that regulates the tumour 
suppressor p53 via phosphorylation of Ser46. The role that HIPK2 plays in cancer with regards 
to p53 has been reviewed extensively.38 LRRK2 is also a kinase, however despite the link of 
kinases to cancers LRRK2 is widely known for its connections to Parkinsons disease. After the 
kinases the histone deacetylase (HDAC) family of proteins, HDAC1, HDAC3 etc, has the 
highest number of binders. The HDAC family deacetylate histones, mediating gene 
expression. The HDAC family as a whole has been targeted for intervention due to its role in 
cancer and psychological disorders such as depression. At the time of writing 5 HDAC 
inhibitors have been approved for use in the clinic (vorinostat, romidepsin, chidamide, 
panobinostat and belinostat) with several more in clinical trials. Apopototic protease-
activating factor (APAF1) also holds a large number of known binders to its name with 640 
unique entries in ChEMBL (198 with an affinity >100 µM). APAF1 Mediates apoptosis via the 
cytochrome c and ATP-dependant activation of caspase 3 via pro-caspase-9. APAF1 is 
associated with a variety of diseases including multiple myeloma,39 kidney neoplasms,40 
cardiovascular diseases41 and depressive disorder.42 The number of binders for each protein 
can be interpreted as a reflection of how successful the research efforts to target the protein 
have been to date. A large number of binders can be interpreted as the target is of great interest 
and therefore has been targeting in many screens, while a small number of binders could 
reflect that the protein is of interest however there has been difficulty targeting the protein or 
its value as a target has only recently been established. This interpretation provides another 
criterion for target determination of a WD40 domain-containing protein that has a small 





Table 3 - List of binders to WD40 domain containing targets extracted from ChEMBL database 






1829 Histone deacetylase 3 607 319 
4284 
Serine/threonine protein phosphatase 2A, 55kDa 
regulatory subunit B, alpha isoform 2 2 
4576 Homeodomain-interacting protein kinase 2 987 828 
6114 Phospholipase A2 activating protein 37 15 
1075104 Leucine-rich repeat serine/threonine-protein kinase 2 983 596 
1075317 WD repeat-containing protein 5 68 40 
1163119 U4/U6 small nuclear ribonucleoprotein Prp4 29 7 
1250378 Splicing factor 3B subunit 3 15 13 
1795093 Apoptotic protease-activating factor 1 640 198 
2093865 Histone deacetylase 534 356 
2096976 
Peroxisome proliferator-activated receptor 
gamma/Nuclear receptor corepressor 2 239 177 
2111363 Histone deacetylase 3/Nuclear receptor corepressor 2 73 66 
2157851 Ubiquitin carboxyl-terminal hydrolase 47 14 12 
2176773 PH-interacting protein 37 0 
2189144 Phosphoinositide 3-kinase regulatory subunit 4 1 1 
3038483 Histone deacetylase 1/3/5/8 25 2 
3038484 Histone deacetylase 3/NCoR1 38 31 
3120040 Regulatory-associated protein of mTOR 1 0 
3137261 PRMT5-MEP50 1 0 
3137282 MLL1-ASH2L-RBBP5-WDR5 complex 1 0 
3137286 EZH2-SUZ12-EED complex 1 0 
3137287 EZH1-SUZ12-EED-AEBP2-RBBP4 complex 1 0 
- Fbox and WD40 domain containing protein 7 1 1 
3.4.5. WD40 Domains of Interest 
The following domains are notable WD40 domain containing proteins for several reasons. 
These WD40 domain containing proteins were short-listed for further investigation as they 
have more data available, including structural information, known binders and known PPI 
binding partners. 
3.4.6. FBW7 
The first known inhibitor of a WD40 domain with a co-crystal structure was discovered via 
the high-throughput screening of a 50,000-compound Maybridge Screening Collection 
library.43 Initially the compound was discovered to bind to Cell division control protein 4 in 
yeast. However, the compound, known as SCF-I2 (Figure 5), also interacts with to the human 
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homologue, F-box/WD repeat-containing protein 7 (FBW7), at higher concentrations (an IC50 
of 274 ± 3 µM to FBW7 compared to an IC50 of 1.9 ± 1 µM with Cdc4).43 
 
Figure 5 - SCF-I2, the first known WD40 domain inhibitor with a determined co-crystal structure 
Despite being a weaker binder to the human homologue the discovery was still ground 
breaking, as it is the first binder to a WD40 domain. First FBXW7 is a target protein of interest 
in leukaemia research,44 but also because this is the first instance of a small molecule binding 
to a human WD40 domain. After obtaining a crystal structure of the interaction 1 was shown 
to bind in an inter-blade space on Cdc4 (Figure 6). 
 
Figure 6 - Overlay of CDC4 (cyan) and FBW7 (green), showing the binding location of SCF-I2 (magenta) on the 
side interface of CDC4. This predicts the binding site on FBW7. 
This is interesting as most commonly WD40 domains are known to be involved in PPIs via 
their top face (reviewed and researched in reference45, 46). This means the SCF-I2 is the first 
example of a small molecule binding to a WD40 domain and the first example of a crystal 
structure showing a ligand binding to the “side” interface of a WD40 domain. In some WD40 
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domains an inter-blade site is also the binding site of natural ligands, as was determined to be 
the case with CDH147 and CDC20.48 However the structure of SCF-I2 is inherently 
unfavourable. The structure is largely hydrophobic, formed of two napthyl ring systems with 
only two carboxylic acids as functional groups. This provides a weak starting point for further 
development, it was therefore determined that this would not be used in this research project. 
3.4.7. CDC20 
Cell Division Cycle homologue 20 (CDC20) is the substrate recognition subunit of the E3 
ubiquitin ligase named the Anaphase Promoting Complex (APC). The APC is responsible for 
driving the cell cycle from metaphase to anaphase. To achieve this the APC ubiquitinates key 
targets such as securing and the S and M cyclins to tag them for degradation.  
CDC20 has strong links to a variety of cancers and is reviewed in depth by Kidokoro et al.49 
The review summarises research on 19 different cancers with regards to the level of 
overexpression of CDC20 recorded. Out of 445 tissue samples 194 (44%) were found to have 
greater than threefold baseline expression of CDC20. Bladder, choleangiocellular and 
pancreatic cancers were found to have overexpression in all samples tested, although n was 
small (20, 7 and 6 respectively).  59% of colon and rectum carcinoma (CRC) samples (16 of 27) 
were found to have elevated expression of CDC20. CDC20 was also studied in another 
statistical analysis that found that CRC patients with high levels of CDC20 show lower 
survival rates at all stages across 5 years .50 
Table 4 - Survival rates of patients with CRC across 2, 3 and 5 years as a function of CDC20 expression levels 
Years survival 2 3 5 
High CDC20 61.4% 45.8% 27.2% 
Low CDC20 81.5% 72.3% 53.8% 
A prevailing theory is that overexpression of CDC20 drives the cell cycle forward more 
quickly. This leads to the improper splitting of sister chromatids. This improper splitting leads 
to aneuploidy. Drugs like taxanes and vinca alkaloids affect the cell cycle by interacting with 
microtubules. These drugs put cells into mitotic arrest which should lead to cell death. 
However, some cells survive, these cells undergo “mitotic slippage” and fall into interphase 
before continuing with their cell cycle. It is thought that the degradation of cyclin B could 
promote mitotic slippage. As cyclin B is a substrate of the APC it may be possible that 
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inhibition of the interactions of CDC20 as a part of the APC could lower the chances of mitotic 
slippage occurring. 
In 2014 a small molecule was determined as an inhibitor of cyclin proteolysis in mitotic 
Xenopus egg extract. It was later determined by the King group that the molecule, named 
Apcin (APC INhibitor), was binding to the CDC20 subunit of the APC 51.  
 
Figure 7 - Structure of Apcin 
This discovery comes after the group determined that Tosyl-argenine methyl ester (TAME) 
was an inhibitor of the APC via displacement and blocking of CDC20 from the APC complex, 










The binding site of apcin was determined via crystallography to be in the predicted 
Destruction box (D-box) binding site (Figure 8). The D-box is a motif that follows the amino 
acid sequence RXXLXXXXN where X is any amino acid. The motif binds with the D-box 
binding site on the side of CDH1 or CDC20. This binding interaction attaches the substrate 
protein to the APC complex for ubiquitination. The D-box binding site of CDC20 was 
Figure 8 - Apcin (APC inhibitor) in D-box binding site of CDC20 (structure from PDB entry 4N14[10] 
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determined by overlaying the available crystal structures of the CDH1-ACM1 interaction and 
the CDC20-BUB1B structures. Apcin directly inhibits the ability of the APC to recognise 
substrates via the D-box motif, this is valuable as the King group also showed that Apcin 
works synergistically with TAME towards the inhibition of the APC 51. The determination that 
Apcin binds to CDC20  
3.4.8. LRRK2 
It has been determined that the leucine-rich repeat serine/threonine-protein kinase 2 protein 
has 596 unique man-made binders of affinities lower than 100 µM affinity. LRRK2 is 
associated with Parkinson’s disease, its mutants are thought to be responsible for the 
oxidation and phosphorylation of key anti-oxidant proteins. This leads to oxidative stress, one 
of the hallmarks of Parkinson’s disease. As mentioned above kinases represent a prominent 
cancer target.  As the protein is a kinase it has appeared as a protein in many large-scale kinase 
inhibitor screens likely screened along with many other kinases in parallel. These larger scale 
screens are where a large portion of the list of LRRK2 binders comes from. Despite this there 
is still a respectable list of compounds that have been found to bind to LRRK2 as a result of 
focused investigations.53 The most potent binder to LRRK2 found by this research effort was 
determined by such an investigation. However no structural information for LRRK2 was 
available at the start of this project (information has since become available54). A focus on 
LRRK2 would not allow for the utilisation of structure-based in-silico methods used by the 
Auer lab, while ligand-based methods and library screening methods have already been used 
extensively to discover new ligands to LRRK2. 
3.4.9. WDR5 
WDR5 provides an excellent example of a WD40 domain containing protein and has also been 
successfully targeted by 2 approaches that using two different starting points. WDR5 has been 
targeted for investigation with the goal of developing a chemical probe due to the roll the 
protein plays in cancer, specifically leukaemia. WDR5 normally plays a structural roll in the 
formation of a complex containing WDR5, RbBP5, ASH2L, DPY-3055 where WDR5 acts as the 
substrate recognition subunit. This complex is required for methylation of H3K4, when MLL1 
joins the complex it is able to methylate H3K4me2. Chromosome translocations on the MLL1 
gene lead to MLL1 fusion proteins that are linked to acute lymphoid leukaemia (ALL) and 
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acute myeloid leukaemia (AML).56 MLL rearrangements produce around 80 different possible 
fusion pairings57 and appear in >70% of infant leukaemia, in adults this reduces to 
approximately 10% of leukemias.58 Topoisomerase inhibitors are often used in the treatment 
of acute leukaemia, however MLL rearrangements are commonly seen after therapy.59 This is 
clearly counterproductive to the treatment of leukaemia patients and drives research for a 
suitable replacement. WDR5 also interacts with MYC, a biomarker for several cancers. This 
interaction has been shown to be required to drive tumorigenesis.12 The interaction between 
MYC proteins and WDR5 occurs on the opposite face of WDR5 to the MLL1 interaction. At 
the time of writing the majority of research has been carried out on the MLL1 interaction 
interface, as summarized in the following sections. 
3.4.9.1. Small molecule screening and optimisation 
A high-throughput screen of a sub set of the 16000 diverse compounds from the Ontario 
Institute for Cancer Research general screening library led to the discovery of three 
compounds that bind to WDR560. The best of these was WDR5-0101 (Figure 3), with a KD of 
5.5 ± 0.6 µM by ITC and a KD of 23 ± 1 µM when displacing a fluorescein-labelled WIN peptide 
(sequence GSARAEVHLRKS), WDR5-0101 was the only compound that was discovered to 
displace this peptide. The group then carried out a commercial expansion to determine similar 
structures to WDR5-0101. This resulted in a screen of 119 compounds that were assayed. The 
most promising result of this screen was WDR5-0103, with a KD of 0.45 ± 0.02 µM and a KD of 
3.0 ± 0.1 µM when displacing the WIN peptide.  
 
Figure 9. Small molecule binders to WDR5, 101 discovered by a high throughput screening effort. 102 and 103 
from the screening of commercially available similars. 
The group then worked to improve on the structure of WDR5-103, 69 compounds were 




Figure 10. (Left) core of WDR5 binders used for SAR experiments. (Right) Structure of compound 47, optimised 
binder to WDR5 
 Compounds were assayed to determine KD, compound 47 scored the best with a KD of 0.27 ± 
0.1 µM. Further optimization was carried out by the SGC-OICR collaboration to further 
develop a binder to WDR5. This improved binder, OICR-9429, has a KD of 52 nM by ITC and 
an IC50 < 1 µM.  Li et al. explores the SAR of compound 47 further62.  
 
Figure 11. Compound 23 from Li et al 
In the publication the authors specify that the affinity could likely be further improved by the 
introduction of a polar group at the 4-fluoro position to allow for a hydrogen bond interaction 
for ASP107. This theory was later explored by the SGC-OICR collaboration. In the final 




Figure 12. (A) WDR5 inhibitor OICR-9429, (B) negative control compound OICR-0547. Both compounds 
developed by the SGC and OICR collaboration. 
OICR-9429  was determined to bind to WDR5 with high affinity (KD = 93 ± 28 nM by 
fluorescence polarisation in a competition experiment against a labelled peptide).63 OICR-9429 
was also tested against primary human AML cells. At 5 µM the compound caused a decrease 
to 53% mean cell viability (n = 8). In AML patient cells without the C/EBPɑ mutation viability 
remained higher at 86% (n=8). Interestingly the almost identical control compound OICR-0547 
shows no affinity to WDR5 and showed no activity on OICR-9429 sensitive cells at tested 
concentrations.64  Figure 13 shows OICR-9429 in the top interface of WDR5, the 
methylpiperazine points down into the pocket. With OICR-0547 it is possible that the lack of 
affinity comes from the oxygen of the morpholine being too negatively charged, repelling 




Figure 13 - Crystal structure of OICR-9429 in the top binding interface of WDR5 
 
 The development of OICR-9429 shows that a classical library screening approach followed 
by optimisation via medicinal chemistry is capable of producing a strong binding compound 
to a PPI target. In the following section a different method for the development of a binder is 
described, for comparison of these as methods to develop binders to WD40 domains. 
3.4.9.2. Peptidomimetics Derived From Protein-Protein Interactions 
The second series of binders to WDR5 discussed in this chapter comes from the Wang group 
of the University of Michigan. Initial research carried out by the group narrowed down the 
key residues of the WDR5 interfacing (WIN) motif (sequence: GSARAEVHLRKS) of MLL1 
and the Histone 3 N-terminus (sequence: ARTKQTARKS) by synthesizing peptide fragments 
of sequence and screening via competition experiments against labelled full length peptides. 
It was determined that both of these motifs could be shortened down to the trimeric peptides 
ARA and ART respectively (Table 5 and Table 6)65. The research indicated that only a small 
loss in inhibition could be achieved, even when shortening to a trimeric peptide, as long as 
the key arginine residue and flanking residues were maintained. The WIN motif of MLL1 is 
needed for the attachment of MLL1 to a preexisting complex formed of WDR5, RbBP5, 
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ASH2L, DPY-30 (WRAD complex). This complex is capable of H3K4 methylation, with MLL1 
it is capable of methylation of H3K4me2.  
Table 5. Affinity of truncates of the WIN motif peptide 
Sequence IC50 ± SD (µM) KI ± SD (µM) 
Ac-GSARAEVHLRKS-NH2 0.75 ± 0.10 0.16 ± 0.02 
Ac-SARAEVHLRKS-NH2 1.04 ± 0.14 0.20 ± 0.03 
Ac-ARAEVHLRKS-NH2 0.02 ± 00004 0.003 ± 0.001 
H2N-SARAEVHLRKS-NH2 0.08 ± 0.01 0.02 ± 0.002 
Ac-RAEVHLRKS-NH2 29 ± 4 6.30 ± 0.80 
Ac-ARAEVHL-NH2 0.16 ± 0.03 0.03 ± 0.01 
Ac-ARAEVH-NH2 0.40 ± 0.10 0.09 ± 0.02 
Ac-ARAEV-NH2 0.75 ± 0.10 0.16 ± 0.03 
Ac-ARAE-NH2 0.40 ± 0.05 0.08 ± 0.01 
Ac-ARA-NH2 0.54 ± 0.03 0.12 ± 0.01 
Ac-AR-NH2 125 ± 6 27 ± 1.4 
The N-terminus of H3 is also able to directly bind WDR5. This interaction stimulates 
methylation of H3K4. The H3 N-terminus was also explored via truncation around the key 
arginine residue (Table 6).   
Table 6. Affinity of truncates of the Histone 3 peptide 
Sequence IC50 ± SD (µM) KI ± SD (µM) 
H2N-ARTKQTARKS-NH2 70 ± 6 15.10 ± 1.30 
Ac-ARTKQTARKS-NH2 0.006 ± 0.002 <0.001 
H2N-ART-NH2 127 ± 12 27.30 ± 2.50 
Ac-ART-NH2 0.08 ± 0.003 0.02 ± 0.001 
H2N-ARTK(Me)QTARKS-NH2 69 ± 7 15.00 ± 1.60 
H2N-ARTK(Me2)QTARKS-NH2 42 ± 6 9.00 ± 1.30 
H2N-ARTK(Me3)QTARKS-NH2 73 ± 6 15.60 ± 1.20 
The N-acetylated trimer peptides were used as a starting point for SAR-driven optimization. 
First by replacing amino acid residues around the key arginine residue, which determined 
that a peptide of Ac-XRV-NH2 (where x is an unknown residue) would be the best starting 
point for further SAR.66 The optimization led to the development of compounds MM-101, 





Figure 14. SAR of MM-10X Series 
Compound MM-102 was found to improve the IC50 250 times to that of the Ac-ARA-NH2 
peptide. MM-102 was also shown to inhibit cell growth in 2 leukaemia cell lines, MV4;11 and 
KOPN8. Further optimisation of MM-102 led to the development of MM-401, a cyclic 
analogue of the MM-10X series (Figure 15)67. 
 
Figure 15. Structure of WDR5 inhibitor MM-401 
MM-401 was determined to have an IC50 of 0.9 ± 0.2 nM to WDR5, a significant increase in 
affinity compared to the MM-10X compounds and better than OICR-9429 (Figure 12). 
Compound R1 




MM-101 -H 2.9 ± 1.4 <1 
MM-102 -F 2.4 ± 1.7 <1 
MM-103 -Cl 4.5 ± 0.6 <1 
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Similarly to MM-102, MM-401 was screened against leukaemia cell lines. MM-401 was shown 
to inhibit the growth of MV4:11, MOLM13 and KOPN8 leukemia cells, cell lines that contain 
a single allele MLL1 translocation. This method, taking a natural interaction and improving 
upon it, was shown to produce a binding compound with a higher affinity than the small 
molecule described in the prior section.  It is rare to be able to compare these two methods in 
the context of targeting WD40 domains. At the time of writing WDR5 is the only WD40 
domain containing protein to have been targeted via two methods on the same interaction 
interface. 
3.5. Conclusions and Further work 
Initially the database was started to determine WD40 domains of interest. During its creation 
proteins of interest were determined, more data was gathered. Based on the information 
collected on human WD40 domains it was determined that WDR5 would be an interesting 
target for further research. At the time at which this project was started WDR5 had no known 
small molecule binders, but the biological information available suggested that the protein 
could make for an attractive target for further investigation (discussed above). As mentioned 
previously the links between WDR5 and MLL1 and MYC strongly suggest that WDR5 and its 
interactions may play an important role in a number of cancers. During the course of the 
research project the publications discussed above were published. It was shown that MM-401 
and OICR-9429 are active in cancer cell lines, inhibiting cell growth and reducing cell 
viability.63 These results further verified the possibility that WDR5 could be an interesting 
target to investigate. The structural information that had been published encouraged further 
research. Crystallographic data of interactions on both the top and bottom interfaces would 
later prove to be invaluable in the development of a new binder to WDR5. This information 
would later prove invaluable when used as input for the MorPH process as described in 
chapter 6. MorPH is a computational tool which uses a peptide sequence for input and outputs 
a selection of amino acid replacements for each. This method will improve the stability of the 
peptide and through screening amino acid replacements improve the affinity between protein 
and peptide can be determined. Structural information on the interactions of WDR5 allows 
for the comparison of the output from MorPH with the results from the published 
optimisation efforts that led to the development of MM-401.66   
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The database was maintained throughout the research project. This makes the database useful 
for future work in several ways. The database contains alternate names and identifiers that 
can be used to search for the proteins in literature or other databases. Data on interaction 
partners, biology and disease allows researchers to easily evaluate a WD40 domain containing 
protein as a target. The database includes references to known binders to proteins that can be 
used to evaluate screening research that has been carried out on a protein. The information 
on binders can also be used to determine if a positive control is available for screening 
experiments against a target protein.  
The compiled database largely consists of information from other databases, the value of this 
database is in the aggregation of information into one database allows users to quickly find 
all available information on a given WD40 domain containing protein or group of proteins. 
Future work utilising the database requires that the database itself is maintained. Without 
updating the database still holds value, however by keeping relevant information such as 
disease associations updated the value of the collected and curated information will increase 
over time. Further research can also be carried out curating the data to search for patterns in 
WD40 domains and relevant diseases. For example if a project is focusing on the discovery of 
novel small molecules for the targeting of a specific pathway the database can be used to find 
WD40 domain containing proteins in the pathway and information on relevant biology. 
An alternative could be to consider research into the WD40 domains with the lowest amount 
of information available in the database. A low level of detail in the database is a reflection of 
the lack of data available in literature. These overlooked WD40 domain containing proteins 










4. Affinity Selection Testing of Small Molecules From 
Computational Techniques 
4.1. Introduction 
The application of in-silico techniques can contribute greatly towards the discovery of novel 
binders. Many computational tools exist that can be accessed online, websites for the 
determination of hotspots in protein-protein interactions,17 to aid in the filtering of pan assay 
interference compounds (PAINS) in compound datasets68 and many tools for the 3D 
modelling of protein structures11, 17, 68, 69. The most challenging, and potentially rewarding, 
application of computational tools to the drug discovery process is the suggesting of potential 
binders and inhibitors. In this chapter two distinct approaches to in-silico drug discovery are 
discussed and applied in an effort to discover novel small molecule binder to WDR5. The first, 
method to be discussed does not involve any protein structures or docking. Instead USRCAT 
is a ligand-based method that suggests compounds based on their having similar structural 
descriptions to that of known binders. The second method is the structure-based docking 
method, the Q-mol platform. This is a structure-based method of discovering potential 
binding sites on a protein surface. A binding site is a specific region of a protein that is capable 
of entering into a stabilising reaction with another entity.70 After potential binding sites are 
found small molecule libraries can be docked against the newly discovered binding sites and 
suggested for screening experiments. 
4.1.1. Ligand-based techniques 
The application of ligand based techniques requires small molecule structural information for 
known binders to the target.  They do not require target information, instead, looking for 
common binding motifs, molecular shape and electrostatic similarities. The rationale behind 
this is the molecular similarity principle,71 which simply states that similar molecules should 
make similar interactions.  Substructure techniques involve a search of a compound database 
for 2D or 3D structures that contain a substructure of interest, while similarity techniques 
search for compounds that are ‘similar’ in their features.72 Often substructure techniques will 
involve the aggregation of the structures of known ligands into a pharmacophore. A 
pharmacophore describes the ensemble of the spatial arrangement of steric and electronic 
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features in a binding interaction site.70 Note that a pharmacophore is not itself a chemical 
entity. From this, a pharmacophore can be used as a template to find compounds with similar 
structures. Molecular similarity analysis allows for the comparison of chemical structures in 
terms of similar chemical moieties and their relative distance from one another. This 
description of the structure can be presented in 1, 2 or 3 dimensions, where 1 dimension is 
simply a vector of features, 2 dimensions includes graph connectivity and 3 dimensions 
include the distributions of charges.73 The simplest description of a chemical structure can be 
presented as a bit string fingerprint, a series of 1s and 0s that simply describe whether certain 
moieties are present in a structure. There is an expectation that the 3-dimensional similarity 
methods would be more successful in their ability to determine novel binding partners than 
description based similarity methods, however the opposite has been proven in some studies 
against certain targets true.72 There are a huge variety of methods available for the conversion 
of molecules into a set of descriptors.72, 74 For example, one open source software package 
PaDel-descriptor is able to calculate 663 1D and 2D descriptors and 134 3D descriptors.75 
For analysis a chemical structure can be converted into its descriptors, these descriptors are 
then be compared to one another through simple mathematics to determine how structurally 
similar they are. For example the most common approach for the comparison of molecular 
fingerprints is the Tanimoto index, more complex 3D comparisons and scoring methods are 
discussed later in this chapter.  
Equation 1 - The Tanimoto index 
𝑇𝑎𝑛𝑖𝑚𝑜𝑡𝑜 =
𝐹𝑎
𝐹𝑡 + 𝐹𝑞 + 𝐹𝑎
 
Where Fa refers to all of the features present in both the target and the query molecule, Ft is 
the number of features present in the target and Fq is the number of features present in the 
query molecule. The result of this equation will be a value between 0 and 1, where a score of 
0 indicates that the two structures have nothing in common and a score of 1 suggests that the 
two are identical. 
The popularity of the Tanimoto scoring method could be partly due to its adaptability to many 
different input criteria and gives an easy to compare score as an output. Due to its prominence 
the Tanimoto index is often compared to other methods of investigating similarity,76 generally 
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it is accepted that it is the best method for group fusion.77 Group fusion is a method combining 
data from several different sources, allowing for broader comparisons of structures.78 The 
Tanimoto index however has also received some criticism, the most notable statement being 
that the method has a bias to score small molecules more favourably.79, 80 Molecular similarity 
depends on a simple principle, that similar compounds with similar properties should have 
similar activities. This is known as the similarity property principle.81 According to the similar 
property principle suitably similar compounds should show similar affinity. However the 
similar property principle does not perfectly describe the relationship between similar 
structures and the same target. Consider investigations into structure activity relationships 
(SAR). Classical SAR approaches make small, progressive changes to a larger structure and 
monitor the effect that the change has on the affinity. Over the course of some of these 
investigations however it can be found that very small changes in structure can lead to very 
large changes in affinity, for example in chapter 2 OICR-9429 shows an affinity of 93 nM to 
WDR5, however the remarkably similar structure OICR-0547 shows no affinity and is used as 
a negative control in later literature experiments. Despite this caveat molecular similarity can 
allow for the change from one core structure (sometimes referred to as a scaffold) to another.82 
This would be an ideal result from a molecular similarity project, as it would allow for SAR 
exploration and optimisation around a different structural core.  
4.1.2. Molecular similarity analysis using URSCAT (carried out by Steven 
Shave) 
In this study Ultrafast Shape Recognition with CREDO Atom Types (USRCAT)83 was used to 
determine potential similar structures from the Vichem nested chemical library (NCL, 
https://vichemchemie.com/nested-chemical-library-ncl/). Vichem stipulated that, as a part of 
a collaboration with the company, their compound libraries will be shared with the Auer lab 
in an encoded format. USRCAT is a moment-based virtual screening method that uses the 
relative position of bonded atoms to describe molecular shape.83 Moment-based methods use 
approximations to convert shape information into an invariant numerical form, allowing 
alignment free comparison of small molecule structures. These methods provide data in a 
simple numerical form it allows for the storage of information of many compounds in a 
database. URSCAT is the most recent iteration of a series of moment-based methods. Ultrafast 
Shape Recognition (USR) is the original method, devised to use 4 reference points for each 
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structure from which a set of descriptors can be calculated.84 For each of these reference 
positions a description formed of the mean, variance and skew of the molecular distance 
between the reference point and all atoms in the structure. The 4 reference points are at the 
centre of the molecular structure, the atom closest to the centre point, the atom farthest from 
the centre point and the atom farthest from the point farthest from the centre point. For a 
structure this will output 12 values; 4 points with 3 values for each (mean, variance and skew). 
Comparison of the 2 structures via their descriptions is calculated by the sum of least absolute 
differences of their respective moments. The USR method was validated and improved upon. 
UltraFast Shape Recognition with Atom Types (UFSRAT) also calculates descriptor sets for 
structures, however it also takes into account atom types. The method considers all atoms, 
hydrogen bond acceptors, hydrogen bond donors and hydrophobic atoms. While USR uses 
12 descriptions for each molecule UFSRAT uses 48, giving a more descriptive definition of the 
structure.85 
 




 USRCAT also accounts for atom types in calculations of descriptor sets, the method uses the 
same 4 atom criteria as UFSRAT but also aromatic atoms and defines point distributions in a 
different way to UFSRAT, defining P1 to P4 points and keeping them static between 
distributions. In summary USRCAT describes a structure as 60 numerical values. The 
calculation of similarity between two structures is performed through the sum of the squares 
of the differences between each descriptor. An important factor for consideration regarding 
some ligand based methods, such as molecular similarity, is that the work can be carried out 
with no knowledge of the structures involved, only the numerical descriptions. In many cases 
it is not possible to work backwards and discern the structure of a molecule from the 
description. While this means an additional step is required to ensure a structure suggested is 
suitably similar to the reference structure, it also allows for compound suppliers to provide 
virtual libraries of compounds to collaboration partners be used in virtual ligand screening 
without disclosing the structures included in their library. As is the case with the encoded 
Vichem library that was used to determine possible novel binders to WDR5 in this chapter. 
4.1.3. Structure based techniques 
In contrast to ligand-based methods structure based techniques use known structural 
information of a target protein (usually an X-ray structure) and positions, or “poses” potential 
ligands to defined binding sites on the protein surface. The clear advantage of structure-based 
virtual screening is that there is no requirement for there to be known binders to a target. 
However structural data is not always available for the target of a project, structure-based 
methods are also significantly more computationally intensive compared to ligand-based 
methods.  
Structural based screening has several prerequisites for an experiment. First a database of 
compounds must be available.  Often, the database must have the compounds available as a 
3D structure or the ability to convert the data into a 3D structure. Next the target must be 
prepared using available 3D structural information. At the heart of this stage is definition of 
the binding site, narrowing down the possible binding location and reducing computational 
search space and avoiding exhaustive docking of the compound library to the surface of the 
entire protein. Methods to carry out structure based docking without data on the target 
structure have also been developed.  Protein homology methods use known structures of 
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similar proteins to predict the structure of target binding sites for example the software 
FINDSITEcomb 86. Despite discrepancies between a homology model and a protein target, 
homology modelling methods have been found to be reasonably competent at producing 
accurate representations of target binding sites87. 
Following the preparation of the target structure and compound structure dataset docking is 
carried out. There are a great many docking methods that can be grouped in several different 
ways. In this section methods will be discussed based on their ability to account for the 
flexibility of the ligand or the protein. Predicting the flexibility of the ligand can be carried out 
several ways. For example FlexX (BioSolvIT) is a method that breaks a structure down into 
fragments and systematically builds the structure in the binding pocket based on a database 
of known possible bond angles.88 Glide also accounts for ligand flexibility but instead 
exhaustively trials rotamer states for each bond in the ligand, removing unsuitable 
conformations as it progresses89. Trying to account for flexibility can lead to a great increase 
in computational intensity, however rigid ligand structures cannot describe the nature of a 
binding interaction. A compromise that some methods use is to take several conformations of 
each ligands structure which are docked rigidly to the protein separately, this is known as 
conformation ensemble docking and is used by techniques such as DOCK, FRED and SLIDE90, 
91. A similar compromise can be made with regards to the protein flexibility by using 
molecular dynamics simulations, several example structures from a single molecular 
dynamics experiment can be used as a rigid structure for the docking of potential ligands92. 
Although the sampling rate of the molecular dynamics study will have a large effect on the 
results of such work. Alternatively more intense methods attempt to more accurately 
represent the binding interface, SLIDE for example simulates the relaxation of residues in the 
binding pocket upon docking of a structure91. 
When docking a potential ligand to a protein there are many possible metrics that can be used 
to score the predicted interaction. These scoring methods can be grouped as knowledge-
based, physical-based or empirical. Knowledge-based methods use statistical-mechanics to 
calculate an approximation of the binding free energy of the complex, based on observed 
binding interactions from databases. Physical-based scoring functions are sometimes referred 
to as force-field scoring functions. These functions use a force-field function for the interaction 
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partners, this gives an energy value that is used as the score for the ligand. DOCK is an 
example method that uses physical scoring methods93. Empirical-based functions determine 
the binding free energy as a function of the contributions of different interactions detected, 
such as hydrogen-bonding or hydrophobic interactions, and scores them based on known-
experimental binding energies for these interactions. Examples of methods that use empirical-
based scoring functions include Flexx,88 Chemscore94 and SCORE95.  
4.1.4. Q-mol (carried out by Anton Cheltsov of Q-mol LLC) 
Q-mol is an in-silico method that uses two steps to determine novel possible ligands to protein 
targets. The first step determines possible binding interfaces on the surfaces of proteins. 
This method moves amino acids across the surface of the target protein and predicts sites 
where there is an increase in affinity. In the output possible binding sites are visualised as 
these areas of the protein surface will be surrounded with spheres with each sphere 
representing an amino acid binding site and the size and colour being proportional to the 
affinity of an amino acid to that region. Q-mol uses all-atom optimized potential for liquid 
simulations (OPLS), a combination of molecular dynamics and Monte Carlo approximations, 
to simulate the environment of a protein in solution96. Q-mol then simulates a binding 
interaction and possible conformational changes in the protein that occur on the binding of a 
small molecule13, 97, 98. As a whole the Q-mol package is able to define new possible binding 
sites to proteins, then use a docking simulation to determine possible ligands to these sites. 
The Q-mol virtual ligand screening method has been used to determine a possible binding 
site on importin alpha 5 with the goal of evaluating the proteins role in influenza. After this 
possible binding site was determined the National Cancer Institute compound library was 
used for a preliminary virtual ligand based screening effort. This virtual screen produced 
many suggestions including several known anti-viral agents98. The Q-mol approach was also 
used to target protease region of the multifunctional NS3 protein. The NS3 protease domain 
(NS3pro) is responsible for viral polyprotein production. Virtual ligand screening determined 
76 compounds that included ligands with a previously identified phenyl(sulfonyl-pyrazol 
scaffold. The ligands were fully characterised and their mechanism of action investigated.13 
Given the relative success of the Q-mol software package it was determined that WDR5 
should be targeted in a similar manner to the targets described above. 
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4.1.5.  Label Free Affinity Methods 
The Auer lab has developed a fully integrated platform of label free affinity selection methods 
for the screening of small molecules against protein targets in-vitro. There is no requirement 
to express the target as a fluorescent protein conjugate or carry out chemical labelling of the 
protein or ligand, these methods also avoid the requirement of assay development. Both of 
these barriers can impose a cost or time demand. In this section several methods that were 
considered for label free screening of compounds against WDR5 are discussed. 
4.1.5.1. Surface Plasmon Resonance 
Surface plasmon resonance (SPR) uses an experimental set up is known as the Kretschmann 
configuration99. A prism is attached to one side of a metal plate, usually gold. On the other 
side of the metal plate is an attachment point for protein, usually antibodies for the protein. A 
polarised light source fires a beam through the prism, the beam is reflected off the metal plate 
at a specular angle and into a detector. Given the experimental set up there will be an angle 
at which a significant decrease in reflected light, this is known as the resonance angle. At this 
angle the light resonantly couples with the electrons on and near the surface of the metal. This 
creates oscillating electrons near the surface of the metal called plasmons.  
 
Figure 17 - a) diagram showing the Kretschmann configuration commonly used in SPR, adapted from 
reference.100 b) plot of reflectivity vs angle of light source relative to the incident surface, a large dip in 
reflectivity indicates the resonance angle. The angle shifts on the binding of small molecules to the surface 
A flow of buffer containing the ligand is passed over this face of the plate. As ligand is flowed 
over the plate binding interactions with the immobilized protein will leads to a change in the 
mass of the surface of the plate. This change in mass, indicating a binding event is recorded 




SPR is able to characterise the on and off rates of a ligand to an immobilised target. As buffer 
containing ligand is flowed over the immobilised protein there is an abundance of binding 
sites, the on-rate is high. After some time an equilibrium will be reached where the on and off 
rates are equal, seen as a plateau in the SPR response curve. Following this the buffer will start 
to wash away the ligand as it becomes unbound from the binding sites, at this point the off-
rate is significantly higher than the on-rate. 
 
Figure 18 - Example SPR resonance curve showing the different stages of binding, equilibration and 
dissociation. 
From the on and off rates the dissociation coefficient KD can be calculated. While this method 
provides a large amount of information, the method is limited as it has a lower throughput 
than other methods discussed in this section. This makes the method less favourable for 
application as a primary screening technique. 
4.1.5.2. Isothermal titration calorimetry  
In Isothermal Titration Calorimetry (ITC) 2 chambers are set up, a standard chamber and a 
chamber containing the target protein. Both chambers are heated with extremely high 





Figure 19 - Simplified schematic of and ITC calorimeter. 
Upon addition and mixing there will be a temperature change dependant on the nature of the 
interaction between protein and ligand. The sample chamber will control the heating or 
cooling of the sample in order to maintain the temperature as close as possible to the standard 
chamber. The energy required to maintain this temperature is plotted over time.  
 
Figure 20 - Left) example output of an ITC experiment, each dip in the plot represents the addition of ligand 
prior to allowing the temperature to return to normal. Right) Wiseman plot example. 
Once the sample temperature no longer requires intervention from the temperature controller 
another sample of ligand is added. This pattern of adding ligand and monitoring the energy 
required to maintain the temperature is repeated several times, each time the energy required 
to normalise the temperature of the chamber reduces. The output of an ITC experiment can 
reveal much about the nature of a binding interaction. Plotting the data in a Wiseman plot 
(Figure 20) will reveal the KD (from the slope of the curve), the stoichiometry of the interaction 
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(the ratio of ligands binding to proteins is equal to the molar ratio at the middle of the slope) 
and the vertical size of the curve can suggest whether the mechanism of the interaction is 
entropy or enthalpy driven. Similarly to SPR, ITC provides a large amount of information at 
the sacrifice of throughput. 
4.1.5.3. Protein Thermal Shift Analysis 
Thermal shift analysis (TSA), sometimes referred to as thermal denaturation analysis, thermal 
denaturation fluorescence or differential scanning fluorimetry, is another thermal based 
screening method that takes advantage of the stabilising effects imparted upon proteins by 
the binding of small molecules or other proteins to the target protein surface. In a TSA 
experiment the protein is incubated with SYPRO orange dye, this dye binds non-specifically 
to hydrophobic patches of the protein. When in a hydrophobic environment SYPRO orange 
has a much higher fluorescence than in aqueous conditions (ex/em 485/575 nm). The sample 
of protein and SYPRO orange dye is then heated, the protein denatures and in doing so reveals 
its hydrophobic interior. The SYPRO orange dye fluoresces in the hydrophobic environment 
presented, allowing for the detection of the denaturation of the protein as in increase in 
fluorescence. In the event of a binding interaction between the protein and a ligand the 
thermal stability of the protein will increase, seen as a delay in the fluorescence increase 
compared to a control experiment. The difference in melting temperature (Tm) in the presence 
of a ligand is compared to the (Tm) of the control experiment is referred to as the ΔTm. The 
stabilising effect of a binding interaction increases as a function of affinity and concentration, 
theoretically allowing for the ranking of hits from a TSA screen.101 This allows TSA to be used 
as a preliminary label-free screening method. The experiments in this chapter were carried 
out using a Biorad IQ5 ICycler, a real-time quantitative PCR machine. Many quantitative PCR 
instruments can be configured to be used for a TSA assay allowing for screening in a 96 well 
format with relatively low concentration of protein per assay (5-15 µM in an assay volume of 
50 µl). The output from the experiment is a plot showing the change in fluorescence as 





Figure 21 - Example of the results of a TSA experiment. As temperature increases the protein denatures 
revealing its hydrophobic interior. SYPRO orange dye binds and its fluorescence intensity increases 
significantly in the hydrophobic environment, allowing for determination of the protein melting temperature 
(Tm). 
From the resulting melting curve it can be difficult to reproducibly determine the melting 
point of the protein, as it is defined as the point of inflection in the protein melting curve. The 
negative differential of the data (-d(RFU)/dT) however transforms the melting curve into a 
peak (note that some programs alternatively use d(RFU)/dT). The melting point (Tm) is then 
determined as the x value for the lowest y value in the data set. Figure 22 below shows the 





Figure 22 - Example plot of -d(RFU)/dT  data. This plot is used to determine the protein melting temperature of 
a sample. 
However TSA has several downsides that must be considered in experimental planning. 
Mainly that the use of a dye that fluoresces in a hydrophobic environment leads to a poor 
tolerance of detergents in the assay buffer. It was previously stated that the increase in protein 
stability is a function of the affinity between the protein and ligand, however the relative 
stabilising effect of a ligand to a protein will vary from protein to protein. Generally proteins 
with a higher thermal stability show a small increase of stability on ligand binding, making 
the determination of lower affinity hits more difficult. Compared to ITC and SPR TSA has 
much higher throughput, screening in a 96 well-plate format with acquisition times that can 
be varied depending on the desired resolution. As the degree of stabilisation is reflected as a 
shift in melting temperature results of TSA screens can also be ranked. These reasons make 
TSA a favourable initial screening technique. 
4.1.5.4. Microdialysis 
Microdialysis allows for affinity determination while also evaluating the ligands behaviour in 
the assay environment. In a microdialysis experiment a rapid equilibrium dialysis (RED) 
cartridge (Thermo Scientific) is held in a specialised RED plate, the cartridge is made up of 2 
chambers separated by a nitrocellulose membrane with an 8000 dalton molecular weight cut 
off. Compound and protein are mixed in a single chamber at the start of incubation (referred 
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to as the incubation chamber), to the connected chamber (the diffusion chamber) buffer is 
added. The principle of microdialysis is that the free ligand will pass freely through the 
membrane into the second chamber (referred to as the diffusion chamber).  
 
 
Figure 23 - Schematic of a microdialysis experiment. Protein and ligand are added to the red chamber, after 
being agitated for a time the ligand will pass through the membrane and an equilibrium concentration 
established. 
Microdialysis experiments can reach equilibrium in 2-4 hours of agitation, in experiments 
discussed in this chapter the duration was increased to 16 hours to allow in order to avoid 
precipitation of protein. An equilibrium will be reached where the concentrations of free 
compound are constant on both sides of the membrane. Should the ligand have an affinity for 
the protein in the incubation chamber then the different concentrations of ligand in each 
chamber at equilibrium will reflect this. This is because the ligand bound to the target protein 
is trapped in the incubation chamber with the protein, while the free compound can move 
freely. As a result the incubation chamber will have a higher concentration of ligand, as a 
function of the affinity between the ligand and the protein, the volume assay volume and the 




Figure 24 - The effect of increasing affinity on the distribution of ligand in the incubation and diffusion 
chambers. Concentration of protein and compound are 80 µM and 200 µM respectively. 
Figure 24 shows that as affinity increases (KD decreases) the difference in ligand concentration 
becomes smaller, this plot illustrates that at higher affinities small changes in ligand 
concentration reflect larger changes in KD. When discussing the equilibrium of a microdialysis 
experiment it is easiest to define the equilibrium numerically, for this the partition coefficient 
(P) is used. The partition coefficient is the concentration of ligand in the incubation chamber 
(the starting chamber) divided by the diffusion chamber. In this chapter the partition 
coefficient of the control experiment is referred to as Pc, the partition coefficient is referred to 
a Pt. Other label free assay methods discussed above provide limited information on the 
behaviour of the ligand in the assay environment. Some compounds may, for example bind 
to the walls of the assay vessel or precipitate out of solution. This would lead to a lower free 
concentration of the compound in solution and skew the perceived affinity of the compound 
to the target. In a microdialysis investigation a control experiment is carried out in parallel 
that evaluates the behaviour of the ligand is carried out. In this control experiment a known 
volume and concentration of compound alone is added to the incubation chamber and a 
known volume of buffer is added to the diffusion chamber. The plate is sealed and agitated 
for 16 hours and the concentration of compound in the two chambers is determined using 
HPLC and a calibration curve. From the results of the control experiment the behaviour of the 
ligand in the experiment is determined. For example if 100 µl of a 200 µM solution is added 
65 
 
to the incubation chamber and 300 µl of buffer is added to the diffusion chamber the total 
volume of the system is 400 µl. Therefore it is expected, with ideal behaviour, that the 
concentration of ligand in both chambers will be 50 µM.  
The concentration in each well is determined by HPLC by using a calibration curve, area 
under HPLC trace peak vs known concentration of sample. If the value is lower than 50 µM 
in each well this would suggest that the compound is aggregating on the vessel walls. The 
compound is expected to be in equal concentrations either side of the dialysis membrane, the 
Pc should be ≈ 1, this indicates that the ligand is able to pass freely through the membrane. 
.The results of the control experiment are also used in the interpretation of the results from 
the main experiment. Next we extend the example above to include an experiment carried out 
in parallel that uses the same conditions but includes the target protein in the incubation 
chamber (200 µM ligand and 80 µM protein in 100 µl added to the incubation chamber, 300 
µl of buffer added to the diffusion chamber). As the incubation chamber contains protein it is 
more difficult to evaluate the concentration of ligand in the chamber. HPLC analysis using 
some systems would require the removal of protein from the sample as protein can lead to 
blockages in columns. In summary 3 experiments are run in parallel: The test experiment 
where test compound and test protein are incubated together in order to determine the affinity 
between the two. A control experiment, where just the ligand in buffer is left to equilibrate in 
the microdialysis cartridge, is used to determine what the expected total concentration of 
ligand in the microdialysis system is after equilibration. From this total the amount of ligand 
in the diffusion well of the test cartridge is subtracted to calculate the amount of ligand in the 
incubation chamber, from this Pt can be calculated. This control also provides information on 
the behaviour of the ligand in the assay environment. A second control experiment is carried 
out where Bovine Serum Albumin (BSA) is used in place of the test protein. This control is 







This project aimed to utilise 2 different in-silico methods, the structure-based docking of Q-
mol and ligand-based molecular similarity method USRCAT, to determine potential binders 
to the WD40 domain containing protein WDR5. The compounds suggested by these in-silico 
methods were to undergo screening via label free affinity methods. Initial screening was 
carried out using thermal shift analysis as it allowed for the screening of all 81 compounds 
suggested by the in-silico tools. Further characterisation of potential hit compounds was 
carried out using microdialysis. 
4.3. Results 
4.3.1. Suggestions from Q-mol software 
In-silico work carried out by Anton Cheltsov of Q-mol LLC (http://q-mol.com/). 
 
 
Figure 25 - Top (left) and bottom (right) interfaces of WDR5 (blue). MLL1 peptide (green) shows top binding 
interface. Spheres (blue to white, to red) indicate possible binding sites, note the predicted binding site on the 
top interface: The binding site of peptide ARA. 
Figure 25 shows the results of the Q-mol software amino acid binding site search. The spheres 
across the surface indicate where amino acids showed the highest affinity in virtual screening. 
The colour and size of the spheres indicates the affinity of amino acids in this region. Generally 
low affinity regions are spread across the surface of the protein. However in the top and 
bottom interface sites larger spheres of white to red are highly concentrated, indicating higher 
affinity of amino acids in these known binding sites. 
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The compound library of the National Cancer Institute (NCI) were used for virtual ligand 
screening. Potential hit compounds from this virtual screen were forwarded to the Auer lab 
by collaboration partner Anton Cheltsov of Q-mol LLC. Compounds were filtered for possible 
pan-assay interference compounds (PAINS) and the structures checked again by eye to ensure 
no unreasonable compounds were screened. 66 unique compounds were ordered from the 
NCI. The NCI specifies that compounds sent from their library are not guaranteed to match 
the structures ordered or to be of high purity. With this in mind all batches of compounds 
were tested by HPLC and LCMS on arrival for quality control to ensure they matched with 
the structures suggested by the Q-mol package and were of reasonable purity. 
 
Figure 26 - Histogram showing the purity of compounds received from NCI compound library 
62% of compounds received were of above 80% purity. All compounds were incorporated 
into the screening process and their purity accounted for. 
4.3.2. Suggestions from USRCAT software (carried out by Steve 
Shave) 
For the purposes of targeting WDR5 the structures of 9 known binders were used as starting 
points. Binders were each analogues from the same SAR series that was carried out by the 
Structural Genomics Consortium (SGC), targeting the top interface of WDR5103. These input 
structures are summarised in Table 7.  
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Table 7 - Structures of molecules used as input for USRCAT 
 
CHEMBL ID R1 R2 R3 R4 R5 
CHEMBL1407785 H H H NO2 
 
CHEMBL2337031 H OMe F NO2 
 
CHEMBL2337029 Cl H F NO2 
 
CHEMBL2337035 Cl H H NO2 
 
CHEMBL2337032 Cl Me F NO2 
 
CHEMBL2337021 Cl H H CO2Me 
 







CHEMBL1457864 H OMe H NO2 
 
The descriptors of the compounds in Table 7 were extracted and compared to descriptors of 
compounds in the Vichem NCL. The structures of the Vichem NCL were not released. 60 
compounds were suggested to be structurally similar by USRCAT. Table 8 lists the Vichem 





Table 8 - 60 Vichem suggestions and their known active analogue ID. 










CHEMBL2337031 753739 19.886 CHEMBL2337031 831487 58.776 
  569490 21.742   227480 59.279 
  26098 21.912   989582 64.435 
  540656 22.886   901864 64.882 
  919704 28.443   633975 67.363 
  200748 30.643 CHEMBL2337017 231498 37.080 
  651631 31.694   767674 38.404 
  426460 34.551 CHEMBL1457864 205790 27.766 
  16281 35.290   48729 31.486 
  368132 35.568   198490 33.264 
  45851 35.913   465960 33.357 
  106710 38.751   237847 36.354 
  656584 39.532   859152 37.600 
  716300 39.900   256638 41.835 
  842952 41.901   931779 44.085 
  632479 41.925   629613 49.154 
  825861 42.282   135975 49.773 
  103983 43.488 CHEMBL2337032 867989 28.347 
  924807 43.903   966518 28.843 
  645779 44.726   8936 30.879 
  741125 44.858   442333 64.321 
  393581 46.679 CHEMBL2337035 133829 47.172 
  763039 50.336 CHEMBL2337021 176995 40.810 
  88484 50.412 CHEMBL2337026 284066 62.748 
  878668 53.636 CHEMBL2337029 966518 25.208 
  506057 53.677   867989 31.069 
  279910 56.513   8936 34.328 
  282276 56.659 CHEMBL1407785 541316 30.303 
  448902 57.274   775754 43.872 
  356408 57.588    
 
USRCAT scoring is a function of the difference between the descriptors of the known binder 
from CHEMBL and the Vichem compound. A lower score reflects that the two compounds 
have more similar descriptors. 
Of the 60 suggestions the 15 compounds with the lowest scores (highest similarity to known 
binders) that were available from Vichem were ordered and assayed against WDR5 by TSA 
in the same manner as the Q-mol suggested compounds. 
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Table 9 - Final list of 15 compounds suggested by USRCAT screened against WDR5 
Vichem ID CHEMBL ID of known active USRCAT score 
753739 CHEMBL2337031 19.886 
966518 CHEMBL2337029 25.208 
569490 CHEMBL2337031 21.742 
205790 CHEMBL1457864 27.766 
26098 CHEMBL2337031 21.912 
26098 CHEMBL2337031 21.912 
867989 CHEMBL2337029 31.069 
867989 CHEMBL2337032 28.347 
867989 CHEMBL2337029 31.069 
540656 CHEMBL2337031 22.886 
540656 CHEMBL2337031 22.886 
919704 CHEMBL2337031 28.443 
541316 CHEMBL1407785 30.303 
426460 CHEMBL2337031 34.551 
8936 CHEMBL2337029 34.328 
8936 CHEMBL2337032 30.879 
16281 CHEMBL2337031 35.290 
651631 CHEMBL2337031 31.694 
45851 CHEMBL2337031 35.913 
465960 CHEMBL1457864 33.357 
The USRCAT score is a dissimilarity score, i.e a score of 0 would be given for two identical 
structures.  Compounds underwent quality control as with the Q-mol suggested compounds, 
all compounds were determined to be of >95% purity. 
4.3.3. Screening of Q-mol Suggested Compounds 
4.3.4. Thermal Denaturation Fluorescence 
4.3.4.1. Control Results 
Figure 27 shows that the melting temperature of WDR5 alone is 62.5 °C. There is a 9 °C 
stabilisation of the melting temperature of the protein on inclusion of the control peptide Ac-






TM1 (°C) TM3 (°C) TM3 (°C) 
Control 62.2 62.8 62.5 
ARA 71.5 71.2 71.2 
Figure 27 - Control experiment results. Melting experiments were repeated in triplicate. On inclusion of control 
peptide ARA melting curves shifted significantly to the right, indicating an increase in thermal stability. 
4.3.4.2. Screening Results 
Screening of the NCI compounds gave a single hit, NCI-292249 Figure 29. Compounds with a 
similar structure, NCI292250 and NCI292251 (Figure 32) showed no increase in stability. 10 




Figure 28 - Summary of temperature shifts caused by incubation of WDR5 with NCI compound selection. 
NCI292249 is highlighted in red. 
Compounds NCI292251, NCI710574 and NCI247023 were also seen to have similar stabilising 
effects but only in singular experiments, while 292249 was seen to increase the melting 
temperature of WDR5 in multiple experiments. Repeated screens of 292249 against WDR5 
showed no notable increase in stabilisation. Table 10 below cross references the compound 
number of Figure 28 with the corresponding NCI number.   
Table 10 - Complete list of NCI compounds screened against WDR5, NCI292249 highlighted in grey. 
# NCI# ΔT # NCI# ΔT # NCI# ΔT 
1 4945 -1.5 11 71016 -0.5 19 119728 -0.2 
1 4945 -1.5 11 71016 -0.5 19 119728 0.8 
1 4945 -1 11 71016 -0.5 19 119728 -0.7 
2 16881 -0.7 12 78039 -0.5 20 134126 -0.7 
2 16881 -1.2 12 78039 -0.5 20 134126 0.3 
2 16881 -1.2 12 78039 -0.5 20 134126 -0.7 
3 26808 -0.5 13 79629 -0.7 21 134142 -12.2 
3 26808 0.0 13 79629 -8.7 21 134142 -6.7 
3 26808 -0.5 13 79629 -0.7 21 134142 -3.2 
4 29598 -1 14 101590 -12.2 22 152524 -0.5 
4 29598 -1 14 101590 0.8 22 152524 0.0 




Table 10 cont. 
# NCI# ΔT # NCI# ΔT # NCI# ΔT 
5 41312 0.5 14 101590 -35.5 23 163571 -0.2 
5 41312 0.0 14 101590 0.0 23 163571 -0.2 
5 41312 0.0 14 101590 -1.5 23 163571 -0.7 
6 45031 -1 15 106502 -12.2 24 165704 -1.5 
6 45031 -0.5 15 106502 -11.2 24 165704 -0.5 
6 45031 -1 15 106502 -1.2 24 165704 -1.5 
9 45939 -0.2 17 114360 -1.2 26 167707 0.0 
9 45939 -0.7 17 114360 -0.7 26 167707 -0.5 
9 45939 0.3 17 114360 -12.2 26 167707 -35.5 
10 46210 -0.7 18 119689 0.8 26 167707 -35.5 
10 46210 -0.2 18 119689 -1.7 26 167707 0.0 
10 46210 -1.2 18 119689 -0.2 26 167707 -35.5 
27 174930 0.0 35 247023 1.8 40 294166 0.0 
27 174930 -1.0 35 247023 0.0 40 294166 -0.5 
27 174930 -0.5 35 247023 -1.0 40 294166 -0.5 
28 174931 -0.7 35 247023 -1.2 41 295516 -0.2 
28 174931 -0.7 35 247023 -0.7 41 295516 0.8 
28 174931 -0.2 35 247023 -2.0 41 295516 -0.2 
29 185348 -4.7 36 290753 -0.5 42 321518 -0.7 
29 185348 -5.2 36 290753 -1.0 42 321518 -0.7 
29 185348 -11.7 36 290753 -0.5 42 321518 -0.7 
30 201914 -0.5 37 292249 -0.2 43 329276 -1.5 
30 201914 -0.5 37 292249 -0.7 43 329276 -1.5 
30 201914 -0.5 37 292249 0.5 43 329276 -1.0 
31 202116 0.0 37 292249 2.0 44 338076 0.0 
31 202116 -0.5 37 292249 3.0 44 338076 0.0 
31 202116 -0.5 37 292249 -1.2 44 338076 0.0 
32 202428 0.5 38 292250 -1.5 44 338076 -0.7 
32 202428 0.0 38 292250 -1.0 44 338076 -0.7 
32 202428 0.0 38 292250 -1.2 44 338076 -0.7 
33 202477 -0.5 38 292250 -1.2 44 338076 -1.5 
33 202477 -1.5 38 292250 -1.0 44 338076 0.5 
33 202477 -0.5 38 292250 -1.2 44 338076 0.0 
34 215624 -1.0 39 292251 -1.5 45 339182 -0.5 
34 215624 -0.5 39 292251 -1.0 45 339182 0.0 
34 215624 -0.5 39 292251 -1.0 45 339182 0.0 
34 215624 -0.5 39 292251 -1.2 46 340965 -0.5 
34 215624 -0.5 39 292251 -0.2 46 340965 0.0 
34 215624 -1.5 39 292251 2.3 46 340965 -0.5 
34 215624 -0.5 40 294166 0.0 47 348965 -0.2 
34 215624 0.0 40 294166 -0.5 47 348965 -0.2 
34 215624 -0.5 40 294166 -0.5 47 348965 -0.2 





Table 10 continued 
 
      
# NCI# ΔT # NCI# ΔT # NCI# ΔT 
48 367458 0.0 54 613679 -3.0 63 710766 -35.5 
48 367458 0.0 54 613679 -1.0 63 710766 -2.0 
48 367458 -0.5 54 613679 0.5 63 710766 -35.5 
48 367458 0.5 55 622608 -2.2 64 715809 -0.2 
48 367458 0.5 55 622608 -3.2 64 715809 0.3 
48 367458 0.0 55 622608 -2.2 64 715809 0.3 
48 367458 -0.5 56 622622 -12.2 65 724956 0.5 
48 367458 -0.5 56 622622 -8.2 65 724956 0.5 
48 367458 -0.5 56 622622 -12.2 65 724956 0.0 
49 373089 -0.2 57 635302 -3.0 66 1000129 -0.5 
49 373089 0.3 57 635302 -2.0 66 1000129 -0.5 
49 373089 -0.7 57 635302 -2.5 66 1000129 0.0 
49 373089 -0.2 58 635443 -0.5 
   
49 373089 -0.2 58 635443 -1.0 
   
49 373089 -0.2 58 635443 -1.2 
   
50 379379 0.0 58 635443 -1.2 
   
50 379379 -1.0 58 635443 -0.7 
   
50 379379 -1.0 58 635443 0.0 
   
51 401293 -0.5 59 656633 0.0 
   
51 401293 -0.5 59 656633 0.0 
   
51 401293 -1.0 59 656633 3.0 
   
51 401293 -1.5 60 665606 0.5 
   
51 401293 -0.5 60 665606 0.0 
   
51 401293 0.0 60 665606 0.0 
   
52 401294 -35.5 61 667453 -1.0 
   
52 401294 -35.5 61 667453 -1.0 
   
52 401294 0.0 61 667453 -1.5 
   
53 401302 0.5 62 710574 -8.2 
   
53 401302 0.5 62 710574 7.3 
   
53 401302 -0.5 62 710574 -4.7 









NCI292249 (Figure 29) was the only screened compound to show a borderline stabilising effect 
in more than a single screen (ΔT > 3 °C) and so was selected for further investigation. 
 
NCI-292249 
Purity by HPLC: >95% 
Mass: 337.41 
m/z by LCMS: 338.34 [M+H]+ 
Figure 29 - Structure and quality control data of NCI292249 
NCI-292249 was further characterised by microdialysis below. 
4.3.4.3. Microdialysis of NCI292249 
To determine the affinity of NCI292249 microdialysis was used. First a series of concentrations 
of NCI292249 solutions were analysed by HPLC to determine a concentration gradient. 
Table 11 - Results of HPLC analysis of concentration gradient of NCI292249 
   Peak Area 
[NCI292249] µM RT (min) 220 nm 255 nm 
10 14.47 228.6 6.2 
25 14.46 451.4 12.8 
50 14.47 920.4 25.5 







Figure 30 - Calibration curve of NCI292249, analysed by HPLC 
A blank experiment where NCI292249 was incubated alone in a microdialysis cartridge was 
carried out. This was to verify that the compound dialysed across the nitrocellulose membrane 
with no loss of material. Table 12 shows the results of HPLC analysis after incubation for 16 













Table 12 - Results of NCI292249 microdialysis equilibration evaluation. 100 µl of 200 µM NCI292249 was 
injected into the incubation well, 300 µl of buffer was injected into the diffusion well. Plate was sealed, shaken 
20°C for 16 hours. Concentration in each well was determined by HPLC with a concentration curve. 
 
 Peak Area 








220nm 255nm 220 nm 255 nm 220nm 255nm 220nm 255nm 
Incubation 
Chamber 1 






14.47 955.5 27.2 54.02 52.61 
Incubation 
Chamber 2 






14.47 978.9 27.5 55.35 53.19 





    
 
Using the calibration curve it was determined that the concentration of compound on either 
side of the membrane was slightly higher than expected. 100 µl of a 200 µM solution was 
diluted into a 400 µl solution, giving an expected concentration of 50 µM either side of the 
membrane. The value is close to the expected value, error from pipetting, evaporation etc can 
lead to errors. This indicates that the compound is not binding to the membrane or walls of 
the vessel. The partition coefficient, Pc, (incubation chamber concentration divided by 
diffusion chamber concentration) after 16 hours incubation is close to 1.0. This indicates that 
the compound is able to pass freely through the membrane. 
Once it had been verified that NCI292249 behaves well under the applied assay conditions the 
compound was assayed against WDR5 and a control protein, BSA. Table 13 shows the results 
of this assay. Values for protein chamber (incubation chamber) concentrations of NCI292249 
were calculated by subtracting the peak area of the diffusion chamber from the average total 




Table 13 - Results of the microdialysis of NCI292249 against WDR5 and BSA. 100 µl of 200 µM NCI292249 and 
80 µM protein was injected into the incubation well, 300 µl of buffer was injected into the diffusion well. Plate 
was sealed, shaken 20°C for 16 hours. Concentration of material was determined by HPLC concentration curve. 




220 nm 255 nm 220 nm 255 nm 220 nm 255 nm 
WDR5 –  
Incubation Chamber 
  1035.2* 29.8* 58.53* 57.64* 
1.136 1.173 
WDR5 –  
Diffusion Chamber 
14.45 911.0 25.4 51.51 49.13 
BSA –  
Incubation Chamber 
  1048.5* 30.1* 59.28* 58.22* 
1.168 1.199 
BSA –  
Diffusion Chamber 
14.46 897.7 25.1 50.75 48.55 
*calculated through subtraction of diffusion chamber values from the average total 
concentration calculated from the control experiment (Table 12). 
The partition coefficient of NCI292249 when incubated with either BSA or WDR5 is > 1, 
showing that NCI292249 has an affinity to both WDR5 and BSA. The partition coefficient is 
converted into a KD using an equation derived by the Mathmatica software package by Steve 
Shave. A partition coefficient of 1.136 gives a KD of 564 µM. The microdialysis results suggest 
that NCI-292249 is a very weak binder to WDR5, showing a similar affinity to BSA (KD 
calculated to be 452 µM). As discussed in the introduction small changes in ligand 
concentration reflect larger changes in KD, making it possible that the affinity of NCI292249 











4.3.5. Screening of USRCAT suggested compounds. 
 
Figure 31 - Summary plot of the change in melting temperature of WDR5 when incubated with USRCAT 
suggested Vichem compounds 
Data shown in Figure 31 reveals that the compounds assayed against WDR5 from Vichem 
showed a much smaller range of temperature shifts compared to the Q-mol suggested 
compounds from the NCI library. Table 8 below cross references the compound number of 
Figure 31 with the corresponding Vichem number. No compounds showed any significant 
change in the melting temperature of WDR5.  
Table 14- Results of TSA assay of Vichem compounds against WDR5 
# Vichem Number ΔT # Vichem Number ΔT # Vichem Number ΔT 
1 867989 -0.5 6 16281 0.0 11 753739 0.0 
1 867989 -1.0 6 16281 -0.5 11 753739 -0.5 
1 867989 -0.5 6 16281 0.0 11 753739 -0.5 
2 45851 -1.0 7 569490 0.0 12 541316 -0.5 
2 45851 -1.0 7 569490 -0.5 12 541316 -1.0 
2 45851 -1.0 7 569490 -1.0 12 541316 -0.5 
3 26098 0.0 8 8936 -1.0 13 919704 -0.5 
3 26098 -0.5 8 8936 -0.5 13 919704 -0.5 
3 26098 -0.5 8 8936 -0.5 13 919704 0.0 
4 651631 -0.5 9 966518 0.0 14 540656 -0.5 
4 651631 -0.5 9 966518 -0.5 14 540656 -0.5 
4 651631 -0.5 9 966518 0.0 14 540656 -0.5 
5 205790 -0.5 10 426460 -1.0 15 465960 0.0 
5 205790 -0.5 10 426460 -1.0 15 465960 -0.5 
5 205790 -1.0 10 426460 -1.0 15 465960 0.0 
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4.4. Discussion and Future Work 
The Structural Genomics Consortium carried out a TSA screening project between WDR5 and 
1600 compounds. In this screen compounds were considered hits when they stabilised the 
protein melting temperature by ≥3°C.105 Comparatively the only compound seen to have a 
stabilising effect of this significance in repeated screens was NCI292249. Further testing 
showed that this binding was likely low affinity and possibly non-specific as the compound a 
similar affinity to BSA in microdialysis. It was determined that the interaction between 
NCI292249 was too weak to pursue any optimisation efforts from the structure. The structure 
of NCI292249 shows little similarity to any known WDR5 binding compounds. NCI292250 
and NCI292251 (Figure 32) were also assayed against WDR5 in the TSA experiment. Due to 
their similar structure and consecutive numbering it is possible the compounds were a part of 
a series screened against a different target prior to their addition to the NCI library. Despite 
their similarity NCI292250 and NCI292251 showed no affinity to WDR5. 
 
Figure 32 - Structures of NCI292249, NCI292250 and NCI292251 
Searching for the structure of NCI292249 finds that compounds that are the most similar in 




Figure 33 - Structures of naltrexone and morphine. Compounds with similar molecular structures to NCI292249 
Compounds supplied by the NCI compound library were variable in quality, in any screening 
experiment this is an unfavourable situation as it can draw into question any results of the 
experiments. Several compounds screened from the NCI library were recorded as causing a 
negative thermal shift. These compounds seem to cause a destabilisation of the protein, 
literature suggests that this destabilisation is likely concentration dependent and could be a 
symptom of the compounds displaying low solubility.106  
4.4.1. Ligand Based In-Silico Methods Q-Mol and USRCAT 
Despite the unfavourable results of the compound screening experiments the Q-mol software 
package did determine the top and bottom interface sites of WDR5 (Figure 25), showing that 
the software is capable of determining sites for its docking experiments. The compounds 
provided by Vichem based on suggestions from similarity analysis are much harder to 
compare as their structures are unavailable. Having the structures of compounds suggested 
by a molecular similarity method allows for researchers to compare structures to their input. 
In this instance it is unknown whether the compounds screened were reasonable analogues 
of the known binders to screen against WDR5. However the results of the similarity analysis 
can be discussed. The similarity scores of the Vichem compounds screened against WDR5 had 
a range of 20 – 36. Given that the USRCAT compares the distances of similar atoms to calculate 
a score these values are high, suggesting that the screened compounds are not as similar to 
the known binders as would be desired. It is also important to consider the results of SAR 
work that was carried out to develop the known binders for WDR5 that was used as input for 
USRCAT. The Structural Genomics Consortium determined that affinity of the compounds 
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developed in their SAR series was highly sensitive to very small changes in structure.103 
Without being able to compare the output of USRCAT to known binders to WDR5 or carry 
out any in-silico docking investigations it is impossible to assess the output any further than 
the results of screening experiments.  
Ligand-based virtual screening methods provide an additional tool for the discovery of novel 
ligands to protein targets. In this instance a new potential binder to WDR5 was determined, 
however due to the poor affinity and complex structure it was determined that NCI292249 
was limited in terms of opportunities for further development.  
4.4.2. Microdialysis 
Microdialysis provided a simple method of characterising the affinity of NCI292249 to WDR5 
and BSA. Part of the characterisation process was the determination of the behaviour of the 
compound in the assay vessel. Ligands can be promiscuous and bind with the negatively 
charged nitrocellulose membrane or the walls of the incubation chamber, or may precipitate 
out of solution. Without correcting for these factors the concentration in of ligand in the 
protein incubation chamber would be calculated to be higher, resulting in inaccurate KD 
determination. In the control experiment it was determined that the concentration of ligand 
was higher than expected, this could have been the result of evaporation reducing the sample 
volume or an error in pipetting. As the experiments were carried out in parallel the average 
total peak area from the control experiment was used as the total peak area for the affinity 
determination experiment. From this the peak area for the incubation chamber was calculated. 
Error! Reference source not found. shows the expected equilibrium concentration of c
ompound in microdialysis chambers as a function of the affinity between the protein and the 
ligand. The plot uses the concentrations of protein and ligand used in the experiment 
described in this chapter, 80 µM and 200 µM respectively. The plot shows that as KD increases 
(affinity decreases) the respective concentrations in either chamber plateau. This makes 
affinity determination at lower affinities less accurate, as small changes in concentration 
correspond to large changes in KD. 
NCI292249 was determined to have a KD of 564 µM to WDR5 and 452 µM to BSA. Shows that 
a simulation of the experiment puts these results at the upper limit of the simulation, where 
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small changes in the concentration of ligand equate to large variations in the calculated 
affinity. This means that the calculated KD values have a large error associated with them.  
4.4.3. Future Work 
4.4.3.1.  In-silico Methods 
Future screening experiments could be made more successful by combining structure-based 
and ligand-based techniques using the same database of ligands. For example using molecular 
similarity techniques to create a short-list of potential compounds, followed by docking 
studies using this priority set of compounds, preferably using different docking programs. 
Multiple techniques could also be applied to the same dataset to develop a consensus scoring 
approach. A key advantage of molecular similarity methods is that they allow for the 
reduction of a structure to a string of numbers. This string of numbers is significantly simpler 
than a structure and allows for a great many structures to be collected in the same format in a 
database. A database of molecular descriptions from CHEMBL entries, the NCI or other 
databases or libraries could be used for a broader search for compounds with similar 
structures to known binders. Searching many thousands of compounds could potentially 
return many possible similar compounds to use as input for a structure based methods.  
4.4.3.2.  Screening Methods 
TSA was shown to be only be a useful label free affinity technique if the affinity of the 
compounds to the target protein is high enough, the thermal shift of weaker binders is difficult 
to detect. Though the method is cost effective with reasonable throughput thanks to the 96 
well plate format. In the future TSA could be further utilised as a label free screening method 
for WDR5 or other WD40 domain containing proteins to determine potential hits for further 
characterisation. The method could also be used to characterise protein-protein interactions 
of WD40 domains.107 Methods exist for the determination of KD from the results of TSA 
assays,108 however these methods require further characterisation of thermal denaturation of 
the protein. While determination of affinity from a primary screen is advantageous, without 
the KD determination it is still possible to rank hits by their thermal shift. As discussed in the 
introduction, the use of microdialysis as a KD determination technique has the distinct 
advantage of characterising the behaviour of ligands in the assay environment. This makes it 
a staple of the Auer lab screening process, ensuring that it will be used for future screening 
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experiments. In order to better characterise a binder an alternative method of KD 
determination should be used as well as microdialysis. ITC or SPR (as discussed in the 
introduction) are reasonable choices for KD determination and can also offer more information 
on the mechanism of binding. An alternative to these, given a compound shown to bind to a 
target protein through label free techniques, would be to carry out a competition experiment 
where a labelled, known binder to WDR5 or another WD40 domain containing protein is 
displaced by the unlabelled ligand. In the case of WDR5 both the top and bottom interfaces 
have known peptide binders that can easily be synthesised in a labelled form using methods 



















5. Synthesis and Screening of a Scanning One-Bead, 
One-Compound (SOBOC) Peptide Library 
5.1. Introduction 
5.1.1. WDR5 – Structural core to therapeutically relevant complexes 
In recent years protein-protein interactions (PPIs) have become increasingly targeted as a 
result of better understanding of their nature both, from the view of biological pathways and  
structural data.109 Classically PPIs have been defined as difficult targets due to their 
characteristic flat, hydrophobic surfaces. Despite this generalisation structural data of 
interactions between proteins indicates that relatively short stretches of protein are 
responsible for interactions.46 These areas that have a more significant contribution to binding 
are referred to as hotspots.2 Through alanine scanning it is possible to determine the relative 
contributions of amino acid residues to the PPIs. Using this information it is possible to use 
peptides, derived from known interacting sequences in the development of a new or 
optimized peptide-derived binder for target PPIs. In this chapter a method is described 
whereby a known binding peptide is fragmented into all possible peptide truncates of the 
original full length sequence. By reducing a long peptide to a smaller fragment it becomes 
much more manageable to improve on the interaction through SAR studies, screening all 
possible fragments is the most thorough method of achieving this. WDR5 is an example of 
WD40 domain involved in several different protein-protein interactions including two 
validated cancer targets, MLL1 (mixed linked leukemia 1) protein and MYC proteins. The 
WDR5 crystal structure revealed that its 334 amino acid sequence exhibits two major 
interaction surfaces, the top and bottom faces. The smaller top interface is the interaction site 
for mixed lineage leukemia 1 (MLL1), as discussed in chapter 3 translocation in the MLL1 
gene can lead to the formation of MLL fusion proteins that are linked to leukemia.  A notable 
example is the MLL1-AF9 fusion protein that has been shown to cause acute leukemia in mice 
when introduced as a fusion gene.110 Inhibition of these mutant fusion complexes from 
binding with WDR5 has been the subject of extensive research regarding the top interface of 
WDR5. MLL1 dependant cancers, including AML (Acute Myeloid Leukemia) and ALL (Acute 
Lymphoblastic Leukemia).111 MYC is a highly validated target known to bind to WDR5. MYC 
is a prominent cancer biomarker that is seen in a variety of cancers.15, 16 Recently it has been 
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determined that the sequence H2N-DEEEIDVVSVE-CO2H from MYC binds to the larger 
bottom interface of WDR5 (Figure 34).12  
 
Figure 34 - Crystal structure of MYC peptide binding to the bottom interface of WDR512 
MYC is not the first protein found to bind to the bottom interface of WDR5, retinoblastoma-
binding protein-5 (RbBP5) also binds to the flat interface as a part of the MLL1 complex where 
the absence of WDR5 and RbBP5 significantly inhibits methylation of H3K4.112 KAT8 
Regulatory NSL Complex Subunit 2 (KANSL2) also binds to the bottom interface as a part of 
the non-specific lethal (NSL) complex, a complex that is responsible for the regulation of gene 
expression.113  
5.1.2. MYC 
The MYC gene encodes for 3 different oncoprotein transcription factors, c-MYC, N-MYC and 
L-MYC. MYC proteins bind with the protein Max to form a transcription factor complex. The 
3 MYC proteins are linked to a huge variety of cancers and are expressed at different levels in 
different cancers.15 The following are a few examples of the diverse range of both blood-borne 
and solid tumours that different MYC proteins appear deregulated in. C-MYC is closely 
related to Burkitt’s lymphoma, appearing in deregulated in the majority of cases.114 In breast 
cancer C-MYC amplification was found in 28 % of tumours in a study of 457 primary breast 
cancers,115 amplification of C-MYC in breast cancer was also found in an earlier study in 1986, 
where a 2-15 fold increase in amplification was found in 32 % of 121 tumours.116 In 1985 a 5-
40 fold increase in expression was found in a study of primary human colon 
adenocarcinoma.117 N-MYC has been linked to neuroblastoma since 1984, reported as being 
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overexpressed in a third of cases.118 More recent studies confirmed these findings. L-MYC, C-
MYC and N-MYC have links to small cell lung cancer,119 with L-MYC being linked as early as 
1985.120 N-MYC and C-MYC expression appears to be highly variable, the frequency of 
overexpression is reported to range from 2-30 %121 depending on the nature of the sample 
tested. The level of overexpression also varies from 5 fold to over 100 fold (reviewed 
extensively in reference).121 It has been reported that half all cancers are linked to an amplified 
expression of MYC (The Myc oncoprotein as a therapeutic target for human cancer). Many of 
the examples of misregulation of MYC in this section specify dates around the mid-80s as 
when MYC proteins were determined to be linked to different cancers. MYC proteins are 
linked to such a large number of cancers and have been recognised as a target for around 30 
years, despite this there is a notable lack of small molecule binders for this prolific set of 
targets. There exists a small number of compounds that target MYC activity by inhibiting its 
interaction with MAX, either through the direct inhibition of binding or through stabilisation 
of Max dimers.122 BET bromodomain inhibitors have also been determined to be inhibit MYC 
activity by repressing MYC transcription. These methods all avoid direct binding to MYC, an 
indication of the challenges of directly targeting of MYC proteins. This is partly due to the 
three MYC derivatives having different structures. 
 
Figure 35 - Visual representation of MYC proteins and the relative locations of their conserved sequences. Note 
that MYC proteins vary in size and that region IIIa is absent in L-MYC. 
Although MYC proteins are different sizes with different sequences several regions are 
conserved across multiple MYC proteins, these sequences are sometimes referred to as MYC 
boxes (Figure 35). The DNA binding Helix-loop-helix leucine zipper (HLH-LZ domain) and 
these five MYC boxes appear in all 3 MYC proteins with the exception of MbIIIa which is 
absent in L-MYC. As expected these homologous regions are of significant importance to the 
interactions of MYC proteins. MbI and MbII have been the most widely studied of the 5 MYC 
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boxes. MbI is known for its accumulation of mutations in Burkitt’s lymphoma. It is also the 
site of phosphorylation which allows for the binding of the ubiquitin ligase SCFFBXW7 (another 
WD40 domain containing complex). MbII has been found to be essential for MYC proteins to 
drive tumorigenesis in vivo. MbII is required for the transcription of MYC genes through 
binding to the Transformation/transcription domain-associated protein (TRRAP). This 
recruits a histone acetyltransferase complex that opens the chromatin structure of H4 to 
promote the transcription of genes. MbII is also linked to the degradation of MYC proteins by 
acting as a binding site for the ubiquitin ligase SCFSKP2. Like MbI and MbII MbIIIa is linked to 
tumorigenesis and is a binding site for ubiquitination complexes. With MbIIIb and MbIV 
much less is known, though it is known that MbIV regulates DNA binding, apoptosis, 
transformation, and G2 arrest.123 Little is currently known about the function of the MbIIIb 
region is conserved in all MYC proteins, making it particularly attractive for the subject of 
research in the inhibition of MYC protein activity. As mentioned in the section above it was 
recently determined that MYC proteins bind with WDR5 via the MbIIIb sequence, with a 
peptide consisting of the sequence being found to bind with an affinity of 9.3 µM.12 
5.1.3. Targeting the WDR5-MYC Interaction Interface 
Alanine scanning of the sequence reported by Lance et al. has revealed several residues that 
significantly contribute to the affinity of the 11 residue sequence.12 
Table 15 - Results of an alanine scan of the WDR5 binding MYC peptide. KDs determined from competition vs 




While the alanine scan suggests the central IDVV residues are the greatest contributors to the 
interaction, the affinity of the full length peptide is low. By truncating the peptide to just IDVV 
we would expect to see a very weak affinity that would likely be an unfavourable starting 
point for the development of a modified molecular probe. The goals of this project are 
comparable to the work carried out to develop a binder for the top interface of WDR5. First 
an alanine scan was carried out to determine key residues, then a series of truncates around 
these key residues were tested. SAR was then carried out on the smallest truncate to develop 
a molecular probe with a significantly increased affinity.66, 104, 111 
The articles describing this process were published over the course of 4 years (from truncate 
screening to optimised structure). The Scanning One Bead One Compound (SOBOC) method 
described in this chapter was designed to determine a reasonable starting point for the MorPH 
process, an in-silico SAR tool developed by the Auer lab to provide suggestions for possible 
building block replacements based on crystal structures of peptides. Using MorPH can speed 
up the SAR investigation process by offering possible suggestions for replacements for amino 
acids in a peptide starting point based on a crystal structure. However without a reasonable 
peptide starting point this potentially powerful tool cannot be exploited. This brings a 
pressure to develop a method of rapidly evaluating the shortened possible peptide inputs, 
based on known binding sequences, for the MorPH process. The SOBOC synthesis process 
discussed in this chapter was developed with this goal in mind. 
5.1.4. Scanning One-Bead One-Compound (SOBOC) library 
Inspired by One-Bead One-Compound (OBOC) combinatorial chemical libraries, a method 
was designed towards the synthesis of a library of peptide truncates based on the known 
WDR5 interacting sequence from MYC. OBOC methods produce a library of compounds on 
the solid phase with each resin bead having only one kind of chemical structure attached. One 
method of screening OBOC libraries on the solid phase is by confocal nanoscanning 
(CONA),124 where fluorescently labelled protein is incubated with a monolayer of library 
beads. A confocal imaging set up scans the monolayer, exciting and detecting the fluorescently 
labelled protein. Beads containing hit compounds are visible via fluorescent rings around 
their periphery due to the higher local concentration of the bound, labelled target protein. 
OBOC libraries are classically produced through split-mix synthesis, allowing for the rapid 
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synthesis of thousands of compounds attached to the solid phase in a small number of 
reactions. In the last round of coupling reactions, it is usual to screen the sub-libraries as 
opposed to combining them. This aids deconvolution of hits from screening as in the event of 
a hit bead being found in a sub-library as all compounds in the sub-library experienced the 
same coupling reaction i.e. the moiety last added to the hit compound is already known. 
Deconvolution is further aided through the removal of resin after each coupling step, creating 
a collection of pre-cursor sub-libraries. After a sub-library is determined to contain a hit 
compound the precursor sub-libraries can be reacted with the known building block of the 
sub-library that contains the known hit. The resulting series of compounds is screened, the 
sub-library that contains a hit bead reveals the identity of the penultimate building block, this 
method can be repeated, working backwards to determine the identity of the hit.125 This 
classical approach to deconvolution sees less use in an age where mass spectrometry methods 
are powerful enough to accurately determine the mass of different products within fractions 
of mass units, however this method of deconvolution did inspire the development of a 
SOBOC library synthesis. To synthesise an OBOC combinatorial library solid phase peptide 
synthesis is used. In the case of Fmoc solid phase peptide synthesis each coupling reaction 
adds a new amino acid residue to the N-terminus of the previously attached building block. 
Removal of resin after each amino acid coupling removes an N-terminal truncate of the 
complete peptide. By synthesising a separate C-terminal truncate of a complete peptide and 
isolating all N-terminal truncates of each of these C-terminal truncates all possible truncates 
of a peptide sequence can be isolated with the products isolated as one-bead one-compound.  
5.1.5. Screening 
5.1.5.1. Confocal Nanoscanning 
As discussed above CONA is a method for screening OBOC libraries, invented by the Auer 
lab. CONA has been applied in the successful hit identification of several PPI targets126, 127. 
However in OBOC library screening each sub-library contains many different compounds on 
each of the different beads as a result of the split-mix library synthesis methods. As a result, 
screening a sub-library screens hundreds or thousands of compounds, depending on the 
library design. In a SOBOC library each aliquot of isolated resin contains only a single peptide. 
This is by design, as the objective of a SOBOC library is to characterise each of the truncated 
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peptides individually before evaluating the contributions of different residues towards a 
binding event. The relative intensity of the fluorescent rings indicating a binding event can be 
used to relatively rank on-bead peptides by affinity, although on bead affinities are non-
linearly different to affinities of the same peptides in solution due to on-bead avidity and 
enthalpic effects130. As the loading on each bead might vary dependant on the sequence, both 
the protein and the ligand would be labelled using two different fluorescent dyes. This would 
allow for a ratiometric read out for each measurement, allowing for the accurate comparison 
of the ratio of ligand to protein as a function of their local concentrations. Synthesising a 
peptide on Tentagel resin and moving to screening on the same resin makes control of the 
concentration of peptide difficult, as some reaction series may have accrued more impurities 
than others. It must also be considered that peptides labelled via the copper-catalysed 
Huisgen alkyne-azide cycloaddition27 often require a purification step to remove any 
unlabelled peptides. There is also the issue of the fluorophore being trapped within the resin 
bead, giving an erroneous signal in screening. Tentagel resin is also known to have 
autofluorescent qualities in some screening experiments131, however for the purposes of 
CONA this has shown to be less of an issue132. A common alternative to Tentagel resin (a 
polystyrene core coated in polyethylene glycol) is PEGA resin (a 
polyacrylamide/polyethylene copolymer). While PEGA resin has benefit of being reported to 
lack autofluorescence seen in some screens using Tentagel130 it does not solve the problem of 
unlabelled peptide being present on the resin during screening. It suffers from a lack of 
mechanical durability, making it unfavourable for synthesis. Therefore, it was decided that 
rather than screening the peptides isolated on beads the protein would be immobilised 
instead. Ni-nitriletriacetic acid (Ni-NTA) non-covalently binds His-tagged proteins with a 
high affinity and is usually utilised in the purification of proteins after expression. 
5.1.5.2. Fluorescence anisotropy 
Molecules in solution diffuse through the solution at a speed proportional to their size. With 
regards to its movement through solution a small molecule that is bound to protein will 
behave as the protein does. Fluorescence anisotropy uses this principle to characterise binding 
interactions. A fluorescent label attached to a small molecule of interest is excited using plane 
polarised light of a suitable wavelength. A distribution of these fluorophores will be suitably 
aligned with the polarised light and be excited. The molecule will tumble through solution 
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and soon after excitation will emit light at the emission wavelength of the fluorophore. 
Compared to a compound in solution the rate a protein diffuses through solution is 
significantly slower, due to the vast differences in size.  
5.1.6. Assessment of the binding interactions between WDR5 and MYC peptide 
While the top protein-protein interaction interface of WDR5 resembles a binding pocket, 
complete with a deep pocket that strongly binds arginine, the bottom interface holds no such 
pocket. A crystal structure showing the interaction between WDR5 and the MYC MbIIIb 
peptide shows that the peptide sits in a trench along the bottom interface (Figure 34). This 
interface is largely hydrophobic with a small number of charged residues along the edges on 
the surface. The screening of peptide fragments of the MYC MbIIIb peptide will help to 
describe the contributions of residues towards the interaction between MYC and WDR5. 
There are also in-silico techniques available that can be used to predict which peptide truncates 
will bind with high or low affinity (relative to one another) and which residues are potentially 
vital to the interaction. 
5.1.6.1. Hotspot Determination with Hotpoint 
Hotpoint is a hot spot prediction server for protein interfaces.17 A hotspot is a residue or group 
of residues in a protein-protein interaction interface that if mutated into an alanine would see 
a significant drop in affinity. Experimentally this is tested using alanine scanning. As 
mentioned above an alanine scan of the MYC peptide has been carried out. However Hotpoint 
analyses contributions from both sides of the interaction, providing information on potential 
key residues on both WDR5 and the MYCIIIb peptide that are involved in the interaction. 
These residues could prove to be important guidelines should an SAR project be carried out 
on the bottom interface of WDR5. Hotpoint considers the solvent accessibility and contact 
potential of interface residues and uses structures of proteins and their protein or peptide 
binding partners as input. The server returns the relative complex accessible surface area 
(relCompASA), the relative monomer surface area (relMonoASA) and the potential of the 
residue. Should a residue have a potential > 18 and a relative complex accessible surface area 
of > 20% then it is flagged as a hotspot contributing residue. 
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5.1.6.2. Docking with FRED 
As discussed in chapter 3 Fast Rigid Exhaustive Docking (FRED) is a part of the OEDocking 
suite (OpenEye scientific http://www.eyesopen.com/). FRED is a method that docks rigid 
ligands to rigid protein structures. To compensate for the reduced accuracy of docking rigid 
structures each ligand is converted into a series of different conformations for docking against 
the target site. FRED then systematically searches rotations and translations of each of the 
conformations provided within the binding site. Top scoring poses are optimised and a final 
score is assigned to each of the poses using the Chemgauss4 scoring method. Chemgauss 
scoring is a force-field method of scoring which recognises shape, hydrogen bonding (both 
between ligand and protein and with solvent) and metal-chelator interactions. Chemgauss 
scoring is only concerned with heavy atoms (atoms that are not hydrogen) and hydrogen 
bonding score contributions better than its predecessors.133 Chemgauss4 will be used to score 
peptide fragments based on the MYC MbIIIb-WDR5 interaction structure from literature.12 In 
the past the OEDocking suite has been used to discover novel binders through virtual 
screening.134 
5.2. Aims 
To develop a method for the synthesis of all possible truncates of a set length in a quick and 
efficient manner, based on known solid phase peptide synthesis techniques.  This method 
would then be tested using the MYC-WDR5 interaction as a starting point. The synthesised 
library is then to be screened against WDR5 using an on-bead assay. The on bead assay is to 
use a 2 colour system to allow for a ratiometric measurement of the ligand-protein interaction. 
In order to carry out this screen WDR5 will be chemically labelled with a suitable fluorescent 
probe. The results of this screen are to be ranked and the shortest binder showing good affinity 
to the target is to be further characterised in solution phase KD determination using 
fluorescence anisotropy. To use a combination of in-silico techniques and the SOBOC peptide 
fragment synthesis technique to probe the lower interface of WDR5 and assess its potential as 
a site for possible intervention. 
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5.3. Experimental design 
5.3.1. Synthesis method and rationale 
Fmoc SPPS allows for the synthesis of peptides starting from the C-terminus. Amino acids are 
added on one residue at a time with the N-terminal protected with an Fmoc group and the 
side chain protected, this form is referred to as a building block. To add an amino acid, or 
building block, to elongate the peptide chain on the solid phase there are 2 steps. First the 
Fmoc group of the peptide is removed with a base, usually with piperidine, then the new 
building block is coupled to the peptide through the use of a coupling reagent. The nature of 
this method allows for manipulation in several ways that allows for the synthesis of several 
peptides sequentially. During the synthesis of a peptide using SPPS all N-terminal truncates 
(peptides that are shortened versions of the final full length peptide) are produced in the 
process of making the full length peptide. As the synthesis is produced on a solid phase resin 
isolation of these truncate intermediates is simply a matter of removing a sample of the resin 
after each coupling step. C-terminal truncate series cannot be synthesised in a single reaction 
series on a single sample of resin. The C-terminal is the attachment point to the resin, all chain 
elongation occurs at the N-terminus. This means that from a single solid phase synthesis only 
N-terminal truncates can be produced. Each sample of resin is a single C-terminal starting 
point, from which all N-terminus derivatives with this same C-terminus can be synthesised. 
 
Figure 36 - Visualisation of truncates produced from each C-terminal starting point, each in a different reaction 
vessel. 
 



















Based on these facts it was determined that the synthesis of this complete truncate library 
would be produced using each of the amino acid residues in the full length peptide as a C-
terminal starting point, from which a series of N-terminal truncates would be synthesised 
from each starting point. 
5.3.1.1. Minimum truncate size 
 
Figure 37 - Total number of peptides requiring synthesis as a function of truncate size. Example values 
calculated using a full length peptide 10 amino acid residues in length. 
Figure 37 shows that the minimum truncate length has a large effect on the total number of 
truncates in a library. Smaller minimum sizes for truncates dramatically increases the number 
of truncates that need to be synthesised. From a practical standpoint, every decrease in 
truncate size by one amino acid residue another reaction vessel has to be used and all other 
reaction vessels must carry out one additional reaction. Increasing the number of peptides 
naturally will increase the amount of material required for the complete synthesis and the 
time required to carry out the synthesis. This includes the cleavage and quality control 
analysis of the crude peptides. Following this the labelling of the peptides and the purification 
of the labelled peptides also require an investment of time and materials. These factors would 
suggest that it would be best to favour a larger minimum size for truncates, however the 
purpose of the technique is to produce the smallest possible binding sequence. This 
philosophy requires that we favour the shortest possible truncates. In order to find balance 
between the ideal scenario and the practical synthesis of so many truncates we must consider 
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what size of sequence is the most likely to bind. Figure 38 shows a graph comparing pIC50 
against heavy atom count, each data point representing a compound from a data set of known 
protein binding compounds.135, 136 
 
Figure 38 - Graph illustrating the relationship between ligand affinity (pIC50) vs size of ligand (heavy atom). 
Edited from reference135 
Figure 38 shows that with increasing heavy (non-hydrogen) atom count ligand efficiency 
increases up to around 25 HA per compound. The average HA count for an amino acid is 8.3 
HA (red line, Figure 38), therefore a trimer contains 24.9 HA (green line, Figure 38) – extremely 
close to the maximum effectiveness while keeping the total size of the compound small. Figure 
39 shows the distributions of length of a peptide motif (red), number of specified positions 
(positions where the residue is always one of several amino acids) (green) and where the 




Figure 39 - Frequency of motif lengths, number of specified positions and invariant positions of peptide motifs 
in proteins. Calculated by DILIMOT137 
The data in Figure 39 was determined by Discovery of Linear Motifs in Proteins (DILIMOT).137 
DILIMOT is a server that was developed to find short linear motifs in proteins that are over 
represented. Figure 39 shows that the majority of motifs are between 3-7 residues in length, 
reinforcing the suggestion of producing truncates of 3 amino acid residues or longer. In the 
past trimer base compound libraries have produced hits against protein targets, for example 
trimeric peptoids (peptides where the R group is substituted onto the N) were found to bind 
to GCPRs with high affinity.138 The top interface of WDR5 was targeted started from a trimer,66 
and other interactions with WD40 domains have been considered to be dependent on motifs 
of 3 or 4 amino acids, for example the D-box-CDC20/CDH1 interaction.139 Based on these 
points it was decided that the smallest truncate size would be 3.  For the targeting of the 
bottom interface of WDR5 the sequence DEEEIDVVSVE is a known binding peptide from 
literature and was chosen as a starting point. Using a minimum truncate size of 3 with a full 
length peptide 11 amino acid residues in length gives 45 truncates synthesised in 9 reaction 
vessels. In comparison if the minimum truncate length were 2 then 55 truncates would be 
synthesised, labelled, purified and quality controlled. Some of these dimeric truncated 
peptides would also be duplicates of one another, adding an element of redundancy to their 




5.3.2. Design of the On-Bead Screening of SOBOC peptides against WDR5 
2 possible methods for screening were considered. First the classical on-bead library screening 
approach used by the Auer lab. This method would allow for the rapid determination of hits 
from the truncate library. However, with so many peptide truncates that are likely to have a 
similar affinity a 2 colour method could allow for better ranking of hits via a ratiometric 
measurement, comparing the brightness of a labelled truncate to the brightness of a labelled 
protein. It was determined that altering the classical on-bead approach and simply labelling 
the peptides would have problems accompanying the method. Peptide synthesis and labelling 
methods have high conversion rates, however a purification step is still required to ensure 
that only the pure labelled peptide is present in screening experiments. This suggests that the 
synthesis and screening should be carried on different resin. As there is no requirement for a 
linker suitable for on-bead screening it was determined that the solid phase synthesis was to 
be carried out on Rink amide linker. To perform the ratiometric measurement it is required 
that the binding interaction must be localised to ensure the detected signal is strong enough 
for comparison between different truncates. It was decided that the fluorescently labelled 
protein would be isolated on Ni-NTA agarose beads, washed, and incubated with the peptide 
truncates. 
 
Figure 40 - Illustrated planned workflow of SOBOC library screening protocol using an OPERA screening 




5.4.1. Library synthesis 
All truncates were synthesised in 8 working days, average purity was 73 % as determined by 
HPLC. Generally longer peptides showed a lower purity. 
 
Figure 41 - Histogram of purities of crude peptides from SOBOC synthesis 
The majority of peptides were of > 70% crude purity. 
5.4.2. Cy5-Labelling of WDR5 
To verify the labelling of WDR5 would not interfere with the bottom interface of WDR5 the 
crystal structure of WDR5 was investigated for possible dye amino acids, Lys and Cys which 




Figure 42 - The bottom interface of WDR5 (white) was determined to have several lysine residues (blue) in close 
proximity to the MYC peptide binding interface (left image, MYC backbone highlighted in red). Cysteine 
residues are shown in yellow. The bottom interface holds no surface accessible cysteines. 
The bottom interface is surrounded by lysine residues, making labelling with an activated 
ester such as an NHS ester less favourable compared to cysteine labelling. The protein was 
labelled with Cy5 maleimide (details in materials and methods section 9.3). 
 
Figure 43 - Overlay of HPLC traces of Cy5-labelled WDR5. 280 nm absorbance and fluorescence intensity (Ex = 
650 nm, EM = 670 nm) 
The labelled protein was purified by size exclusion and characterised by HPLC and UV-VIS. 
The degree of labelling was determined to be on average 1.9 Cy5 molecules per molecule of 









5.4.3. Synthesis of Labelled peptides 
Peptides of lengths 11-7 were labelled with tetramethylrhodamine azide (TMR-N3), 
thoroughly washed and cleaved. The resulting peptides were purified to > 95 % purity by 
preparative HPLC.  
Table 16 - Results of synthesis and purification of labelled SOBOC peptides 
Sequence Expected Mass M/Z detected [identity of ion] 
DEEEIDV 1613.69 808.23 [M+2H]2+ 1614.09 [M+H]+ 
EEEIDVV 1583.71 792.75 [M+2H]2+ , 1584.10 [M+H]+ 
EEIDVVS 1541.70 771.70 [M+2H]2+ , 1542.82 [M+H]+ 
EIDVVSV 1511.73 757.18 [M+2H]2+ , 1512.00 [M+H]+ 
IDVVSVE 1511.73 756.85 [M+2H]2+ , 1512.12 [M+H]+ 
DEEEIDVV 1698.74 850.69 [M+2H]2+ , 1700.10 [M+H]+ 
EEEIDVVS 1670.75 836.34 [M+2H]2+ , 1672.18 [M+H]+ 
EEIDVVSV 1640.77 821.23 [M+2H]2+ , 1641.11 [M+H]+ 
EIDVVSVE 1654.79 821.22 [M+2H]2+ , 798.49 [M+H]+ 
DEEEIDVVS 1785.77 893.82 [M+2H]2+ , 1787.21 [M+H]+ 
EEEIDVVSV 1769.81 885.74 [M+2H]2+  
EEIDVVSVE 1769.81 885.78 [M+2H]2+ 
EEEIDVVSVE 1898.86 950.38 [M+2H]2+ , 1899.17 [M+H]+ 
DEEEIDVVSV 1900.87 950.38 [M+2H]2+  













5.4.4. On Bead and Solution Phase Screening of SOBOC Peptides 
5.4.4.1. Screening of Cy5 Labelled WDR5 
Well 
contents 

























Figure 44 - Comparison of Cy5 labelled WDR5 and unlabelled WDR5 in on-bead binding assay. The 
Tetramethylrhodamine channel is excited at 561 nm, 1000 µW power, 200 ms exposure time, primary dichroic 
445/561/640, detection dichroic 568sp, filter 585/40. The Cy5 channel was excited at 640 nm, 500 µW power, 120 
ms exposure time, primary dichroic 445/561/640, detection dichroic 650sp, filter 690/70. The ligand (TMR 
labelled MYCIIIb peptide) concentration was 500 nM. 
Cy5 labelled and unlabelled WDR5 was incubated with filtered Ni-NTA agarose resin 
(Quiagen) in separate Eppendorf tubes. Beads were then washed with buffer and incubated 
with 500 nM TMR labelled MYCIIIb peptide and screened on an OPERA unit (Perkin Elmer). 
The results of this experiment showed that when the Cy5 labelled protein is isolated on-bead 




5.4.4.2. Screening of labelled peptides against unlabelled WDR5 
Due to the lack of binding seen in the Cy5-WDR5/MYC peptide preliminary experiment 
further screening experiments were carried out using unlabelled WDR5 protein. While this 
meant that a ratiometric measurement between protein and ligand was not possible, hits could 
still be ranked by the intensity of the rings. Ring fluorescence intensity being a function of the 
concentration of protein-ligand complex. 
 
Figure 45 - Mean ring fluorescence intensities of beads incubated with WDR5 and 500 nM of TMR labelled 
SOBOC peptides. TMR excited at 561 nm, 1000 µW power, 200 ms exposure time, primary dichroic 445/561/640, 
detection dichroic 568sp, filter 585/40 
Ni-NTA agarose resin beads (Quiagen) were incubated with 6xHIS WDR5, washed with 
buffer and the resin slurry split equally between 17 eppendorf tubes. To each of these 
Eppendorf tubes a labelled peptide in buffer was added (200 µl of 500 nM ligand), including 
control samples which contained TMR-N3 or buffer alone. Further control samples were made 
by incubating the Ni-NTA resin beads without 6xHIS WDR5 with each of the labelled test 
peptides. The results of the initial screen were analysed using Auer lab proprietary on-bead 
screening analysis software, BREAD (Bead Ring Evaluation and Analysis of Data). The 
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analysis showed that some peptides had marginally higher ring intensity than in their 
corresponding control wells. Specifically, peptide sequence EEEIDVV-DOA-PRA(TMR) was 
noted as having the highest mean intensity of all 7mer peptides screened, the shortest length 
of peptides screened. Control experiments showed that the peptides all give similar mean ring 
fluorescence intensity values when labelled peptides were incubated with Ni-NTA agarose 
resin in the absence of 6xHis-WDR5.  
 
Figure 46 - Control results. Labelled SOBOC peptides incubated with Ni-NTA agarose beads that had not been 
incubated with 6xHIS-WDR5. 
Although EEEIDVV-DOA-PRA(TMR) was seen to have a higher ring intensity compared to 
other peptides of the same length the intensity is remarkably low. The fluorescence intensity 
profiles of rings from the CONA screen were analysed using ImageJ software 




Figure 47 - Example bead profiles. Top - Full length MYC peptide shows a clear increase in fluorescence 
intensity at the edges of beads. Bottom - The bead profile of EEEIDVV shows no clear bead edge and a high 
background signal. 
Evaluating the ring intensity manually the ring intensity profile is extremely noisy, although 
looking at the bead image (Figure 47, left) the characteristic rings indicative of a binding event 
are visible, however the background signal is high. To investigate further the effects of varying 











5.4.4.3. Effects of Increasing Protein Concentration 
As the initial screening experiment suggested a very low affinity for some of the truncated 
peptides it was first decided to investigate the effects of increasing protein concentration. 
Increasing ligand concentration would require the introduction of a washing step to avoid 
increasing the background signal. If the binding interaction between the protein and the 
peptide was too weak then introducing a washing step could wash the ligand from the 
sample. 
 
Figure 48 - Effects of increasing concentration of 6xHis-WDR5. WDR5 beads were washed and incubated with 
500 nM EEEIDVV-DOA-PRA(TMR). Excess ligand was not washed away prior to imaging. TMR Imaging 
carried out as in section 5.4.4.2. LED channel: brightfield top illumination, 50 % LED, 200 ms exposure time, 
detection dichroic 650sp, filter 690/70. Details in section 9.3. 
Ni-NTA agarose resin aliquots (3 µl of 50 % slurry) were incubated with 2, 4, 10 and 20 µM of 
6xHIS-WDR5 (7 µl), washed with buffer. 500 nM of the TMR labelled EEEIDVV peptide (25 
µl) was added to the resin which was agitated and added to a 384 well glass bottom plate. At 
lower concentrations an increase in fluorescent ring intensity was seen. However increasing 
the intensity further led to an increase in ring thickness. 
5.4.4.4. Increasing ligand concentration 
Ni-NTA agarose resin aliquots (3 µl of 50 % slurry) were incubated with 2 µM of 6xHIS-WDR5 
(7 µl), washed with buffer. 500, 1000, 2000 and 4000 nM of the TMR labelled EEEIDVV peptide 
(25 µl) for 20 minutes. The resin was quickly washed and resuspended in buffer, as the ligand 
concentration would otherwise be extremely high. The resin was added to a 384 well glass 




Figure 49 - Effects of increasing ligand concentration in the on-bead screen. Beads were incubated with 2 µM 
WDR5 and washed prior to incubation with ligand solutions. After incubation with ligand resin was washed 
prior to imaging. Imaging parameters as described in section 5.4.4.3. 
Increasing ligand concentration was shown to lead to an increase in ring intensity. This 
suggests that the peptide EEEIDVV-DOA-PRA(TMR) binds to WDR5 in these on-bead assays. 
Figure 50 visualises this result as a plot, showing that the mean ring fluorescence intensity is 
concentration dependent. 
 





5.4.4.5. Control Experiments 
Due to the significantly increased concentration of ligand, controls were repeated to verify 
that any perceived binding interactions were not related to the TMR label portion of the ligand 
binding to WDR5 or either the peptide or label binding with the Ni-NTA agarose resin.  
 
Figure 51 - Results of control experiments using 4 µM ligand concentrations and 2 µM WDR5. Only the TMR-
labelled truncate is visually confirmed to show the characteristic binding rings. Screening parameters as in 
section 5.4.4.4. 
In the TMR channel only the well holding TMR labelled peptide and WDR5 incubated beads 
was shown to have a ring intensity. For comparison of intensities between samples see Figure 
52. 
 
Figure 52 - Results of numerical analysis of the on-bead control experiment. TMR labelled truncate peptide 
(EEEIDVVSVE) screened against 6xHIS-WDR5 immobilized on NI-NTA resin. 
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These controls showed very low signals for negative controls compared to the well containing 
the test truncate, EEEIDVV-DOA-PRA(TMR).  Control experiments all showed a low mean 
ring fluorescence intensity around 20 units, while EEEIDVV-DOA-PRA showed and intensity 
value 4 times higher.  
5.4.4.6. Planning of Flu Anisotropy Analysis of EEEIDVV-DOA-PRA(TMR) 
OriginLab version 9.0 was used to simulate a binding curve. The plot assumed a KD of 100 µM 
(an order of magnitude weaker than the literature affinity of the MYC MIIIb peptide12) and a 
ligand concentration of 50 nM. This was used to determine the range of concentrations of 
protein which should be used in a titration experiment. 
 
Figure 53 - Simulated curve for fluorescence anisotropy experiment. Assuming a KD of 100 µM and a ligand 












5.4.4.7. Fluorescence Anisotropy Analysis of EEEIDVV-DOA-PRA(TMR) 
 
 
Figure 54 - Plot of fluorescence anisotropy with increasing concentration of WDR5. 50 nM ligand concentration, 
slits: 4 and 6 nM. Windowed 200 µl quartz cuvette. 
KD determination was carried out in a 200 µl windowed cuvette with a starting volume of 175 
µl and ligand concentration of 50 nM. The end point was not reached at the concentration of 
protein titrated but was determined to be 0.14 by GraFit (Erithacus Software) software using 
Equation 15 in materials and methods. 
5.4.5. In-silico analysis of bottom binding interface of WDR5 
5.4.5.1. Results of OEDocking suite analysis of MYC peptide fragments 
(carried out by Steve Shave) 
Peptide fragments from literature structural data was used as input for FRED, scored by 










Table 17 - Results of docking fragments of MYC peptide with the bottom interface of WDR5.  Left: sorted by 
score. Right: Sorted by fragment length and score (lower values equate to higher predicted affinity). 
Sequence Chemgauss4 Score  Sequence Chemgauss4 Score 
IDVV -4.530  Length = 3 residues 
IDV -4.515  IDV -4.514 
IDVVS -3.695  DVV -2.690 




DVV -2.690  EEI 1.474 
EIDVVS -2.646  VSV 2.174 
VVS -2.490 
 
Length = 4 residues 
IDVVSV -2.481  IDVV -4.530 
DDVS -1.854  EIDV -3.466 
EIDVVSV -1.433  DVVS -1.854 




EEIDV -1.261  Length = 5 residues 
DVVSV -0.640  IDVVS -3.695 




EEIDVVSV 0.773  DVVSV -0.640 
EEI 1.474  Length = 6 residues 




EEID 2.237  EEIDVV -1.276 
   Length = 7 residues 
   
EIDVVSV -1.433 
   EEIDVVS -0.441 
   Length = 8 residues 
   EEIDVVSV 0.773 
 
The results of this docking exercise appears to favour shorter sequences, which is in 
opposition to the experimental data. However the central sequence IDV appears in the 





5.4.6. Results of Hotspot Determination by Hotpoint Server  
Table 18 - Output from the scoring of residues in the interaction interface by the hotpoint webserver17. Predicted 




Number Residue ID RelCompASA RelMonomerASA Potential Prediction 
WDR5 181 R 55.36 66.66 3.70 NH 
 223 S 3.12 7.96 14.51 NH 
 224 P 39.43 55.67 10.75 NH 
 225 N 6.61 49.19 12.91 NH 
 228 Y 13.78 33.89 28.33 H 
 240 L 0.00 5.55 62.96 H 
 249 L 44.77 53.34 26.90 NH 
 250 K 7.34 28.07 9.29 NH 
 266 F 7.83 11.10 38.86 H 
 268 V 30.03 44.61 14.34 NH 
 272 K 38.62 48.97 4.38 NH 
 288 L 0.43 14.56 38.85 H 
 289 Q 21.57 59.25 10.66 NH 
MYC 260 E 110.12 122.29 5.66 NH 
 261 E 83.11 98.75 3.45 NH 
 262 I 8.81 77.99 32.93 H 
 263 D 51.58 66.76 4.97 NH 
 264 V 1.21 86.70 40.24 H 
 265 V 40.41 79.82 12.24 NH 
 266 S 48.74 66.76 4.04 NH 
 267 V 87.06 134.50 8.65 NH 
 
Table 18 shows the predicted hotspot contributing residues for WDR5 and MYC based on the 
structural information from PDB entry 4Y7R. RelCompASA (relative complex accessible 
surface area) refers to the accessible surface area of the residue in complex. RelMonomerASA 
(relative monomer accessible surface area) refers to the accessible surface area of the residue 
when the protein exists out of complex. Prediction refers to non-hotspot (NH) or hotspot (H). 
The output of the hotspot determination agrees with the FRED docking that MYC residues 
I262 and V264 are key contributors to the WDR5-MYC interaction. Unsurprisingly it also 
suggests that residues on WDR5 that are near to these key MYC residues are also hotspots. 
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5.5. Discussion and Future Work 
5.5.1. Library synthesis 
This first synthesis of a scanning truncate library showed that the concept succeeds in 
producing all possible truncates in a timely fashion, 9 parallel reactions in place of 45, however 
due to time constraints the shorter peptides were not labelled or screened against WDR5. As 
length increased, purity decreased, an unfortunate result of the sum of multiple small 
impurities that were added during each coupling. However, these lower purities became of 
less relevance, as the truncated peptides were purified by preparative HPLC labelled. After 
the peptides were labelled a purification step was required prior to analysis and screening. A 
possible cause of the decreased purity is the removal of resin from each reaction vessel after 
an amino acid coupling step leading to discrepancies between the expected mass of resin in 
the sample. After each step the resin was dried via vacuum overnight to remove as much 
solvent as possible. The following day resin was weighed, an aliquot removed and the bulk 
of the resin weighed again in order to calculate the amounts of different reagents required for 
the next coupling. However, it is possible that the drying was not thorough enough and the 
resin was not completely dried prior to weighing. The inaccuracy between the weighed mass 
of the resin and actual mass due to the solvent would have led to the use of a larger 
equivalence of coupling reagents being used per coupling, this possibly led to the lower 
purities of longer peptides due to the accumulation of the effects of erroneous couplings. In a 
future experiment using this method of truncate synthesis it would be prudent to increase the 
drying time of the resin, use a more powerful vacuum or wash the resin with a more volatile 
solvent prior to drying. 
For comparison to this method of library synthesis quotes from peptide suppliers were 
gathered. Quotes were generally above £700 and had constraints on minimum peptide size 
and minimum number of peptides. For example, one supplier limited the minimum peptide 
length to 6 amino acid residues and a minimum of 24 peptides per order. However using MYC 
as an example removing all truncates smaller than 6 amino acid residues in length draws the 
total number of peptides to below 24. As discussed previously there is a great deal of evidence 
to suggest that motifs of 3 residues in size can be key contributors to interactions between 
proteins. Additionally, the synthesis method described in this chapter can be carried out by 
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any researcher with a basic knowledge of solid phase peptide synthesis and offers complete 
control over the range of truncate sizes incorporated into the library. 
5.5.1.1. Future Work 
Future work would be to validate the synthesis method further by applying the truncation 
method to other peptides against other targets. In the work carried out in this chapter only 
the minimum truncate length was considered, however the maximum length of the peptide 
truncates could also be incorporated into the synthesis. If a long sequence, for example 20 or 
more amino acid residues, was to be broken down using this method of truncation it would 
lead to over a hundred different truncates to synthesise, label and quality control. With the 
goal of this method to be the determination of a suitable starting point for further work many 
of the longer truncates would be of little use but their production would increase time and 
cost. In the experimental design section of this chapter the occurrence of different lengths of 
interaction motifs in nature was discussed (Figure 39), with motifs of a size 4 appearing the 
most frequently and the frequency decreasing greatly around 7-9 residues in length. Future 
truncation experiments could be made more efficiently by limiting the range of truncate sizes 
to a more pragmatic window, for example 3-9 amino acids in length. 
5.5.2. Screening experiments 
The control screens of Cy5 labelled WDR5 showed no binding to the full length peptide, 
despite the work undertaken to show that there should be no interference with the bottom 
interface site by a dye. A search of the literature shows that generally efforts to screen WDR5 
utilise a fluorescently labelled antibody as opposed to direct labelling of the protein. This 
could be an indication that other researchers have seen a similar result when trying to work 
with labelled WDR5. The bottom interface also has many lysine residues, making labelling 
with an activated ester unfavourable as labelling close to the binding interface may affect any 
binding interactions. While the screening methods described in this chapter allowed for a 
ranking of the truncates of the MYCIIIb peptide, the issues with labelling WDR5 are an 
important consideration for future work. For example, it would have made screening with the 
peptides unlabelled, bound on bead impossible. The use of fluorescently labelled antibodies 




Increasing the concentration of ligand or protein resulted in an increase in the ring 
fluorescence intensity. This allowed for the confirmation of the activity of a weak binder to 
WDR5 in the on-bead assay. Increasing the incubation concentration for protein loading above 
10 µM saw an increase in the internal fluorescence of the agarose resin during imaging. This 
indicates that the concentration of protein on the bead surface was increasing but that the 
ligand was diffusing further into the resin matrix. By comparison increasing the ligand 
concentration saw only an increase in ring intensity. When designing the experiment, a 
concern was that lower affinity binders would dissociate from WDR5 after washing, but this 
was proven not to be the case. 
The results of the on-bead truncate screen suggested that there was a significant decrease in 
affinity of the labelled truncates of a length shorter than 9 residues. The mean ring 
fluorescence intensity decreases as peptide truncate length decreases (Table 19). 
Table 19 - Labelled SOBOC peptide screening results sorted by mean fluorescence intensity (highest to lowest). 
Length Sequence Mean fluorescence intensity Standard Deviation 
11 DEEEIDVVSVE 287.846 92.467 
10 DEEEIDVVSV 135.988 47.434 
9 EEEIDVVSV 122.799 44.312 
9 EEIDVVSVE 110.397 37.035 
9 DEEEIDVVS 50.592 17.842 
10 EEEIDVVSVE 30.969 9.901 
8 EEIDVVSV 20.331 7.055 
8 DEEEIDVV 20.219 6.967 
8 EEEIDVVS 17.169 7.389 
7 EEEIDVV 16.595 5.539 
7 EIDVVSV 16.027 5.491 
8 EIDVVSVE 14.156 4.685 
7 DEEEIDV 14.014 4.934 
7 EEIDVVS 13.099 4.759 
7 IDVVSVE 10.408 4.084 
A notable unexpected result is the 10 amino acid peptide EEEIDVVSVE-DOA-PRA(TMR), 
despite only missing the N-terminal aspartic acid residue the mean bead ring fluorescence 
intensity is significantly lower than similar truncates. This could be an indication that some 
characteristic of the peptide is having a negative effect on its affinity, however the DOA spacer 
and TMR label does not appear to have such a large effect in any of the similar sized peptides. 
In these experiments it was found that truncates of a length of 7 amino acids were binding, 
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but weakly. However, when analysed, both numerically and by eye, the rings were not 
convincing, showing very weak brightness even compared to the control wells that contained 
beads with no WDR5 on bead. To clarify whether the result was evidence of a true binding 
interaction experiments varying the concentrations of the interaction partners was carried out. 
First the concentration of the protein incubated with the Ni-NTA resin was changed, this saw 
an increase of in the thickness of the rings. This suggests that rather than seeing an increase in 
the surface concentration of the protein on the bead the protein instead diffuses further into 
the resin. Next the concentration of the ligand was varied, increasing the concentration as high 
as 4mM and introducing a washing step. Initially there was concern that if the ligand is too 
weak a binder then after the washing step the protein-ligand complex would simply dissociate 
and there would be no visible binding of the ligand to the resin bound protein. Experimentally 
it was shown that this was not the case and rather that increasing ligand concentration led to 
increasing fluorescence intensity localised around the resin. The increased concentration of 
protein-ligand complex that gave the increased ring intensity is possibly a result of the high 
localised concentration of protein. As the ligand dissociates from the protein it is in an 
environment of high protein concentration and is more likely to bind to another protein. This 
is likely the same reason that His-tagged proteins remain bound to Ni-NTA resin after the 
repeated washing steps this screening protocol required. This experiment suggested that the 
interaction between the ligand and the protein was concentration dependent. To confirm this, 
the fluorescently labelled peptide was screened against WDR5 by fluorescence anisotropy. It 
was determined that the labelled truncate had an affinity of 96 µM to WDR5, for comparison 
the full length peptide was determined to have an affinity of 10 µM. Interestingly the sequence 
of the truncate is similar to a motif seen in several binders to the bottom interface of WDR5.12  
Table 20 - Example binders to the bottom interface of WDR5 and their binding motif. "IDVV" box in red, 
conserved negative residues in blue. 





While alanine scanning suggested that the IDVV sequence was mandatory for binding the 
negatively charged residues of the sequence, across several different proteins, N-terminal to 
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IDVV gives weight to the suggestion that they have an important role to play in the binding 
interaction. The fluorescently labelled truncates screened in this series of experiments were 
determined to have higher affinities when C-terminal residues were still present (Table 19). 
5.5.2.1. Future Work 
Future work using this bead based assay would likely involve screening a concentration 
matrix, varying the concentration of both ligand and protein. This would allow for a clearer 
characterisation of the method and what range of affinities is detectable using the method. 
Validating a 2 colour ratiometric measurement method would allow for the definitive ranking 
of peptides with respect to their affinities towards the target of the screen. In the case of WDR5 
this could possibly be achieved using labelled antibodies. Further investigation into the low 
affinity of EEEIDVVSVE-DOA-PRA(TMR) would be a necessary follow up experiment, either 
repeating the on-bead screening or taking it through to fluorescence anisotropy to verify that 
the affinity is as low as perceived in this initial screen and not due to some sort of error. 
Another possible follow up project to this work would be to use the truncate EEEIDVV as 
input into the MorPH process. First the software would use the known crystal structure of the 
MYC peptide as input. Alternatively, and ideally, a new crystal structure would be obtained 
with the help of a collaborator using the truncate to construct a co-crystal structure. It is 
possible that the truncate has a slightly different binding mode compared to the full length 
peptide. Next the MorPH software would replace single amino acids of the binding peptide 
with commercially available building blocks, docking them and ranking them based on their 
score in the docking experiment. Several peptides based on these suggestions would be 
synthesised and screened against WDR5. Ideally the process would be carried out in multiple 
iterations, the strongest binder from the initial series of MorPH peptides would be incubated 
with WDR5 for a crystal structure. This new structure would be used as input for another 
MorPH and lead to another set of suggestions from the software. This would be to offset the 
changes in backbone structure and possibly positioning in the binding interface by the new 
replacement residue. The sequence EEEIDVV-DOA-PRA(TMR) has been determined to have 
an affinity of 96 µM to WDR5 and could be used as a starting point for the MorPH process. 
Further characterisation of the MYC-WDR5 interaction could be carried out, primarily further 
screening of truncates. This would allow for a more thorough understanding of the 
contribution of residues to the interaction between the MYC sequence and WDR5. While 
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useful there is an argument to be made that testing smaller peptides is of limited value, as 
they will be expected to be of lower affinity of the peptides screened in this study. 
5.5.3. Analysis of the interaction interface 
The OEDocking suite and the Hotpoint online service were used to evaluate potential binding 
contributions of different residues of the MYC peptide. These different methods of predicting 
the contributions to a binding interaction were in agreement in their assessment of the WDR5-
MYC interaction.  
5.5.3.1. OEDocking Suite (FRED, scored by Chemgauss4) 
The FRED docking software was used to evaluate the expected affinities of the truncates 
produced by SOBOC. Interestingly the scoring algorithm determined that the sequence IDVV 
was the highest scoring out of all truncates. This is likely due to IDVV in the original sequence 
sitting deeper within the hydrophobic trench on the bottom interface of WDR5 than other 












Figure 55 - H2N-IDVV-CONH2 in the WDR5 binding interface. Top: viewing from the C-terminus of the IDVV 
peptide. Bottom: viewing from the N-terminus of IDVV 
Despite the binding interface being hydrophobic in nature the structural information available 
suggests that the backbone of the IDVV portion of the MYC MbIIIb peptide finds several 
possible polar contacts. ILE262 is predicted to interact with both its N and C terminal residues, 
both ASP263 and VAL264 are predicted to interact with the interface via their carbonyl 
groups. The residues ILE262 and VAL264 appear in all of the top 5 results scored using the 
Chemgauss4 algorithm. The results from Hotpoint are in agreement with the output from 








WDR5. The results of an alanine scan also suggested that IDVV was core to the interaction 
between MYC and WDR5. However, it also showed that alteration of any residues of the 
peptide has a negative impact on affinity, even in the cases of sidechains that appear to be 
pointing into solvent and contributing little to the interaction. Using Pymol to highlight 
predicted polar and hydrogen bonding interactions for the full length peptide shows that 
none of the polar side chains are predicted to interact with WDR5. Measuring the distance 
between the polar sidechains of the peptide and protein gives a distance of 4.5 Å or 4.4 Å 
between heavy atoms. At this distance it would suggest that the interactions between 
sidechains are weak (Figure 56). 
 
Figure 56 - Possible interactions between MYC GLU260 and WDR5 LYS250 (left), MYC GLU261 and WDR5 
GLN289 (centre), MYC VAL267 and WDR5 LYS227. 
While the conclusion that the core sequence of IDVV is at the heart of the interaction between 
these two binders is sound there are some notable anomalies in the data. The OED results also 
suggest that the full length peptide would be among the weaker binders to WDR5. Grouping 
the peptides by length and averaging their scores gives the full length peptide the worst 
overall average score (0.773), while on average fragments 5 amino acid residues in length 
have, on average, the best score (-2.269). 
Comparison between the labelled SOBOC peptides and the predictions from FRED is difficult 
due to the spread of data available, from both the screening results described in this chapter 













characterises fragments of between 11 and 7 residues in length from the sequence 
DEEEIDVVSVE, the structural data available is for the sequence EEIDVVSV. However, the 
residues that were left unassigned in the crystal data were likely omitted due to poor density, 
suggesting that they only weakly interact with WDR5. This is contrary to the results of the 
labelled SOBOC peptide screening result where the removal of C or N terminal residues saw 
a significant decrease in ring intensity. This could be due to the screened truncates of the MYC 
peptide being different to the unlabelled forms tested in the docking study, due to the 
presence of the DOA spacer and fluorescent label.  
5.5.3.2. Hotpoint 
Hotpoint is a web service that was developed specifically for the computational determination 
of hotspot residues in protein-protein interactions.17 While FRED scored fragments of the 
MYC peptide to allow for the evaluation of the binding interaction Hotpoint analyses 
individual contributions of residues on both sides of the WDR5-MYC interaction.  The 
analysis suggested that 262I and 264V of MYC are hot spots in the interactions. This is in 
agreement with the results from FRED and the OEDocking suite. FRED predicted that that 
IDV would be the highest ranking trimeric peptide, the sequence IDV also appears in each of 
the top 5 results as scored by FRED. The hotspot residues on the bottom interface of WDR5 
were determined to be 228Y, 240L, 266F and 288L. As hotspot residues these 4 are predicted 
to contribute more to the binding interaction than other residues. This suggests that the 
bottom of the hydrophobic interface contributes more to the binding interaction than 
anywhere else (Figure 57). When developing tool compounds targeting this interface this 
result would suggest that the compound should be designed with filling the bottom of the 




Figure 57 - Hotspot residues of the MYC-WDR5 interaction. Hotspot residues shown as sticks, MYC peptide is 
shown in cyan, WDR5 surface shown in white. Hotspot residues are shown in stick format. WDR5 hotspot 
residues are in green and labelled, MYC hotspot residues are in cyan. 
5.5.3.3. Future work 
The results of this in-silico portion of work suggested key residues on both sides of the MYC-
WDR5 interaction. Future work would be to investigate these hotspots for the targeting of the 
interaction. Both in-silico methods described in this chapter are in agreement that the bottom 
of the hydrophobic trench is a major contributor to the interaction, in vitro work suggests that 
the C-terminal acidic residues are also important to the interaction. These facts are of 
important consideration for the purposes of designing a tool compound for the probing of 
lower-face interactions of WDR5. If desired further information could be drawn from the 
investigation of other WDR5-bottom-interface binding interactions with KANSL2 and RbBP5. 
A similar analysis as carried out on the MYC MbIIb peptide could be carried out using known 
structural information on these interactions, however due to the similarities in sequence it is 




Figure 58 - WDR5 bottom-interface binding sequences of MYC (cyan), RbBP5 (magenta) and KANSL2 (green) 
constructed from the overlaying of PDB files 4Y7R, 2XL3 and 4CY1 respectively. 
Figure 58 shows that peptides based on both RbBP5 and KANSL2 bind, as expected, in the 
same manner as the MYC MbIIIb peptide and have similar sequences. It is therefore 
reasonable to assume that the contributions of residues towards these interactions is 














6. Synthesis of Peptides Developed with MorPH 
Software for the Targeting of Survivin 
6.1. Introduction 
This chapter documents work on the non-WD40 domain containing protein Survivin. The 
high value target Survivin was selected as a candidate for the peptidomimetic ‘MorPH’ 
procedure.  The results of this investigation will be described and its potential application in 
targeting the WD40 domain containing protein WDR5 is discussed. 
6.1.1. Survivin 
Survivin was discovered in 1997. Its initial discovery indicated that the protein was not 
present in healthy adult cells, only in cancer cells and embryonic cells.140 This initial discovery 
directed the future of Survivin research and its validation as a target. It was later determined 
that Survivin was not absent in healthy cells but instead highly regulated, expressed 
significantly more during the G2M phase of the cell cycle.141 In 2000 the crystal structure of 
Survivin was determined (PDB code: 1F3H), the work showed the protein to exist as a 
dimer.142 
Survivin is a part of the Chromosomal Passenger Complex (CPC). The CPC is made up of 4 
proteins: Survivin, Borealin, Aurora B kinase, and inner centromere protein (INCENP).  
Survivin and Borealin are responsible for the localisation of the CPC to kinetochores during 
mitosis. Aurora B kinase differentially phosphorylates components of the kinetochores in 
response of varying tension between the kinetochore and microtubules. Connecting these is 
the structural unit INCENP. At the N-terminus of INCENP are the localisation proteins 
Survivin and Borealin, at the C-terminus is Aurora B kinase. INCENP, Survivin and Borealin 
form a triple helical bundle, this bundle is required for the complex to bind to spindle and 
mid-body localisation. Shugoshin 1 (hSgo1) is known to bind to histone H2A when the histone 
is phosphorylated by the kinase Bub1, in turn hSgo1 is known to bind to Borealin. 
Interestingly a fragment of hSgo1, a peptide with the sequence AKER, was found to also bind 




Figure 59 - 3D structure of AKER peptide binding to Survivin from PDB 4A0I. The lysine residue of the 
sequence does not have density assigned and appears as an alanine. 
Survivin is also responsible for inhibition of apoptosis in healthy cells. During normal 
apoptosis caspases are responsible for the breaking down of cellular components. Caspases 3 
and 7 are activated at the end of both the intrinsic and extrinsic apoptosis pathways, their 
activation leading to cell death. Survivin’s antiapoptosis mechanism functions by inhibiting 
caspase 3 and 7, binding to them with nanomolar affinity.18 However this apoptosis inhibition 
is also responsible for securing the survival of cancer cells overexpressing Survivin.  
The protein is found in significantly higher concentrations in cancer cell lines. Out of the 
National Cancer Institute cancer cell lines Survivin was found in increased concentrations in 
all of 60 tested.21 Particularly high levels were found in lung and breast cancer cell lines. 
Increased Survivin expression has been linked to a poor prognosis and reduced patient 
survivability in the clinic.19, 20, 143-146 It was also determined that Survivin and another inhibitor 
of apoptosis; XIAP, are able to significantly reduce the rate of apoptosis in cells at elevated 
levels of expression.21  
The first Survivin interference compound was an oligonucleotide discovered in 1997.147 It was 
determined that the oligomer inhibited endogenous Survivin RNA expression in HeLa cells, 
inhibiting the expression of the protein. It was found that this interference saw an increase in 
apoptosis. Since this validation many more attempts at targeting Survivin, it’s interactions148 
or its expression.149  
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In 2007 a publication from Abbott Laboratories described a potential new small molecule 
binding site for Survivin, near to the dimerization site.150 This was an important development 
as previously only the binding site known on Survivin was the baculovirus inhibitor of 
apoptosis repeat (BIR) domain. Binders to the peptide binding site generally were shown to 
have a weak affinity. It was determined that this new site had a hit rate of 0.35% compared to 
a hit rate of 0.01% for the BIR domain by screening their libraries via NMR. Since identification 
of the dimer site, new small molecule binders to Survivin have been published.151 Binders to 
the site located near the dimer interface site were found to increase cell death and delay the 
cell cycle in concentrations in the nanomolar concentration range.150  
Referenced publications are indicative of the challenge and the value of targeting Survivin. 
The development of novel and tool binders to Survivin would allow for a better 
understanding of the roles it plays in a variety of cancers. In this chapter a novel in-silico 
technique and its application to Survivin will be discussed. 
6.1.2. MorPH – Software for the iterative optimisation of peptide 
binders 
The crystal structure of the AKER sequence of hSgo1 binding to the BIR domain of Survivin 
offers a valuable starting point for the development of a tool compound able to bind to 
Survivin to better establish the effects of chemical inhibition of the proteins interactions. 
Crystallographic data provides invaluable insight towards possible routes towards the 
development of a novel ligand, however given the number of commercially available building 
blocks that are available for use in Fmoc SPPS guidance towards the most promising routes 
of optimisation could save much time and effort. To this end, the in house proprietary peptide 
replacement software MorPH was developed by Steven Shave. MorPH takes an input 3D 
structure of a peptide and target protein and systematically replaces amino acids at each 
position of the peptide with commercially available building blocks, scores and ranks these 
replacements using a molecular force field. The current scoring process utilises the 





Figure 60 - Visualisation of MorPH Process. A 3D structure of a peptide-protein interaction is used as input 
(top). For each residue of the peptide MorPH docks and scores potential replacement residues. Example of 
isoleucine and glutamic acid residue replacements are shown in the yellow and orange boxes respectively. 
The process outputs a ranked list of top scoring amino acid replacement suggestions for each 
amino acid position, along with a predicted 3D structure which may be visualised in many 
molecular visualisation packages. Manual inspection is then a key step in shortlisting of 
potential building blocks at each position which can then be ordered for synthesis and 
screening.  When the best suggestion for a position is determined, the ideal next step would 
be co-crystallisation of the peptide with the protein. The structure would then be used for 
input for the MorPH process again. This will compensate for any changes in the peptide 
backbone structure that occur as a result of difficult to predict and model amino acid residue 
substitution or changes in the mode of binding. As well as potentially sequentially improving 
the affinity of a peptide one position at a time, the replacement of natural residues with non-
natural amino acids is expected to improve the stability of the peptide against peptidases. This 
is an important consideration for the purposes of cellular assays as peptides are highly 
susceptible to digestion, however non-natural residues will be less likely to be recognised by 
enzymes. To evaluate the MorPH process a series of peptides based on MorPH suggestions 
for the targeting of Survivin were to be synthesised. In order to conclude the project peptides 
representing the best replacements for each position were synthesised and characterised. The 
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MorPH process was then to be applied to the MYC-WDR5 interaction discussed in the 
previous chapter and the results interpreted. 
6.2. Aims 
To synthesise a set of example peptides based on MorPH suggestions for further testing. 
Testing includes affinity determination with Survivin and plasma stability characterisation. 
To apply the MorPH process to the MYC-WDR5 interaction and to determine potential 
replacement building blocks for a series of SAR syntheses. 
6.3. Results 
6.3.1. Peptide synthesis 
All peptides were synthesised using methods described in section 9.4. 
Table 21 - Results of the synthesis of TMR labelled example Survivin Morph Peptides 
 
Abu-K-E-R-DOA-PRA(TMR) 
Purity by HPLC: > 95 % 
MS results 
Mass of peptide: 1268.63,  
seen 1269.26 [M+H]+,  
and 635.29 [M+2H]2+ 
 
Abu-CarbPhe-E-R-DOA-PRA(TMR) 
Purity by HPLC: > 95 % 
MS results 
Mass of peptide: 1331.62.  
Seen 1331.21 [M+H]+  
and 666.44 [M+2H]2+ 
 
Table 21 summaries the results of the synthesis of 2 labelled example peptides synthesised for 
further characterisation using on-bead methods of peptide synthesis and labelling. In the 
experiments described in the following section another labelled peptide, A-K-E-R-DOA-
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PRA(TMR), is used in experiments. The peptide used was from a prior large scale synthesis 
carried out by Peter Dodd of the Auer lab.  
Table 22 - Results of the synthesis of unlabelled Survivin Morph example peptides 
 
A-K-E-R 
Purity by HPLC: > 95 % 
MS results 
Peptide mass: 501.59.  
Seen: 502.57 [M+H]+ 
 
Abu-K-E-R 
Purity by HPLC: > 95 % 
MS results 
Peptide mass: 515.62. 
Seen: 516.38 [M+H]+ 
 
Abu-CarbPhe-E-R 
Purity by HPLC: > 95 % 
MS results 
Peptide mass: 577.64.  
Seen: 578.55 [M+H]+ 
Table 22 summaries the results of the synthesis of 3 unlabelled example peptides synthesised 
for future planned experiments, primarily for use in competition experiments with their 
labelled counterparts and Survivin. 
For HPLC analysis the unlabelled peptides were characterised with their Fmoc protecting 
group left intact. This is due to the small, polar nature causing them to elute very quickly. 
Leaving the N-terminal Fmoc group significantly slows the elution of the peptide and allows 
for more accurate determination of purity. The unlabelled peptides did not require any 
purification after their cleavage from the resin other than the standard Fmoc protocol of 




6.3.2. Screening of labelled peptides against Survivin (carried out by Nhan 
Pham) 
Note that the peptides used for KD determination experiments were synthesised by Olivier 
Barbeau. Anisotropy was measured via 2D-FIDA with 2 nM labelled peptide concentrations, 
9 measurements per protein concentration. Curves were plotted using Equation 15 (materials 
and methods). 
 
Figure 61 - Results of 2D-FIDA anisotropy experiments screening labelled peptides against Survivin. 
These 2D-FIDA anisotropy experiments were carried out to compare the change in affinity as 
more of the natural sequence is replaced with the best-in-place suggestions from the MorPH 
software. The results suggest that as more of the peptide is replaced with the MorPH 
suggestions the KD decreases. 
[Survivin] uM

























Kd = 4.21 +/- 0.56 uM;
Abu-Cp-E-R-(TMR)
A-K-E-R-(TMR)
Kd = 3.03 +/- 0.43 uM;
Kd = 7.35 +/- 0.26 uM;
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6.3.3. Plasma Stability Analysis of MorPH Peptides (carried out by Nhan Pham) 
 
Figure 62 - Plot indicating the rate of degradation of AKER and MorPH suggested variants 
Peptides are naturally broken down very quickly under cellular conditions, analysis was 
carried out to characterise the effects of replacing natural residues with best-in-position 
suggestions from MorPH on the plasma stability of the peptides. Figure 62 shows that the 
stability of peptides containing non-natural residues is significantly improved over the 
natural sequence, AKER. This shows that the incorporation of non-natural amino acids into 
the sequence  
6.3.4. MorPH Suggestions for targeting the MYC-WDR5 interaction 
3D structural data of a peptide based on the WDR5 interaction sequence from MYC was used 
as input for MorPH. The structure was taken from PDB entry 4Y7R. The 3D structure included 
information on the residues EEIDVVSV of the peptide sequence DEEEIDVVSVE binding with 
the bottom interface of WDR5. MorPH output the top 500 scored conformations for each of 
the 8 positions of the peptide that had been assigned in the structure. These results are 


































6.4. Discussion and Future Work 
6.4.1. Survivin 
6.4.1.1. Survivin MORPH Peptide Synthesis and Screening 
The aim of this project was to synthesise and characterise peptides for the targeting of Survivin 
based on suggestions from MorPH software, in order to validate and evaluate MorPH as a 
tool prior to its utilisation against WDR5. Prior to the synthesis of the peptides described in 
this chapter many other derivatives were synthesised and characterised against Survivin, 
based on suggestions from MorPH. The peptides described in this chapter represent the best 
replacements for each position, determined by this prior work that was carried out by post-
doctoral researchers Olivier Barbeau and Peter Dodd. Peptides previously synthesised based 
on MorPH suggestions for the Survivin-hSgo1 interaction included suggestions for the two C-
terminal residues. These were tested and determined to have a detrimental effect on the 
affinity of the peptide. Therefore it was determined that the sequence H2N-Abu-CarbPhe-E-
R-CONH2 was the highest affinity binder based on suggestions from MorPH. This final 
peptide synthesised based on suggestions from MorPH was found to have a similar affinity 
to the input sequence but a significantly increased plasma stability. The plasma stability 
testing experiment indicated that with increasing substitutions of amino acid residues with 
non-natural suggestions stability increased. This was an expected result, increasing the 
proportion of non-natural amino acids moves the peptide further away, in terms of structural 
similarity, from naturally occurring peptides that are enzymatically digested in plasma. This 
increased plasma lifetime confirms that peptides constructed of non-natural amino acids are 
stable for use in cellular assays. In the case of studying Survivin this is an important 
consideration as Survivin has several vital roles in the cell cycle. A tool compound that is able 
to withstand longer incubations in cells could provide valuable information on the effects of 
inhibiting the interactions of Survivin over the course of the cell cycle. Overall this initial test 






Table 23 - Tabulated results of the affinities of MorPH suggested replacements. Kd determined by fluorescence 
anisotropy 
Peptide KD (µM) 
A-K-E-R-DOA-PRA(TMR) 7.35 ± 0.26 
Abu-K-E-R-DOA-PRA(TMR) 4.21 ± 0.56 
Abu-CarbPhe-E-R-DOA-PRA(TMR) 3.03 ± 0.43 
As the proportion of suggested residues increases the affinity increases (Table 23). The effects 
of replacing an alanine with and Abu saw a slight decrease in stability compared to the natural 
residue. Replacing the lysine with a carbamoylphenylalanine however significantly increases 
the stability. An increased plasma stability makes a compound much more appealing for use 
as a tool compound in cellular assays. Peptides have notoriously short lifetimes in cells and 
are usually quickly degraded by enzymes, as indicated by the rapid degradation of AKER-
DOA-PRA(TMR) in the stability testing experiment. Survivin is a protein that has roles at the 
heart of the cell cycle and cell death, should a tool compound be completely degraded after 
incubation for one hour the effects on the cell cycle will be very small compared to a 
compound with a longer lifetime. It could be assumed that by replacing the two unchanged 
C-terminal residues that stability could be further improved. However replacements for these 
positions were proven to reduce affinity. The 3D structural information for the AKER-
Survivin interaction suggests that the glutamic acid and arginine residues are both involved 
in strong electrostatic interactions via their sidechains. 
 
Figure 63 - Interactions of glutamic acid and arginine residues of the sequence AKER with Survivin. 
In this instance these residues have been determined to be invariable. The sidechains of both 
the glutamic acid and the arginine side chains are specifically positioned towards oppositely 
charged residues on the surface of Survivin. 
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6.4.2. WDR5 MorPH 
6.4.2.1. Suggestions for MYC-WDR5 interaction 
For each position the top 500 conformations and their Chemgauss4 score were output. In this 
section the commonly suggested motifs and suggestions that are thought to be of serious 
consideration for an SAR investigation are discussed. For reference the average Chemgauss4 
score for the natural peptide (sequence: H2N-EEIDVVSV-CO2H) was -0.5188. The scoring for 
each suggestion is relative to the position, values lower than -0.5188 are considered to have a 
higher affinity than the input sequence according to the Chemgauss4 scoring system. 
Position 1 – Glutamic Acid 
 
Figure 64 - Possible interaction between position 1 glutamic acid and LYS250 on WDR5 
Position 1 is naturally a glutamic acid residue, it is possible that a long range interaction is 
occurring between the amino acid side-chain and LYS250 of WDR5.  
Table 24 - Examples of MorPH suggestions for position 1 glutamic acid 
    
Replacement Phenyl pyrazine nitrile 






Figure 65 - Potential interactions of homotyrosine at position 1. 
A large portion of suggestions from MorPH include larger side chains that have the potential 
to reach for alternative interactions. Figure 65 above for example shows a homotyrosine, an 
example of the phenyl suggestions for the position. The alcohol of which could potentially 
donate a hydrogen bond with the backbone carbonyl of LEU249 (3.3 Å) or, less likely, CYS248 
(4.2 Å), however the phenyl ring itself does not appear to have any considerable contribution 
to the interaction, instead the ring is used to better position the alcohol. 
 
Figure 66 - (S)-2-Amino-5-(pyrazine-2-carboxamido)pentanoic acid suggested by MorPH for position 1 
(S)-2-Amino-5-(pyrazine-2-carboxamido)pentanoic acid is positioned to accept a hydrogen 
bond from LYS291 with a distance of 2.9 Å (Figure 66). This replacement was ranked 15th with 
a score of -1.574. 
For this position MorPH takes advantage of the charged residues surrounding the mostly 
hydrophobic protein-protein interaction interface. 
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Position 2 – Glutamic Acid 
 
Figure 67 - Glutamic acid residue from natural MYC sequence binding to the bottom interface of WDR5. 
As with the previous position the natural residue is predicted to be binding to WDR5 via an 
interaction with the charged residues around the hydrophobic trench. GLU2 from the MYC 
peptide appears as though able to bond with GLN289 in WDR5 (Figure 67). As with the 
previous position the distance is far (4.4 Å), making the interaction very weak. 
Table 25 - Example suggestions from MorPH for position 2 
 
 
     
Hydrophobic chains  amines and nitriles  Cyclohexane 
Length average score   suggestion average score   Suggestion average score 
Hexyl -0.655  nitrile -0.740  ethyl spacer -0.474 
Pentyl -0.826  amines -0.677  no spacer -0.463 
Butyl -0.815       
Propyl -0.512       
Ethyl -0.970       
methyl -1.214       
branched -0.696       
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MorPH suggested a broad selection of suggestions for the position (Table 25). The software 
suggested mostly hydrophobic replacements for the position, which naturally contains an 
acidic residue. Of the suggestions containing hydrocarbon chains there was a tendency 
towards shorter chains to be scored more favourably. A small number of nitriles and amines 
were suggested as polar replacements for the position, which naturally holds and acid. The 
distance between the suggested amines and any polar groups on WDR5 were generally large, 
reflected in the poorer scores for the replacements. 
Position 3 – Isoleucine 
 
Figure 68 - Natural residue 3ILE is oriented directly towards the bottom of the hydrophobic trench of the MYC 
binding interface on WDR5. 
Naturally an isoleucine residue points directly down into the hydrophobic base of the trench 
of WDR5. As expected MorPH outputs almost exclusively hydrophobic suggestions that aim 











Table 26 - Summary of three common motifs appearing in suggestions for position 3. 














average score -0.443 -0.570 -0.155 -0.394 
 
The majority of the best scored suggestions fall into 2 categories; long hydrocarbon chains 
across the bottom of the hydrophobic interface and a series of suggestions based on (3S)-3-
amino-5-methyl-2-oxo-6-phenyl-hexanoic acid (Figure 69).  
 
Figure 69 - Structure of the building block (3S)-3-amino-5-methyl-2-oxo-6-phenyl-hexanoic acid 
All variations of the structure that appear in the suggestions appear to have modifications at 
the para position of the ring. The majority of suggestions based on this structure are in the top 
10 % of suggestions for this position. The majority of suggestions could be classified as small 
hydrophobic suggestions. These suggestions generally were of a similar size to the isoleucine 
residue. It was established in the previous chapter that this position naturally contains a key 
residue in the MYC-WDR5 interaction. The predicted electron density for this core indicates 
that the residue is expected to fit the contours of the bottom interface. This series of 




Figure 70 - Visual representation of (3S)-3-amino-5-methyl-2-oxo-6-phenyl-hexanoic acid core interacting with 
a large portion of the bottom of the WDR5-MYC interface. Suggested peptide shown in blue, WDR5 shown in 
green. 
A small number of recommendations include charged groups. These generally did not score 
a well with the exception of 2-Amino-6-ureidohexanoic acid (ranked 10th for the position with 
a score of -0.394) that appears as though it may be able to interact with LYS245 of WDR5 
(distance of 3.3 Å).  
 





Position 4 – Aspartic acid 
 
Figure 72 - Position 4ASP appears to point directly away from the binding interface. 
The natural amino acid side chain at this position does not appear to directly interact with 
WDR5 according to the structural data available. MorPH failed to present many convincing 
suggestions for this position, however there were two suggestions of note.  
 
 
Figure 73 - Example position 4 suggestions from MorPH that are predicted to interact with LYS227 (left) or 
LYS272 (right). 
Small number of reasonable recommendations that pick up potential electrostatic interactions 
with WDR5, directed towards interaction with LYS227 (Figure 73, left) or LYS272 (Figure 73, 
right) on WDR5. 
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Position 5 – Valine 
 
Figure 74 - Residue 5VAL is oriented directly towards the hydrophobic trench in the MYC binding interface on 
WDR5. 
 In the natural sequence this valine residue is located towards the lowest section of the 
hydrophobic pocket. Reflecting this, the suggestions from MorPH are suggested due to their 
ability to fill the pocket. 
Table 27 - Suggestions for position 5VAL from MorPH. 
     
Suggestion Hexafluorovaline 4,4,4-trifluorovaline cyclopentylglycine 3-ethylnorvaline 
Score -1.206 -1.222 -0.734 -0.383 
 
Suggestions for position 3 (isoleucine) also appear to have been suggested for the purposes of 




Position 6 – Val 
 
Figure 75 - Natural residue 6VAL of the MYC peptide resides in a small hydrophobic cleft at the side of the 
binding interface on WDR5. 
While the previous valine pointed directly towards the bottom of the interaction interface this 
residue points towards the charged sides of the trench. MorPH takes advantage of this and 
suggests a number of replacements that may be able to interact with these charged residues, 
however hydrophobic replacements were generally better scored. 
Table 28 - Summary of suggestions from MorPH for position 6. 
    
Suggestion 
Small hydrophobic 




average score -1.049 -0.951 -1.088 
Significantly more small hydrophobic replacements were suggested by MorPH, generally 
they scored better than polar replacements but lower scored hydrophobic suggestions 
reduced the average. The two most notable polar suggestions are (S)-2-Amino-3-(2-




Figure 76 - The positioning of (S)-2-amino-3-(2-cyanophenyl)propanoic acid (left) and L-homolysine (right) in 
position 6 suggest possible interaction with the ε-amine of LYS272. 
Both of these suggestions appear to be possibly interacting with LYS272 of WDR5, their 
distance each being 2.8 Å from the amine of the residue. 
Position 7 – Serine 
 
The side chain of the serine residue of EEIDVVSV appears to only be involved in an 
intramolecular interaction with the aspartic acid. Suggestions from MorPH for this position 
were very similar. The majority of replacements suggested appear to have been suggested by 
MorPH because there was not a clear interaction to be targeted, the top 44 scored replacements 
contained only 4 different suggestions, alanine, serine, homoalanine and 2, 3-









Table 29 - 4 best scoring suggestions for position 7S, output from MorPH 
     




score -1.000 -0.626 -0.617 -0.611 
From the results of the alanine scan carried out on the peptide it is known that replacing the 
serine with an alanine increases the KD from 93 µM to 19 µM.12 MorPH ranking alanine and 
other small sidechains so highly for this position could be evidence that MorPH was not able 
to suggest any better replacements for this position. Looking at lower scored suggestions 
reveals other apparently reasonable replacements however. 
 
Figure 77 - Substituting serine with 2-amino-4-hydroxy-pentanoic acid at position 7 potentially allows for 
interaction with LYS227 on WDR5. 
The most notable suggestion from MorPH is shown above. 2-amino-4-hydroxy-pentanoic acid 
contains a slightly longer sidechain than the natural serine. A possible interaction with LYS227 
becomes available (distance of 2.9 Å) with this replacement, this suggestion was ranked 45th 
and scored -0.448. 
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Position 8 – Valine 
 
Figure 78 - Valine in the 8th position in the MYC peptide. Peptide is shown binding to the bottom interface of 
WDR5 
The valine at the C-terminus of the peptide for which structural data is available is at the edge 
of the bottom face of WDR5. The hydrophobic side chain is present slightly above the surface 
of WDR5. 
Table 30- Example suggestions for the replacement of 8VAL and their Chemgauss4 scores 
    
Suggestion homoglutamine Arginine Methly-lysine 
score -2.785 -1.793 -1.067 
 
Polar suggestions appeared to be focussed around interactions with the backbone carbonyl of 
ASN225. The amide containing homoglutamine suggestion for this position scored 








Table 31 - Examples of hydrophobic suggestions for position 8 from MorPH. 
    
suggestion Phenyl with linker short phenyl Hydrocarbon Chain 
score -2.785 -1.191 -1.234 
The larger hydrophobic suggestions are oriented in the same manner as the polar suggestions. 
These suggestions are pointed towards a separate potential binding interface on the bottom 
of WDR5. LYS227 points out of the bottom of WDR5, the sidechains of the best scoring 
building blocks wrap around this residue into a distinctly separate potential binding interface. 
 
Figure 79 - C-terminal modifications suggested by MorPH exploit a separate potential binding interface on the 
bottom interface of WDR5. 
6.4.2.2. Conclusions of MorPH Suggestions for the MYC-WDR5 interaction  
MorPH was used to determine possible suggestions for an SAR investigation for the iterative 
modification of the WDR5 binding sequence. While positions 4D and 7S on the MYC peptide 
proved difficult to replace generally each position was provided with several suggestions that 
are considered worthy of pursuing. Most notably the (3S)-3-amino-5-methyl-2-oxo-6-phenyl-
hexanoic acid based replacements for position 2 appeared ideal for filling the a large portion 
of the hydrophobic pocket on the bottom interface of WDR5. The scoring of MorPH appears 
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to favour alanine, with it appearing in the top 500 conformations for all positions and even 
being the highest scored for positions 1E, 2E and S7. As discussed in the previous chapter 
alanine scanning carried out experimentally on the peptide was demonstrated to reduce 
affinity,12 alanine would be omitted from any SAR synthesis for this reason. Alanine is likely 
scored favourably by Chemgauss4 as it is the smallest suggestion available. This could be 
interpreted as the software being unable to find what it considered a reasonable replacement 
for the position and instead gave a better score for the replacement least likely to have any 
negative consequences. The scores given by Chemgauss4 are best to be taken as a guideline 
used to rank suggestions. Manually checking the output one position at a time, as was carried 
out in this section, is necessary for the proper evaluation of suggestions from MorPH. 
Similarly any suggestion that is scored more favourably than the natural peptide will not 
necessarily be a higher affinity binder in vitro. For the MYC-WDR5 interaction MorPH offered 
some suggestions worthy of serious consideration for incorporation into the development of 
a modified MYC peptide consisting of non-natural amino acids. 
6.4.2.3. Future Work 
6.4.2.3.1. Survivin MorPH Peptides 
Further attempts to improve this example MorPH peptide could be undertaken, however as 
previously stated this would likely prove difficult. The next step would be to put the peptide 
into cellular assays to evaluate its efficacy, previously compounds screened against Survivin 
were found to increase cell death and delay the cell cycle.150 The Auer lab is equipped with a 
Laser-Enabled Analysis and Processing (LEAP) unit (Cyntellect, now Intrexon). The LEAP 
combines imaging (brightfield and multi-wavelength fluorescence) with laser manipulation 
of cells for the purpose of cell purification (destroying unwanted cells) and optoinjection. 
Optoinjection allows for the injection of compounds into cells by using short, intense pulses 
of laser light to create small pores on the surface of the cell. Given the increased plasma 
stability of the peptide a potential application of the MorPH peptide would be to use the LEAP 
to monitor the subcellular localisation of the labelled peptide in the cell. Different splice 
variants of Survivin have been found to localise in different parts of the cell.152 This method 
could be used to identify the differences in subcellular localisation in different cell lines. A 
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possible challenge in such an investigation however could be that the affinity of the labelled 
peptide to Survivin may be too low to see localisation of the peptide to Survivin. 
6.4.2.3.2. WDR5 MorPH 
In the previous chapter a peptide truncate library synthesis method was described that was 
designed with speed and efficiency in mind. This method was developed to probe interaction 
interfaces and determine the relative contributions of peptide residues. After determining the 
relative contributions of residues one of the truncated peptides could be used as a possible 
peptide starting point for an SAR investigation based on known protein-protein or peptide-
protein interactions. There is a clear synergy between these methods, rapid determination of 
a possible starting point for SAR and a tool to suggest possible replacements to guide SAR 
work. Future work could take advantage of both of these new methods to determine a series 
of potential novel binders to a protein target, potentially faster than a conventional approach. 
In the previous section an outline of potential amino acid replacements for the MYC peptide 
targeting WDR5 were described. The next step would be to select a position on the MYC 
peptide and to synthesise a series of peptides incorporating the suggestions from MorPH. The 
peptide containing the replacement with the highest affinity would be co-crystallised with 
WDR5 and the structure used as input for MorPH. This iterative process could be repeated 
until all positions have been optimised. If successful this method could develop a novel binder 
to the bottom interface of WDR5. 
6.4.3.  Discussion and Future Work Regarding MorPH Software 
As MorPH is still a new tool further work must be carried out to better understand its potential 
contributions to the ligand discovery process. Using MorPH to design more peptides for 
different targets and assessing how effective the suggestions are would be the most obvious 
choice of progression. An alternative method of characterising MorPH would be to take a 
series of published SAR results that used a peptide starting point and use the Chemgauss 4 to 
rank the different structures based on the predicted affinity. This result could be compared to 
the actual rankings of the published SAR data. This could be taken further and MorPH could 
be used to suggest possible replacements that were not included in the original SAR series. 
These novel suggestions could be synthesised and compared where they were expected to fit 
into the ranking according to MorPH. One possible candidate for this investigation would be 
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the SAR carried out on the top interface of WDR5 by Karatas et al.66 The publication uses a 
trimeric peptide as a starting point, this small peptide is ideal for rapid synthesis for 
assessment of peptides suggested by MorPH that were not included in the original SAR 
investigation. 
Regardless of the outcome further characterisation is important, if MorPH is shown to be 
unable to predict with any certainty the general rank of potential binders then the scoring 
method must be scrutinised. If MorPH is shown to be able to provide a ranking that is 
generally close to the results of the in vitro analysis then it could be accepted that, with further 
work, the method could be used as a tool to assist in SAR projects. It is highly unlikely to 
expect a result where software will be able to predict with perfect accuracy what alterations 
would see a significant increase in affinity, small changes in structure can sometimes have 
huge effects on affinity. However the method should be able to suggest what variety of 
replacement would have a positive or negative effect on affinity. The scoring of replacements 
is carried out using Chemgauss4. Should it be determined that MorPH is inaccurate in its 
evaluation of replacement residues the replacement or supplementation of Chemgauss4 with 
another method could be trialled. There are a large number of different docking and scoring 
software options that are available for this purpose.153 
One possible future application of MorPH would be to determine which replacements are 
frequently suggested to replace natural amino acid residues. This list of common suggestions 











7. Chemical Tools for Practical On-Bead Methods 
7.1. Introduction 
Solid phase peptide synthesis was pioneered by Merrifield in 1963 in the publication 
“Synthesis of a Tetrapeptide”.23 This development enabled researchers to synthesise peptides 
that do not express well in biological systems, including the incorporation of non-natural 
amino acids. A key advantage of solid phase synthesis is that the synthesis product remains 
attached to the resin after each reaction. To extend a peptide chain by a single amino acid 
residue two reactions are required, a deprotection followed by a coupling. In solution phase 
chemistry this would mean two potentially lengthy washing steps, however in solid phase 
each washing step takes only a few minutes of washing the resin with a suitable solvent. This 
powerful method has been adapted in a great number of ways to aid researchers in the 
synthesis of non-natural peptides, cyclic peptides, chemical tools and libraries of peptidic 
compounds.  
Solid phase synthesis utilises semi-porous polymer resin beads that are functionalised 
depending on their application. Most commonly resin will be amine functionalised for the 
purposes of peptide synthesis. To the resin a linker is usually attached, this linker will be 
chosen based on the final requirements of the synthesis product and will dictate the conditions 
under which the product will be released from the resin. Generally, the linker will also be 
amine functionalised for the attachment of the following building blocks. An acid containing 
building block is incubated with a base such as DIPEA and an activation agent such as HATU. 
This incubation rapidly forms the activated ester that will in turn rapidly react with any 
suitable nucleophile, such as an amine. 
HATU is used preferentially as an activation agent due to the favourable properties of the side 
products formed by coupling reaction, rapid reaction times and low levels of epimerisation. 
Following a successful coupling reaction, the resin is thoroughly washed and the attached 
building block is deprotected. The Fmoc protecting group has a high stability to the coupling 
conditions, however has a half-life of around 6 seconds in the presence of secondary amines 




The Fmoc deprotection is reliable the resulting fulvene unit is photodetectable, allowing for 
the reaction to be monitored. This pattern of acid activation and coupling of an Fmoc-amino 
protected amino acid followed by Fmoc deprotection is repeated to produce the desired 
peptide. By carrying out the synthesis on solid phase the product of each reaction is easily 
purified by thoroughly washing away the excess reagents and side products of the completed 
steps. A great advantage of the use of Fmoc solid phase synthesis is the variety of reagents 
that can be used in the format. Suppliers offer whole catalogues Fmoc-protected amino acids. 
The Auer lab has pioneered methods for the development of chemical libraries and their 
screening methods by using Fmoc synthesis methods.124, 132 Because of the focus on these 
methods it often becomes necessary to consider commonly used reagents used and how they 
can be improved.  
7.1.1. Tetramethylrhodamine 
The chemical label of choice used by the Auer lab is tetramethylrhodamine (TMR). 
Rhodamine dyes have several favourable qualities for a fluorescent label, including high 
photo-stability, high absorption coefficients and high quantum yields. Generally fluorescent 
labels are expensive to purchase due to the difficulty in their synthesis and purification. 
Several methods of synthesis have been published and carried out by the Auer lab, but as 




Figure 80 - General synthetic method towards rhodamines. 
Rhodamines were first developed in 1888 by Maurice Ceresole.155 Since the discovery most 
publications have focused on using some variation of the original process,156 despite 
disadvantages in the synthetic approach. The multistep synthesis requires hash conditions 
and produces a mixture of isomers in relatively low yields. The general synthetic route 
described in Figure 80 above begins with phthalic anhydride as a starting reagent with 2 
equivalents of dimethylaminophenol. Two Friedel-crafts electrophilic aromatic substitutions 
occur sequentially on the phthalic anhydride. The first substitution reaction results in 2 
possible benzephenone intermediates, these intermediates are reacted on by the second 
equivalent of dimethylaminophenol to give the two regioisomers that then must be separated. 
While the two isomers are very similar in both their structure and characteristics it is 
preferable to have the isomers separated. For example the isomers have different 
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electrophoretic mobilities157 and have been reported as having different activities in in vivo 
labelling experiments.158 Note that when referring to the TMR isomers the nomenclature is 
based on the spirolactone form (Figure 80), a tautomer that exists under basic conditions. The 
separation of the 5 and 6 isomers is the topic of several publications. Prior to this project the 
Auer lab used a synthetic method published by Kvatch et al. that relied on fractional 
crystalisation to isolate the intermediate regioisomers. Using this method, the group reported 
that the 5 and 6 isomers could be isolated in 10% and 16% yields with a remaining mixture of 
mixed isomers that could be further purified. The purified intermediates are then reacted on 
to provide isomerically pure rhodamine dyes, however the low yields and potentially lengthy 
crystalisation method are unfavourable in a larger scale synthesis. A novel synthetic route was 
suggested by Gemma Mudd of the Auer lab based on the avoidance of asymetrical anhydrides 
as starting reagents. This route would allow for the regioselective synthesis of rhodamine 
dyes, eliminating the requirement of a difficult purification step. The produced TMR is 
functionalised in the 6 and 5 positions with a carboxylic acid. Generally, for the purposes of 
on-bead labelling of reagents the method of choice is the copper catalysed azide-alkyne 
Huisgen cycloaddition click reaction (Figure 81) due to its specificity. This requires the TMR 
be azide functionalised.  
 
Figure 81 - Reaction scheme of the copper catalysed click reaction, used for the labelling of 
peptides in the Auer lab. 
Fortunately, the acid on the 5 or 6 position can be readily activated into an ester and reacted 
with a reagent that has the desired functional group and a primary amine. A reaction matrix 
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of different acid activating agents and reactions times were tested to determine the optimal 
conditions for the conversion of the TMR acid group to the desired azide. 
7.1.2. Methionine Linker 
The first step of any on-bead synthesis is the attachment of the first building block to the resin. 
Before this it is important to determine what method of attachment is best suited for this 
synthesis. The linkage to resin must be chemically selective, stable to all conditions that the 
resin will be subjected to but readily free the product of the chemical synthesis when desired. 
There is an extremely low tolerance for side reactions that would affect the purity of the final 

















































If the goal of an on-bead synthesis is to simply produce a peptide via Fmoc SPPS and cleave 
it from the resin Rink amide is the most commonly used linker. Rink amide cleaves under the 
same acidic conditions used to remove conventional sidechain protecting groups from amino 
acid building blocks. This allows for a single step cleavage and deprotection, the peptide can 
then be precipitated in cold ether. Alternatively, if the aim of the synthesis is to carry out on-
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bead screening, i.e. the product of the synthesis is to be left attached to the solid phase resin, 
the linker must be able to withstand the acidic conditions used to deprotect the amino acid 
sidechains. In this instance there are a number of alternative solid phase linkers that have been 
developed, each with associated advantages and disadvantages.  The linker of choice used by 
the Auer lab for on-bead screening is the Safety catch - acid labile linker (SCAL linker). Safety 
catch linkers require 2 reaction steps to cleave synthesis products from the resin, in this 
instance the SCAL linker requires that the sulphoxide groups are reduced the amide linkage 
becomes vulnerable to cleavage in acidic conditions. The specific requirements for cleavage 
mean that a wide variety of chemistries are tolerated, making the SCAL linker a valuable tool 
for on-bead synthesis. However the SCAL linker requires a multistep synthesis, despite the 
efforts carried out to optimise the synthetic route at the time of writing the synthesis stands at 
a 22% final yield over 11 steps. This is a serious issue for a core reagent that sees use for the 
in-house production of all on-bead libraries. Additionally the reduction reaction has been 
credited as an occasional source of impurities in the cleaved products. The use of 
trimethylsilylbromide in cleavage has been seen to produce a secondary product with a mass 
78 mass units higher than the product, corresponding with a bromination. With these issues 
in mind it was determined that a suitable replacement linker be found. As mentioned 
previously many potential linkers are described in the literature, however the use of 
methionine as a linker has several distinct advantages. 
Most laboratories that regularly carry out peptide synthesis will likely have methionine 
building blocks. Methionine is highly hydrophobic and most often found on the interior of 
proteins, this is favourable for the investigations of protein-protein interactions as methionine 
has a lower propensity to appear in an interaction sequence. If methionine is used as a linker 
it must be omitted from the sequence of any peptide synthesised on the linker. While not often 
described as a safety catch linker methionine requires very specific conditions to initiate 
cleavage. When a peptide containing a methionine residue is treated with cyanogen bromide 
(CNBr) under acidic conditions the methionine residue undergoes a cyclisation to form a 




Figure 82 - Mechanism of methionine linker cleavage and formation of the C-terminal homoserine lactone. 
This cyclisation separates everything N-terminal to the methionine peptide bond from the 
resin. The C-terminal lactone could be undesirable in the synthesis of some peptides, the 
structure is bulkier than the amide or amine C-terminus produced when cleaving from Rink 
amide or HMBA respectively. However, for the purpose of library synthesis for on-bead 
screening experiments or the synthesis of a C-terminally labelled peptide the structure of the 
C-terminus is irrelevant. In the instance of producing a library for on-bead screening cleavage 
is only carried out if a binding event is detected. The C-terminus is bound to the resin, the 
homoserine lactone is not formed and takes no part in the binding event. In the instance of the 
synthesis of a C-terminally labelled peptide the C-terminus and the attached fluorophore are 
separated from the rest of the peptide by a spacer to ensure that the label does not interfere 
with the binding of the peptide to the target. The Fmoc protected building block of choice 
used by the Auer lab as a spacer is Fmoc-8-amino-3,6-dioxaoctanoic acid (DOA). The structure 
is made up of polyethylene glycol (PEG) units, PEG units also make up a large portion of 




Figure 83 - The DOA spacer separates the peptide from the attachment point or label. This inhibits interference 
with binding to the target protein during screening. 
The DOA spacer unit keeps the synthesis product away from the resin bead and the 
fluorescent label (TMR in this example), ensuring the resin or label do not interfere with a 
binding interaction between the synthesis product and target protein. 
In this project the use of methionine as a solid phase synthesis linker is characterised with 
regards to its suitability with the common chemistries carried out in the Auer lab. To this end 
the methionine linker is compared directly to the SCAL linker, the current lab standard, with 
regards to the synthesis and cleavage of TMR labelled peptides.  
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Methods commonly used by the Auer lab often utilise expensive reagents. To combat the cost 
of carrying out work that is core to our discovery methods it is required that the methods of 
producing reagents or the selection of reagents be open to criticism and improvement. 
Tetramethylrhodamine is an expensive yet highly valued reagent for screening experiments, 
however published methods of rhodamine synthesis are generally time consuming and result 
in low yields. A new synthetic route to tetramethylrhodamine developed by the Auer lab aims 
to solve this issue. The novel synthetic route was to be exemplified as a rigorous, reproducible 
method. Following this the isomerically pure TMR was to be functionalised with an azide 
group for incorporation into the copper catalysed click reaction commonly used for the 
labelling of peptides. 
Solid phase synthesis methods are often used by the Auer lab to produce peptides, on-bead 
compound libraries and chemical tools. In these syntheses it is important to select an 
appropriate method of attachment to the solid phase. For the purposes of library production 
it is necessary to select a chemical linker that is resistant to the chemistries required to 
synthesise and deprotect the library without releasing the product in the absence of specific 
cleavage conditions. A variety of selectably cleavable linkers are available, however several 
publications have shown that the cheap amino acid building block methionine can be used as 
a chemical linker. The nature of methionine as a solid phase linker was to be characterised 




7.3.1. Synthesis of Tetramethylrhodamine-acid (6-isomer) 
 
Figure 84 - Scheme for the synthesis of TMR-OMe 
The use of 2-Formyl-4-methoxycarbonyl-benzoic acid as the reaction starting point in place of 
asymmetrical anhydride led to the isomerically pure synthesis of the TMR methyl ester in 
good yield HPLC analysis allows for the easy tracking of the progress of the reaction as peaks 
for the all intermediates resolve well and are identifiable. The methyl ester was purified by 
column chromatography (70 % yield).  
 
Figure 85 - Scheme for the synthesis of TMR-COOH 
The methyl ester was saponified to produce the free acid form of TMR which was then 
precipitated with HCl and the solution filtered after 3 days. No further purification was 





Figure 86 - H1 NMR analysis of TMR-COOH. All peaks are assigned, indicating the presence of a single 
regioisomer. 








7.3.2. Screening of reagents for amide coupling for azide 
functionalisation 
In order to monitor the coupling reaction by HPLC TMR-COOH and TMR-N3 standards were 
tested. 
 
Figure 87 - HPLC analysis of TMR-COOH and TMR-N3 
The analysis determined that the two forms of the dye resolved well with retention times of 
22 minutes and 24 minutes for TMR-COOH and TMR-N3 respectively. 
Having determined the retention time of the reaction product a matrix of reaction times and 
reagents was tested. TMR-COOH was incubated with the coupling reagents for 5 min before 
3-azidopropylamine was introduced to the reaction vessel. Reactions were monitored after 1, 
2, 4, 8 and 24 hour intervals. 
Table 33 - Results of time course testing of coupling reagents for amide coupling. 
 % Area of azide peak (HPLC, 555 FLD) 
Time 
(Hr) HATU DIC PyBop EDC TSTU 
1 68.62 28.02 6.46 16.32 25.06 
2 82.56 27.30 5.52 28.75 28.68 
4 82.36 28.55 9.47 34.07 28.51 
8 82.35 34.03 8.50 42.83 26.60 






































The product was purified by preparative HPLC yielding pure TMR-N3 (40 % yield). 
Over the course of this thesis the synthesis of both the TMR-COOH and TMR-N3 were 
repeated several times with reproducible results. 
 
 
Figure 88- H1 NMR analysis of TMR-N3 
7.3.3. Methionine linker cleavage method testing 
Testing of acid activating agents in the synthesis of TMR-N3. 
A test peptide TMR*-Ala-Met was synthesised on Tentagel NH2 resin. 4 known literature 
methods of methionine peptide bond cleavage were tested for single bead cleavage: 
Method A: 15 µl of 20 mg/ml CNBr in 0.1 M HCl, 16 hours.159  
 
Method B: 15 µl of 20 mg/ml CNBr in 70 % TFA, 30 % water, 16 hours.160 
 
Method C: 15 µl of 100 mg/ml CNBr in 70 % formic acid, 24 hours.161 
 




Methods were tested on 10 instances of single beads each. 
Table 34 - Results of HPLC analysis of methione linker cleavage methods A and B. 
Methionine Linker Cleavage Method A  Methionine Linker Cleavage Method B 
Sample  RT Area %area  Sample  RT Area %area 
1 20.295 4560.9 67.729  1 20.361 2563.3 93.560 
2 19.351 4093.7 70.769  2 20.257 2026.8 90.789 
3 19.651 6519.0 72.008  3 20.220 1196.4 92.046 
4 19.613 7114.7 68.541  4 18.596 1846.9 92.756 
5 19.836 5464.3 71.260  5 18.873 1678.3 90.404 
6 19.357 3692.2 66.296  6 19.269 2671.3 91.158 
7 19.743 4733.0 69.999  7 19.642 817.3 85.884 
8 19.840 4370.8 68.116  8 19.284 1481.8 90.128 
9 19.280 3212.6 67.052  9 19.599 2345.7 93.338 
10 19.579 6170.1 71.793  10 19.451 2911.0 93.203 
avg  19.655 4993.1 69.356  avg 19.555 1953.9 91.327 
stdev  0.301 1280.2 2.069  stdev 0.591 678.0 2.294 
         
Methionine Linker Cleavage Method C  Methionine Linker Cleavage Method D 
Sample  RT Area %area  Sample  RT Area %area 
1 19.914 5492.2 84.186  1 19.963 154.4 80.362 
2 20.128 5022.2 85.034  2 18.413 37.3 84.055 
3 19.498 6966.0 95.464  3 17.716 120.5 79.944 
4 18.988 8480.0 85.876  4 19.076 142.9 77.048 
5 19.717 8325.9 87.424  5 19.185 114.7 84.621 
6 19.403 8686.4 83.667  6 19.214 196.0 88.479 
7 18.783 6743.7 85.281  7 18.715 43.9 72.391 
8 19.117 9677.5 93.982  8 19.251 119.5 89.554 
9 19.001 6452.9 93.063  9 19.168 39.2 69.171 
10 21.022 6322.7 93.263  10 19.319 147.0 82.113 
avg 19.557 7217.0 88.724  avg 19.002 111.5 80.774 
stdev 0.673 1509.3 4.642  stdev 0.604 54.5 6.527 
 
Methods A and C released a higher concentration of material but analysis indicated 2 
fluorescently labelled products being released from the resin on cleavage. Analysis of the 
minor peaks by LCMS gave m/z values of 18 units higher. Method D released a very low 
concentration of fluorescent label from the resin in comparison to the other methods.  
Method B (15 µl of 20 mg/ml CNBr in 70 % TFA, 30 % water, 16 hours.) proved to be the 
method that provided the highest purity but with a lower cleavage efficiency compared to A 
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and C. Prioritising purity over quantity, method B was used as a starting template method 
from which reaction time and temperature were varied. For each set of conditions 10 
repetitions of 20 beads was tested. The resulting peptide was dissolved in 3 ml of water and 
the absorbance at 555 nm was recorded via cuvette. 
Table 35 - Results of varying reaction times and temperature, based on Method B of methionine linker cleavage. 
Method Average ABS (555nm) pmol/bead 
SCAL standard 0.3083 809.821 
2 hours, room temp 0.0488 128.196 
16 hours, room temp 0.1815 476.795 
40 hours, room temp 0.1187 311.821 
1 hour, 40 ºC 0.1782 468.126 
2 hours, 40 ºC 0.2296 603.152 
16 hours, 40 ºC 0.0839 220.403 
30 mg CNBr, 2 hours, 40 ºC 0.1974 518.564 
50 mg CNBr, 2 hours, 40 ºC 0.1484 389.842 
100 mg CNBr, 2 hours, 40 ºC 0.1212 318.389 
 
Table 35 shows that 2 hours at 40 °C releases the highest concentration of peptide. A sample 
of the same resin was used to synthesise the same test peptide on the SCAL linker. The 
standard linker cleaves with a higher efficiency compared to even the highest yielding 
methionine cleavage method. 
Having confirmed the best methionine cleavage conditions the new method was tested 
against the 20 natural amino acids coupled to methionine. This experiment aimed to test for 









Table 36 - Results of MS analysis of amino acids bound to the methionine linker and cleaved using the adjusted 
Method B. 
Amino acid Expected m/z Reported m/z Amino acid Expected m/z Reported m/z 
Ala 394.15 395.20 Cys 426.12 475.11 
Arg 480.22 480.47 Gly 380.14 381.06 
His 460.17 461.35 Pro 420.17 421.20 
Lys 452.21 452.35 Val 422.18 423.30 
Asp 438.14 439.17 Leu 436.20 437.26 
Glu 452.16 453.18 Ile 436.20 437.28 
Ser 410.15 411.09 Met - - 
Thr 424.16 425.08 Phe 470.18 471.25 
Asn 437.16 438.21 Tyr 486.18 487.24 
Gln 451.17 452.24 Trp 509.20 425.17 
 
The resulting masses indicate that the cleavage conditions generally leave the residues 
untouched with few exceptions. Notably the mass for tryptophan was lower than expected, 
the m/z matches the expected mass of the C-terminal amide form of the amino acid. Cysteine 
was also reported to have a significantly higher mass than expected. 
7.4. Discussion and Future Work 
7.4.1. The synthesis of TMR and azide functionalised TMR 
The aim of this project was to synthesise and purify TMR-COOH and TMR-N3 for use in 
common Auer lab processes. This goal was achieved through the application of a novel 
synthetic route towards xanthene cored dyes developed in the Auer lab. The novel synthetic 
route developed by Gemma Mudd was quickly adopted as the new lab standard for 
rhodamine synthesis. The method has been shown to reproducibly provide isomerically pure 
dye products and was used to produce all of the TMR labelled peptides that appear in this 
thesis. Since the publication of this method further improvements to the synthesis of TMR 




Figure 89 - Reaction scheme describing the synthesis of 6-TMR-COOH by Dwight et al. 
The article describes the method as being applicable to the synthesis of a variety of rhodamine 
and rosamine dyes at a gram scale level. This more recent method avoids the need to 
synthesise the acid via isolating and saponifying an intermediate methyl ester. Future efforts 
to synthesise rhodamine dyes would be best carried out trialling this one-pot method to 
compare the practical differences of the two methods. Between these two methods an 
investigation into the effects of different groups on the properties of rhodamine dyes. 
7.4.2. Methionine linker 
The use of methionine as a linker has been reported in literature to have been used for a variety 
of peptide synthesis projects with general success. This project aimed to specifically 
characterise and review the applicability of methionine as a linker for use in Auer lab on-bead 
synthesis projects. Of the 4 methods tested only 2 showed a reasonable degree of labelled 
product being freed from the resin on cleavage. Method A showed 2 TMR labelled cleavage 
products when tested by HPLC. LCMS analysis showed that the minor peak had an m/z 18 
higher than the expected main peak. This would suggest the addition of water to the structure, 
possibly indicating that the homoserine lactone has opened to form acid and alcohol groups.  
 
Figure 90 - Suggested structure of minor Method A HPLC peak. 
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Having 2 cleavage products can lead to confusion during analysis and therefore makes 
method A unacceptable for common use. Method B showed better purity but a weaker 
concentration of cleaved product. Variations of the method were tested in an attempt to 
improve the reaction. Through testing it has been shown that methionine, as expected, is inert 
to standard Fmoc solid phase peptide synthesis conditions.  The literature cleavage method 
was significantly shortened from 16 hours to 2 hours through heating, making the cleavage 
method much more appealing from a practical standpoint. Additionally, the testing of the 20 
natural amino acids showed that the CNBr containing cleavage conditions generally does not 
have an effect on the purity of peptides synthesised on the methionine linker with few 
exceptions. As expected testing of methionine led to multiple peaks in the analysis, however 
as mentioned previously methionine is generally excluded from library synthesis. The 
cysteine containing test peptide was reported as having a higher mass than expected. 
 
Figure 91 - Scheme of possible bromination of cysteine by CNBr. 
Figure 91 offers a possible explanation for the difference in mass. In Figure 82 the mechanism 
of the methionine linker requires the attack by the sulphur atom to the cyanide group. It is 
feasible that the thiol of cysteine acts in a similar manner, attacking the cyanide group and 
forming a thiocyanate. A bromide ion can then attack and displace the thiocyanate ion. 
Cysteine is omitted as a building block in library synthesis because of its reactivity, its 
incompatibility with the methionine linker cleavage method is not expected to be a significant 
hindrance in its expected applications. The lower mass of the tryptophan containing peptide 
corresponds with the expected mass of the peptide with a C-terminal amide as opposed to the 




Figure 92 - Structures and masses of Fmoc-tryptophan-M* and Fmoc-trptophan-CONH2 where M* denotes the 
homoserine lactone formed by methionine linker cleavage. 
A search of the literature finds that CNBr is used in peptide fragmentation at tryptophan 
residues, however the reagents used suggest that the mechanism requires that the tryptophan 
residues are oxidised for the cleavage to occur.162 A microwave method for the cleavage of the 
methionine linker has been reported that oxidation of the tryptophan residue was avoided by 
carrying out the reaction under argon.163 This adjustment to the method would be simple 
enough to integrate when working with tryptophan containing peptides.  
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7.4.2.1. Future Work 
In the future the Auer lab could consider trialling microwave synthesis methods, they are well 
documented in their application towards peptide synthesis. Microwave irradiation has also 
been applied for linker cleavage. Generally, it is accepted that microwave irradiation is an 
effective method for significantly reducing the reaction times for Fmoc deprotections, 
building block couplings and cleavage reactions.164 Microwave-assisted methods also exist for 
the synthesis of Peptoids (peptides where the R groups are shifted to the nitrogen of the 
backbone)165 and for disulphide bonding for application in the synthesis of cyclic peptides166  
This characterisation project has shown that methionine could be used as a potential 
alternative to other, more expensive linkers for the purposes of solid phase synthesis of 
chemical tools or libraries. Given the harsh cleavage conditions it would likely be a reasonable 


















8. Closing Discussion and Future Work 
8.1. WD40 Domain Containing Protein Database and 
Target Selection 
The first piece of work carried out for this thesis was an exercise in information gathering. 
Collecting data on WD40 domain containing proteins; their structures and their roles in health 
and disease. This piece of work became an ongoing effort to catalogue all human WD40 
domain containing proteins. Through this effort the roles of WD40 domains in nature quickly 
became clear, WD40 domains are important scaffolds on which protein complexes are formed. 
Despite having a common structural motif and similar roles different WD40 domains are 
highly specific in their binding to interaction partners. By investigating the different pathways 
and interactions WD40 domain were involved in several WD40 domain containing proteins 
were determined to be promising as research targets. WDR5 stood out as a high value, priority 
target largely due to the large of literature available on the interactions of WDR5 and roles 
that the complexes it forms play in cancer. 
 
Figure 93 - number of publications containing "WDR5" per year, 2006-2016. 
As the research described in this thesis continued the number of publications on the topic of 
WDR5 began to increase (Error! Reference source not found.), validating WDR5 as a target a
nd offering valuable input for in-silico techniques in the form of protein structures and known 
binders. However, while research on WDR5 became more and more prevalent in the 
literature, other WD40 domain containing proteins that could be of interest remain neglected. 
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For example the protein WD40 domain containing protein 39 (WDR39, also known as Ciao1) 
is known to bind to Wilms Tumour suppressor protein 1 (WT1). The binding of WDR39 to 
WT1 is known to modulate its anticancer activity.167 In comparison to WDR5 which has had 
hundreds of papers in the past decade WDR39 has only 64. With 283 different WD40 domain 
containing proteins WDR39 is just one example of many different potentially interesting 
research targets. Database currently holds information on all human WD40 domain 
containing proteins. The data collected shows that only a small number of WD40 domain 
containing proteins have known inhibitors and some even have very limited information 
available with regards to their role in human biology.  
In summary the data collection exercise successfully determined several potentially 
interesting targets to focus research interests on. Through further research it was determined 
that WDR5 would offer the highest potential out of the shortlist of proteins. In future work 
the compiled information could be used to find other WD40 domain containing proteins that 
could be targeted for the modulation of different pathways. 
8.2. Targeting of WDR5 via In-silico Techniques 
Two in-silico techniques were used to determine a short list of potential binders to WDR5. 
The first of these methods was a structure-based virtual screening platform named Q-mol, 
developed by Anton Cheltsov. Q-mol determined possible binding sites on WDR5, through 
conformer exploration and molecular dynamics. The binding sites identified by Q-mol also 
included known protein-protein interaction sites on the top and bottom interface. Anton 
Cheltsov, using Q-mol, then docked the NCI compound library against these sites and 
determined several potential binders to these pockets. These compounds were screened 
against WDR5 in TDA and of the 66 compounds, one was determined to stabilise WDR5 in 
the assay.  This compound, NCI292249, was further characterised by microdialysis where it 
was determined to have a KD of 564 µM to WDR5. However, the control experiment with BSA 
showed a similar affinity (452 µM), suggesting that the compound binds non-specifically to 
protein. The second in-silico method used was USRCAT, a molecular similarity technique. 
Molecular similarity compares descriptions of compounds as opposed to structures. This 
allowed for the comparison of known binders to WDR5 to compounds available from our 
collaboration partner Vichem, who do not divulge the structures of compounds in their 
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libraries. USRCAT determined several compounds that had similar molecular descriptions to 
known binders to WDR5, the top 15 of which were screened in TDA against the target. In 
screening none of the compounds were determined to have a stabilising effect on WDR5. The 
results of this screening effort highlight the difficulties in determining a binder to protein-
protein interaction targets. The hurdle of determining a starting point from which an 
optimised binder can be developed proved to be difficult to overcome through small molecule 
screening without screening a large number of compounds. Further work could possibly be 
carried out where In-silico techniques are used to target WDR5, however a different library of 
small molecules could be docked against the target. 
8.3. SOBOC and MORPH  
Rather than continue investing in small molecule screening efforts it was decided that efforts 
should be focused on investigating the known interactions of WDR5 and to use these as 
starting points. The top interface of WDR5 has been targeted by Karatas et al.66 through the 
development of a binder based on natural interactions at this site, this inspired the targeting 
the bottom interface (The MYC-interacting interface) in the same manner. The bottom 
interface has structural information available for a number of interactions, however a 
publication by Thomas et.al12 had begun probing the contribution of residues through alanine 
scanning of residues of a peptide sequence conserved in all MYC proteins known in interact 
with WDR5. This sequence is known as the MYCIIIb sequence.15 In an effort to build on this 
research it was determined that the next logical step would be to screen fragments of the 
MYCIIIb peptide. In parallel with this MorPH software had been developed and trialled 
against Survivin. During the course of the work to develop MorPH peptides there was 
discussion on how to best determine what stretch of a long peptide would be best to use as 
input for a MorPH guided SAR investigation. By synthesising fragments of a known peptide 
binder we could investigate the contributions of different residues to the MYC-WDR5 
interaction and also determine a possible starting point for a MorPH guided SAR project. 
However the synthetic effort of manually synthesising 45 individual peptides in separate 
syntheses seemed inefficient. Fmoc solid phase peptide synthesis produces all N-terminal 
truncates in the course of the synthesis of a full length peptide. These truncates are easily 
isolated by removing a sample of resin from the reaction vessel after each amino acid is 
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coupled. By synthesising a series of C-terminal truncates using Fmoc chemistry and isolating 
each N-terminal truncate as they were produced the synthesis was made significantly and 
faster. These peptides were then labelled and screened against WDR5 in an on-bead screening 
format. The original plan was to use labelled WDR5 and labelled peptides in a 2 colour screen 
to allow for an accurate ranking of the peptide fragments. It was however determined that 
chemical labelling of WDR5 is not tolerated. A search of the literature shows that other screens 
involving WDR5 have been carried out using fluorescently labelled antibodies as opposed to 
chemical labelling or fluorescent-protein conjugates. While this was not an ideal outcome the 
screening was carried out using unlabelled WDR5 but still allowed for the ranking of hits via 
the ring intensity of labelled peptides. The data produced from this screen allowed for the 
evaluation of the contributions of amino acids to the MYC-WDR5 interaction. A previously 
published alanine scan of the WDR5 binding sequence from MYC found that the “IDVV box” 
of the sequence was the key contributor, and that the replacement of other residues had a 
comparable effect, suggesting that all other residues contribute almost equally. The in-silico 
work carried out to supplement this investigation suggested that the IDVV sequence is also 
at the heart of the MYC-WDR5 interaction. However the results of this investigation suggested 
that the acidic residues N-terminal to the IDVV box are also important contributors to the 
interaction. This theory is reinforced by comparing to the sequences of other binders to the 
bottom interface of WDR5, such as RBBP5. These other binders also have an IDVV box with 
N-terminal acidic residues. Through this screen it was determined that the sequence 
EEEIDVV was the highest affinity out of fragments of a size of 7 amino acids. This peptide 
was carried through to solution phase characterisation using fluorescence anisotropy. The 
peptide was found to have a KD of 93 µM, the literature affinity of the full length peptide 
(DEEEIDVVSVE) is 10 µM.168 The truncated peptide was considered to be a reasonable 
starting point for an SAR investigation, as further removal of residues would almost certainly 
lead to a further decrease of affinity. MorPH software was utilised to determine possible 
replacements for the natural residues in the WDR5 interaction sequence from MYC. At the 
time MorPH had been undergoing testing using the protein Survivin as a target. The best 
amino acid replacements for each position had already been determined, a final resynthesis 
of exemplar peptides was required to show the effects of iterative replacement of amino acid 
residues with non-natural replacements from MorPH. It was shown that overall there was an 
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increase in affinity from using suggestions from MorPH, increasing the affinity from 7.35 µM 
to 3.03 µM. Plasma stability was also increased, significantly in the case of abu-CarbPhe-E-R. 
This was a promising result for the first trial of MorPH and encouraged its application 
towards developing a novel tool compound for the WDR5-MYC interaction. Evaluation of the 
suggestions from MorPH for the WDR5 interaction sequence from MYC resulted in the 
determination of several promising replacements. This acts as an outline for a possible future 
SAR project for the targeting of WDR5, which would also allow for further evaluation of 
MorPH. 
8.4. Characterisation of Methionine as a Solid Phase Linker and 
Synthesis of TMR-N3 
Finally, in chapter 7, two research outputs were described. The first was a contribution 
towards the determination towards a novel synthetic route to rhodamine dyes. This synthetic 
route was the outcome from the efforts from several chemists in the research group, the 
resulting product is used in the majority of screening experiments in the lab. Functionalisation 
with an azide group allows for the incorporation of the dye in the azide-alkyne Huisgen 
cycloaddition reaction,27 as was the case with the labelling of the peptides synthesised for the 
SOBOC project. The second project was the characterisation of methionine as a linker in solid 
phase peptide library synthesis. The use of methionine as a linker has been described in 
literature, however several different cleavage conditions are also described. At the time there 
was a need for the testing of a different linker suitable for solid phase library synthesis that 
would allow for selective cleavage from resin. The current lab standard required a synthesis 
that was 11 steps long and gave a 22 % yield. Methionine by comparison is commonly 
available from suppliers as an Fmoc protected peptide synthesis building block. Several 
cleavage methods for the methionine linker were tested, the method that resulted in the 
highest purity was used as a starting point and further improved. This final method was then 
tested against the 20 natural amino acids to verify if any undesirable side reactions were likely 
to occur. As expected methionine and cysteine did not tolerate the cleavage conditions, 
tryptophan was also noted to have an unexpected side reaction during cleavage. The final 
cleavage conditions are harsh however, future investigations into possible variations on these 
conditions could allow for the preservation of tryptophan but likely at the cost of yield.  
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9. Materials and Methods 
9.1. General Methods 
NMR Analysis 
1H NMR spectra were recorded on a Bruker AVA500 (500 MHz), Bruker Pro500 (500 MHz), 
Bruker AVA600 (600 MHz) or a Bruker AVA400 (400 MHz) spectrometer.  Chemical shifts (δ) 
are quoted in parts per million (ppm) downfield of tetramethylsilane, using residual 
protonated solvent as internal standard (CDCl3 at 7.27 ppm). Abbreviations used in the 
description of resonances are: s (singlet), d (doublet), t (triplet), q, (quartet), app (apparent), 
br (broad). Coupling constants (J) are quoted to the nearest 0.1 Hz. Proton-decoupled 13C NMR 
spectra were recorded on a Bruker AV500 (125.8 MHz) spectrometer or a Bruker AVA400 
(100.6 MHz) spectrometer. Chemical shifts (δ) are quoted in parts per million (ppm) downfield 
of tetramethylsilane, using deuterated solvent as internal standard (CDCl3 at 77.0 ppm). 
HPLC-MS Analysis 
Samples were analysed on an HPLC-ESI-MS system consisting of a Finnigan Deka XP Plus 
ESI-MS detector connected to an Agilent 1100 capillary LC with a (G1376A) capillary pump, 
a (G1377A) Micro-autosampler and a (G1325B) DAD detector with micro flow cell. The system 
was run with a spray voltage of 5 kV, capillary temperature of 275 °C, a capillary voltage of 
15 V in single MS mode. The LC-system contained a Zorbax-SB-C18 0.5x35mm 3.5 μm particle 
size column and was run with a gradient of solvent A: H2O containing 0.1% trifluoracetic acid 
(TFA) and B: MeCN (LCMS grade) containing 0.1% TFA. Standard Gradient: 2.5 min 0% B, 
22.5 min 0 - 100% B, 25 min 100 - 0% B, 28 min 0% B at a flow rate of 200 μl/min. HPLC-ESI-
MS data were processed using the Xcalibur software package (version 2.0, Thermo Electron 
Corporation, MA, USA). 
HPLC analysis 
HPLC analysis was performed on an Agilent 1100 series HPLC system, consisting of a 
quaternary pump (G1311A), a degasser (G1322A), an FLD detector (G1321A), a DAD detector 
(G1315B) and a 100 sample well plate autosampler (G1367A); columns: Agilent Zorbax C18 
Vydac peptide C18, 4.6 mm x 150 mm, 3.5 μm particle diameter size for peptide and small 
molecule analysis. Vydac C4 for protein analysis. Analyses were performed using a linear 
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gradient of A: H2O containing 0.1% TFA and B: MeCN (HPLC grade) containing 0.1% TFA 
with a flow rate of 0.8 mL/min, Retention times (tR) are denoted in minutes. All analyses use 
standard gradient unless stated otherwise. Buffers: A: water + 0.1 % TFA, B: acetonitrile + 0.1 
% TFA. Standard gradient: 5 min 5% B, 25 min 5 – 95% B, 27.5 min 95 – 5% B, 30 min 5% B. 
Plasma Stability Gradient: 11 min 5 - 90 %, 5 min 90 % B, 3 min 90 – 5 % B, 3 min 5 % B.  
Semi-Preparative HPLC Purification 
Purification of labelled peptides and mg quantities of dyes was carried out using a preparative 
HPLC system (Agilent 1100 prep-HPLC system), equipped with a preparative autosampler 
(G2260A), preparative scale pumps (G1361A), a fraction collector (G1364B-prep) and a 
multiwavelength UV detector (G13658 MWD with preparative flow cell). Material was 
separated at a flow rate of 20 mL/min on an Agilent RP-C-18 column (21.2 x 150 mm, 10 μm 
particle size), using a H2O/MeCN gradient. Solvent A: H2O, 0.1% TFA; solvent B: MeCN, 0.1% 
TFA. The size of collected fractions was varied for each purification. 
9.2. Small molecule screening methods 
Expression, purification and characterisation of 6xHis-WDR5 
Plasmid was prepared by Kris Wilson via a miniprep of Top10 cell stock from Addgene 
(Structural Genomics Consortium clone: WDR5 (2H9L)). 20 µl of chemically competent BL21 
cell stock was incubated with 1 µl of 6xHis WDR5 pet28a plasmid for 10 minutes on ice. Cells 
were heat shocked at 42 °C for 30 seconds before being cooled on ice for a further 20 minutes. 
350 µl of LB broth was added to the cells. Cells were incubated at 180 rpm, 37 °C for 1 hour 
(Infors-HT shaker unit). 200 µl of the cell culture was plated onto a 50 µg/ml kanamycin LB 
agar plate and incubated for 16 hours at 37 °C. 
A culture from the overnight plate was added to 20 ml 2xTY nutrient broth with 50 µg/ml 
kanamycin. Culture was incubated at 37 °C, 180 rpm for 16 hours. Culture was scaled up to 
1000 ml and incubated for a further 2 hours at 37 °C before the temperature was reduced to 
16 °C for 5 hours. Expression was induced with 1 mM IPTG, the culture was incubated for a 
further 16 hours. Culture was centrifuged at 5000 rcf for 20 minutes (Sorvall RC 5C Plus). Cell 
pellets were suspended in 40 ml of buffer (20 mM imidazole, 50 mM Phosphate, 300 mM NaCl, 
pH 7.50) with 1mg/ml lysozyme and 1 tablet of cOmpleteTM protease inhibitor. The lysis 
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solution was stored on ice for 20 minutes. The lysis solution was sonicated (Sonics VibraCell 
CV18) 2x1 min, 10 seconds of 50% amplitude, 10 seconds off. The resulting lysate was 
centrifuged to remove cell debris (5000 RCF, 20 minutes). The lysate was incubated for 2 hours 
with washed Ni-NTA agarose resin beads (Quiagen) from 2 ml of 50 % slurry. Resin was 
isolated from the lysate via centrifugation (5 min at 800 RCF), the resin was transferred to a 
sintered column and washed with buffer containing 40 mM imidazole, WDR5 was eluted with 
buffer containing 250 mM imidazole. The fractions were analysed by SDS-PAGE. SDS-PAGE 
was carried out with Invitrogen Bolt 12 % gels, samples were incubated with Bolt LDS sample 
buffers at 72 °C, shaken at 500 rpm for 12 minutes prior to loading onto gel. Seeblue Plus2 
prestained standard was also loaded onto gels for evaluation of the molecular weight of the 
protein content of the samples. Electrophoresis was carried out at 200 V for 32 minutes. After 
electrophoresis gels were washed with distilled water and stained with SimplyBlue safestain 
overnight. The following day excess stain was removed and the gels washed with distilled 
water. Fractions containing significantly higher proportions of WDR5 were combined and 
concentrated via a 15000 dalton spin column to a volume (Sartorious Vivaspin filter) of <500 
µl. The concentrated solution was injected into an AKTA protein purification system directly 
into the injection valve connected to a 1 ml superloop. Protein was purified by a superdex 200 
size exclusion column (Amersham Biosciences) connected to the AKTA protein purification 
system. The mobile phase was 20 mM HEPES, 250 mM salt, pH 7.00 with a flowrate of 0.5 
ml/min. Collected fractions were 0.5 ml in volume. 
Fractions containing WDR5 combined, determined by AKTA Unicorn software and SDS-
PAGE. Combined fractions were concentrated and characterised by SDS-PAGE and reverse-
phase HPLC (C4 column). Repeat expressions of 6xHis WDR5 used a glycerol stock from the 
initial expression that was stored at -80 °C. On average expression produced 5.5 mg of 6xHIS-
WDR5. 
Protein concentration determination 
Calculation of estimated molar extinction coefficient 
Tryptophan and tyrosine residues, as well as cysteine-cysteine disulphide bonds offer 
considerable contribution to the absorption of a protein at 280 nm. However the absorption of 
these residues is dependent on the local environment, in turn this environment is dependent 
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on the folded structure of the protein. Therefore it is necessary to determine the concentration 
of protein under denaturing conditions. By using guanidine hydrochloride the error is 
reduced to an approximation of the contributions of N-acetyl-L-tryptophanamide, gly-tyr-gly 
and cysteine dimers, as opposed to the ± 11 % error expected through the calculation of the 
molar extinction coefficient using values determined for folded proteins. The molar extinction 
coefficient of a protein in 6M guanidine hydrochloride is calculated as the sum of the molar 
extinction coefficient of the absorbing residues as established by Gill et al.169 (Equation 2 
below).  
Equation 2 
𝜀280 𝑛𝑚 = 5690 × #𝑇𝑟𝑝 + 1280 × #𝑇𝑦𝑟 + 120 × #𝐶𝑦𝑠 
Where ε280 nm is the molar extinction coefficient at 280 nm (units = M-1 cm-1) and #Trp, #Tyr and 
#Cys correspond to the number of tryptophan, tyrosine and cysteine residues in the protein 
sequence.  Substituting in the frequencies of these residues from WDR5 gives Equation 3. 
Equation 3 
𝜀280 𝑛𝑚 = 5690 × 10 + 1280 × 9 + 120 × 10 
𝜀280 𝑛𝑚 = 69620 𝑀
−1𝑐𝑚−1 
Concentration determination 
Having calculated the ε280 nm for WDR5 in 6 M guanidine HCL the protein concentration was 
determined via UV/VIS absorption spectroscopy using an Agilent 8453 spectrophotometer. 
The buffer subtracted spectra was corrected for Rayleigh scattered light according to Equation 
4.170 
Equation 4 
𝐴280 𝑛𝑚 = 𝐸280 𝑛𝑚 − 1.95 × 𝐸330 𝑛𝑚 
Where A280 nm refers to the protein absorption at 280 nm, and E280 and E330 refer to the measured 
absorbance at 280 and 330 nm respectively. The values for A280 nm and ε280 nm are used in the 
Beer-Lambert law (Equation 5). 
Equation 5 
𝐴280 𝑛𝑚 = 𝜀280 𝑛𝑚 × [𝑝𝑟𝑜𝑡𝑒𝑖𝑛] × 𝑙 
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Where A280 nm is the corrected absorbance of the sample, [protein] is the concentration of 
protein in the sample (units = M) and l is the path length of the sample, the length of the 
sample that the light beam passes through (units = cm). 
Compound Preparation 
Compounds from the NCI library were received as solids. These compounds were weighed 
into MS vials and made into 20 mM stock solutions with anhydrous dimethylsulphoxide 
(DMSO). Compounds from Vichem were received as 5 mM DMSO stocks. Stock solutions 
were stored at – 20 °C  
All compounds underwent quality control; analysis via HPLC and LCMS. 
Synthesis of Peptide Control (sequence: ARA) 
All reactions were carried out in solid phase extraction vessels (Supelco), 
dimethylformaldehyde (DMF) used was of peptide grade. Prior to use the solid phase resin 
was washed thoroughly with DMF. 
Amino acid couplings: Amino acid building blocks, Fmoc-alanine and Fmoc-Arginine(PBF), 
(3 equiv.), were dissolved in 1.5 ml of DMF and DIPEA. HATU (2.8 equiv) was added to the 
solution, the solution changed from colourless to yellow. The solution was added to the 
washed resin. Resin was shaken at room temperature for 40 minutes on a platform shaker at 
30 oscillations per minute (OPM). Resin was then washed (see resin washing below). 
Fmoc deprotections: Resin was incubated with 3 ml 20% piperidine DMF for 20 minutes. The 
resin was then washed. The deprotection and following wash were then repeated. 
N-Terminal Capping: 40 equivalents of acetic anhydride and 40 equivalents of DIPEA in 1.5 
ml of DMF was added to the resin. Resin was incubated for 30 minutes with shaking at room 
temperature, then washed. 
Resin Washing: Washing was carried out after all reaction steps. Resin vessel was drained of 
solvent by vacuum manifold. Once drained the resin was washed with 5 x 3 ml DMF, 5 x 3 ml 
DCM, 5 x 3 ml DMF.  
Testing for Primary Amines:  A small sample of solid phase resin was transferred into an 
insert vial using a needle. These were suspended in 10% DIPEA in DMF to which a drop of 5 
% solution of trinitrobenzenesulfonic acid (TNBS) was added. The vial was then sealed and 
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shaken, if free amines were present on the solid phase resin the bead turned deep orange. This 
result indicated either that an amide coupling reaction had not successfully reacted with all 
amines or that Fmoc groups had been removed from the N-terminal amines. 
Cleavage: Peptides were cleaved from 100 mg of the resin in using a solution of 564 µl TFA, 
18 µl triisopropylsilane (TIS), 18 µl water. Resin was incubated for 3 hours in the solution at 
room temperature. Cleavage solution was added dropwise into a solution of ice cold diethyl 
ether where the peptides precipitated as a white solid. The white solid was collected via 
centrifugation and dried in vacuo. To ensure no moisture affected the calculation of the yield 
of peptide the peptide was dissolved in water and lyophilised (MartinChrist Alpha 1-2 
LDPlus). The fluffy white solid was transferred to a pre-weighed Eppendorf tube, flushed 
gently with nitrogen and sealed. The sealed Eppendorf was then sealed in a small plastic bag 
filled with self-indicating silica beads (Sigma Aldrich) to ensure long term dryness.  
Ac-ARA-NH2: Peptide was synthesised using the standard methods described above on 134 
mg of 90 µm Tentagel resin, functionalised with Rink amide linker (loading of 0.26 mmol/g). 
(12.85 mg, 0.027 mmol, 77%), Peptide mass: 357.21. Seen: 358.77 [M+H]+ 
The peptide was dissolved into a 10 mM stock using dry DMSO. A sample of this stock was 
further diluted for use as a stock for this series of experiments. 
Thermal Denaturation Assay 
Protein and compounds were incubated together at concentrations of 5 µM and 100 µM 
respectively in 135 µl of buffer (20mM HEPES, 250 mM NaCl, pH 7.50) for 45 minutes in a 
sealed 96 well plate at room temperature. 15 µl of 50x Sypro orange dye was added and the 
solutions agitated. The 150 µl solutions were split into three 50 µl aliquots in a 96 well PCR 
plate. The plate was sealed and briefly centrifuged (500 RCF for 5 min) to remove air bubbles. 
The plate was transferred to a quantitative Polymerase Chain Reaction unit, a Biorad IQ5 
ICycler, for analysis. The melting temperature of the protein was determined using a 
temperature range of 20 – 80 °C with intervals of 0.5 °C and a hold time of 30 seconds for each 




Concentration gradient for Calibration Curve 
A concentration series of 100, 50, 25, 12.5 µM of NCI292249 were analysed by HPLC (injection 
volume: 15 µl method: 3 % gradient described in general methods section 9.1). Plotting the 
area under the HPLC curve vs the concentration of the solution provided a calibration curve 
for concentration determination. 
Characterisation of the diffusion of NCI292249 
200 µM NCI292249 in 100 µl of buffer (20 mM Hepes, 250 mM NaCl, 5 % DMSO, pH 7.50) 
were injected by autopipette into the incubation chamber of a microdialysis cartridge in a 
microdialysis plate. To the connected chamber, 300 µl of buffer was added. The plate holding 
the cartridge was sealed and shaken for 16 hours at room temperature at 180 rpm on an orbital 
shaker. A sample of the solution from the diffusion chamber was removed and submitted for 
HPLC analysis to determine the concentration of the sample (injection volume: 15 µl, method: 
3 % gradient described in general methods section 9.1).  
Microdialysis of NCI292249 with WDR5 and BSA 
80 µM WDR5 and 200 µM NCI292249 in 100 µl of buffer (20 mM Hepes, 250 mM NaCl, 5 % 
DMSO pH 7.50) were injected into the incubation chamber of a microdialysis cartridge in a 
microdialysis plate. To the connected chamber 300 µl of buffer was added. The plate holding 
the cartridge was sealed and shaken for 16 hours at 25 °C at 180 rpm. A sample of the solution 
from the diffusion chamber was removed and submitted for HPLC analysis to determine the 
concentration of NCI292249 in the diffusion well (injection volume: 15 µl). 
In parallel the experiment was repeated with bovine serum albumin (BSA) in place of WDR5 
as a control experiment to test whether NCI292249 binds non-specifically with protein. 
The concentration of the ligand in the incubation well was calculated based on the total 
concentration determined from the control experiment that was carried out in parallel From 
this the ratio [ligand]incubation/[ligand]diffusion could be determined, referred to as the partition 
coefficient or Pt value. The Pt value was converted into a KD using a calculator tool developed 




9.3. SOBOC Methods 
Protein labelling determination 
Computational Methods 
The following commands were input into a PyMol (ver 18.4) session of 2H9M, a PDB file 
containing WDR5 and a segment of an ART containing peptide. The following commands 
were used to highlight lysine residues in blue and cysteine residues in yellow on the surface 
of WDR5 (coloured white). 
remove resn hoh       # remove water 
h_add                    # add hydrogens 
 as surface                      # shows surface 
color grey90                                # colour surface in grey 
select sulf_cys, (resn cys and (elem S))      # select the sulfur atom of cysteine 
residues 
color yellow, sulf_cys                                           # sulphur of cys are shown in yellow 
select nitro_lys, (resn lys and name NZ)             # select the nitrogens of free amines ("NZ" 
in PDB file) 
select hydro_lys, (elem H and (neighbor nitro_lys))  # select the neighboring H atoms  
select amine_lys, (nitro_lys or hydro_lys) 
color tv_blue, amine_lys # amines of lys residues are shown in 
blue 
This presents the functional groups of the residues as colours as opposed to the entire residue. 
To further clarify the functional groups the command below was entered. 
as spheres, amine_lys + sulf_cys 
In theory the more a sphere presents itself through the surface the more readily able to react 
it will be. 
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Surface residues were counted by eye, 27 lysine and 6 cysteine residues appear on the surface 
of WDR5. 
WDR5 protein labelling and purification 
100 µM of WDR5 and 1 mM Cy5 maleimide were incubated in 200 µl buffer (20 mM HEPES, 
250 mM NaCl, 5 % DMSO, pH 7.00) under argon in a sealed glass vial at 4 °C for 16 hours. 
The resulting solution was purified by size exclusion using a NAP-5 column (Sephadx G-25) 
eluted using 20 mM HEPES, 250 mM salt, pH 7.00. Fractions were eluted by gravity with a 
size of around 0.5 ml per fraction, decreasing to 0.1 ml per fraction as label containing solution 
eluted. The resulting fractions were analysed by reverse-phase HPLC using a C-4 column. 
Fractions containing pure labelled protein were combined and concentrated using a 15000 
Dalton spin column. 
Protein labelling quantification 
Using an Agilent 8453 spectrophotometer in single beam mode and 150 µl glass cuvette the 
absorbance at 280, 330 and 649 nm were determined for a solution of Cy5 maleimide. The 
average 280 and 330 nm absorbance values were each divided by the average 649 nm 
absorbance. This gives the correction factors for 280 and 330 nm, allowing for protein 
concentration determination. A sample of the combined WDR5-Cy5 fractions was analysed 
using an Agilent 8453 spectrophotometer in single beam mode and 150 µl glass cuvette the 
absorbance at 280, 330 and 649 nm. The average 280 and 330 nm absorbance values were 
adjusted using the correction factors determined for Cy5. These Cy5 corrected absorbances 
were then used to determine the corrected 280 nm absorbance (Equation 6). 
Equation 6  
𝐴280 𝑛𝑚 = 𝐸280 (𝑐𝑜𝑟𝑟) − 1.95 × 𝐸330 (𝑐𝑜𝑟𝑟)  
Where A280 nm refers to the protein absorbance at 280 nm, E280 (corr) and E330 (corr) refer to the Cy5 
corrected experimentally observed 280 and 330 nm absorbance. 
The concentration of protein and Cy5 in the sample were then calculated using the Beer-
Lambert law, the previously calculated molar extinction coefficient for WDR5 (69,620 M-1 cm-




𝐴280 𝑛𝑚 = 𝜀280 𝑛𝑚 × [𝑝𝑟𝑜𝑡𝑒𝑖𝑛] × 𝑙     𝑎𝑛𝑑       𝐴649 𝑛𝑚 = 𝜀649 𝑛𝑚 × [𝐶𝑦5] × 𝑙 
Where AX corresponds to the absorbance at wavelength x (280 nm for protein and 649 nm for 
Cy5), εX corresponds to the molar extinction coefficient of the analyte at wavelength X, l cm is 
the distance that the light beam travels through the sample solution, [protein] and [Cy5] 
correspond to the solution concentrations of the protein and Cy5 respectively. 
SOBOC Library Synthesis 
The scanning peptide fragment library was synthesised on Tentagel 90 µm Rink Amide resin 
(Rapp Pulymere) with a loading of 0.23 mmol/g (Rapp Polymere). All reactions were carried 
out in DMF used was peptide grade. Resin was swollen in DMF for at least 20 minutes prior 
to use. Peptides were synthesised with a C-terminal propargylglycine (PRA) residue for 
labelling and an 8-amino-3 6-dioxaoctanoic acid (DOA) spacer between this labelling site and 
the peptide itself. Reactions were carried out in solid phase extraction vessels 
Amino acid couplings: Amino acid building blocks (3 equiv.), were dissolved in 1.5 ml of 
DMF and DIPEA. HATU (2.8 equiv) was added to the solution, the solution changed from 
colourless to yellow. The solution was added to the washed resin. Resin was agitated on a 
platform shaker at 30 oscillations per minute (opm) at room temperature for 40 minutes. Resin 
was then washed 
Fmoc deprotections: Resin was incubated with 3 ml 20% piperidine DMF, agitated for 20 
minutes on a platform shaker at 30 rpm. The resin was then washed. The deprotection and 
following wash were then repeated. 
Testing for Primary Amines:  A small sample of solid phase resin was transferred into an 
insert vial using a needle. These were suspended in 10% DIPEA in DMF to which a drop of 5 
% solution of trinitrobenzenesulfonic acid (TNBS) was added. The vial was then sealed and 
shaken, if free amines were present on the solid phase resin the bead turned deep orange. This 
result indicated either that an amide coupling reaction had not successfully reacted with all 
amines or that Fmoc groups had been removed from the N-terminal amines. 
Washing: Washing was carried out after all reaction steps. Resin vessel was drained of solvent 
by vacuum manifold. Once drained the resin was washed with 5 volumes of DMF, 5 volumes 
of DCM, 5 volumes of DMF. 
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Resin and vessel preparation: 9 sintered solid phase extraction vessels of varying size were 
filled with resin, 1 ml – 10 ml with size selected to allow for 1 ml of solvent per 100 mg of resin. 
The resin added to each vessel was dependent on the number of peptides to be produced by 
the reaction series. 100 mg of resin per final peptide was used per vessel, 4.5 g of resin in total. 
Each sample of resin was reacted to produce the C-terminal trimer with a DOA spacer unit 
and a Pra labelling site (AA1-AA2-AA3-DOA-Pra) using the Fmoc synthesis methods described 
above. 100 mg of resin was removed from each reaction vessel, dried in a fresh sintered SPE 
and stored under vacuum. The remaining bulk resin underwent Fmoc deprotection and 
couplings according to the methods described above. After each coupling the resin was 
thoroughly dried and weighed, ~100 mg of resin was removed and stored under vacuum. The 
cycle of coupling amino acids and removing resin continued until all fragments had been 
produced.  
Cleavage: The labelled peptides were cleaved from the resin using trifluoroacetic acid: water: 
triisopropylsilane in the ratio of 376:12:12 µl. The cleavage mixture was added to the resin in 
a sintered solid phase extraction vessel, the vessel was sealed and agitated on a platform 
shaker at 30 rpmin the absence of light for 3 hours at room temperature. The cleavage solution 
was drained through the sinter and dried in vacuo, resulting in a purple solid or oil.  
Labelling: 10 mg of Fmoc deprotected resin was transferred into an insert vial. 6.4 mg of 
CuSO4 was dissolved in 250 µl water, 5.1 mg of sodium ascorbate was dissolved in 250 µl 
water. These two solutions were combined prior to use to give a yellow solution. 4 mg of TMR 
azide was dissolved in 150 µl tBuOH in H2O (1:2). 100 µl of the copper containing catalyst 
solution and 100 µl of the TMR azide solution was added to the insert vial. Insert vial was 
sealed and heated in a water bath at 40 °C for 16 hours. Resin was washed with water and 
methanol until solutions showed no trace of fluorescent label by eye, then dried. Labelled 
peptides were cleaved from the resin using a solution consisting of 188 µl TFA, 6 µl TIS and 6 
µl water for 3 hours at room temperature in a sealed insert vial, agitated on a platform shaker 
at 30 rpm. Labelled peptides were purified via preparative HPLC. Peptides were concentrated 
via lyophilisation. 
Purification: Peptides were purified by preparative HPLC. Typically dry samples were 
dissolved in 450 µl of 1:1 ACN and water solution. The solution was filtered through glass 
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wool packed into a Pasteur pipette to ensure no possible contamination from fragments of the 
solid phase support into the samples. 400 µl of the samples was injected into the preparative 
HPLC system which was set up to collect on detection of absorbance at 555 nm, fraction sizes 
were typically 200 µl. Preparative HPLC system details found in section 9.1. Fractions were 
tested by LCMS. Pure fractions containing the desired product were combined and 
lyophilised. 
Peptide Quantification 
Peptides were dissolved in water. The concentration of these peptides was determined by 
determination of the concentration of TMR in the solution (peptides were 1:1 labelled with 
TMR with a purity >95 % by HPLC). A 1 in 10 dilution of each peptide was made in water and 
the absorbance at 550 nm determined in a 1 ml quartz cuvette in an Agilent 8453 
spectrophotometer. For each peptide the concentration was determined according to the Beer-
Lambert law and the known molar extinction coefficient of TMR, 57100 M-1 cm-1 in water. 
Equation 7 
𝐴𝑏𝑠 = 𝑙 × 𝜀 × 𝑐𝑜𝑛𝑐 
where Abs, l (cm), ε (cm-1 M-1) and conc (M) refer to absorbance, pathlength, molar extinction 
coefficient of solution at a specific wavelength, and concentration of solution. 
On-bead screening of the labelled peptides 
Ni-NTA functionalised agarose resin (Quiagen) was filtered using 70-100 µM nylon 
membrane filters (FischerScientific nylon cell strainer) in order to increase the uniformity of 
the resin. 3 µl of 50 % slurry of the filtered resin was incubated with 7 µl of 2 µM 6xHis-WDR5 
for 20 minutes at 25 °C shaken at 180 rpm in an Eppendorf in an orbital Eppendorf shaker. 
The resin was washed 3 time with 500 µl of buffer by centrifuging the resin (500 RCF, 2 min 
using an Eppendorf 5417R centrifuge), removing the supernatant and re-suspending the resin 
in buffer. This wash was repeated twice more. The resin was then resuspended and aliquoted 
into separate Eppendorf tubes for incubation with the ligand. The resin was incubated with 
200 µl of 500 nM ligand in buffer for 20 min at 25 °C shaken at 180 rpm in an Eppendorf tube 
placed in an Eppendorf shaker. The resin was suspended in the solution and a 25 µl sample 
transferred to a glass bottomed 384 well plate (SWISSC, PS384B-G175). The samples were 
analysed on a Perkin-Elmer OPERA high content screening unit.  
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Confocal scanning (CONA) 
Images of the beads were taken on an Opera® High Content screening system (PerkinElmer) 
using a 20x air objective, numerical aperture 0.45. Images were acquired by peltier cooled 
CCD cameras with 1.3 megapixel resolution, each well was imaged as 77 overlapping images 
(20 % overlap) over each well area. The focal height in all experiments was set to 30 µm above 
the bottom of the well plate surface.  
WDR5-Cy5 and peptide-TMR screening 
In order to image the resin beads, the labelled protein and the labelled peptides a three 
exposure setup was used. Camera 2 was used for imaging in all exposures: TMR imaging: 
exposure one, cw laser 561 nm, 1000 µW power, 200 ms exposure time, primary dichroic 
445/561/640, detection dichroic 568sp, filter 585/40; Bead imaging: exposure two (brightfield), 
top illumination, 50 % LED, 200 ms exposure time, detection dichroic 650sp, filter 690/70; Cy5 
imaging: exposure three, cw laser 640 nm, 500 µW power, 120 ms exposure time, primary 
dichroic 445/561/640, detection dichroic 650sp, filter 690/70.  
Unlabelled WDR5 and peptide-TMR screening 
In the absence of labelled protein only 2 exposures were used in the bulk of screening 
experiments. Camera 2 was used to for imaging in all exposures: TMR imaging: exposure one, 
cw laser 561 nm, 1000 µW power, 200 ms exposure time, primary dichroic 445/561/640, 
detection dichroic 568sp, filter 585/40; Bead imaging: exposure two (brightfield), top 
illumination, 50 % LED, 200 ms exposure time, detection dichroic 650sp, filter 690/70. 
Image Stitching 
Images from the CONA screen (77 per well) were stitched using BREAD, software delivered 
in the Auer lab that includes a stitching plugin for ImageJ (Fiji Software). The macro utilises 
plugin Grid/Mosaic stitching plugin.171 
Analysis of Bead Intensities Using Bead Ring Evaluation and Analysis of Data (BREAD) 
Stitched images were then analysed using proprietary image analysis software, Bead Ring 
Evaluation and Analysis of Data (BREAD). BREAD determined the locations of all resin beads 
by detecting circular structures of a specified size (60 – 100 pixels in this series of experiments. 
Detection is carried out in both the fluorescent and brightfield channels, allowing for the 
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detection of all beads in the stitched images. Once the location of all beads in a stitched well 
image had been determined fluorescence intensity profiles of each of the resin beads was 
recorded. In this study for each resin bead in each well 5 profiles were taken. Each intensity 
profile is observed as 2 peaks, representing the brighter edges of the bead, between these 
peaks values are expected to be significantly lower as this corresponds to the bead interior. 
The maxima of these two peaks were averaged and the centre percentiles (20-80th) subtracted 
in order to correct for any background intensity seen in the bead interior, the two resulting 
values are averaged. This is repeated 5 times to determine the bead ring intensity of the bead. 
For each well the mean of the bead ring intensity of all beads is taken to give the mean bead 
ring intensity. 
Fluorescence anisotropy  
Experimental planning 
A 1:1 binding interaction was expected between WDR5 and the fluorescently labelled ligand. 
This relationship can be defined via a quadratic equation.  
A binding interaction between two partners can be described as 
 






Where [P]f and [L]f refer to the concentration of free protein and ligand respectively, [PL] 
refers to the concentration of protein-ligand complex.  
The mass balances that describe the amounts of protein and ligand are defined as: 
Equation 9 
[𝑃]0 = [𝑃]𝑓 + [𝑃𝐿] 
[𝐿]0 = [𝐿]𝑓 + [𝑃𝐿] 
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Where [P]0 and [L]0 correspond to the starting or total concentration of protein and ligand 
respectively. [PL] refers to the concentration of protein-ligand complex. [P]f and [L]f 
correspond to the free concentration of protein and ligand respectively. 
These are rearranged to put each equation into the context of the free concentrations of protein 
and ligand.  
Equation 10 
[𝑃]𝑓 = [𝑃]0 − [𝑃𝐿]    
[𝐿]𝑓 = [𝐿]0 − [𝑃𝐿]       
The expressions from Equation 10 are substituted into Equation 8 to give Equation 11.  
Equation 11 
kD =
([𝑃]0 − [𝑃𝐿])([𝐿]0 − [𝑃𝐿])
[𝑃𝐿]
      
This is then rearranged into the format of a quadratic equation (Equation 12). 
Equation 12 
0 = [𝑃𝐿]2 − ([𝐿]0+[𝑃]0 + kD)[𝑃𝐿] + [𝑃]0[𝐿]0 
Which is solved as the quadratic equation (Equation 13). 
Equation 13 
[𝑃𝐿] =
[𝐿]0 + [𝑃]0 + kD
2
− √
([𝐿]0 + [𝑃]0 + kD)
2
4
− [𝐿]0 × [𝑃]0 
Dividing Equation 13 by the concentration of ligand gives the proportion of complexation 
relative to the amount of ligand (Equation 14).  
Equation 14 
Proportion of complexation (
[𝑃𝐿]
[𝐿]0
) =  
[𝐿]0 + [𝑃]0 + kD
2 −






A simulated binding curve was plotted using Origin 9.0 software. The plot assumed a KD of 
100 µM (the literature affinity of the MYC MIIIb peptide12) and a ligand concentration of 50 





Fluorescence anisotropy was determined on a SPEX Fluorolog 𝜏-3 spectrofluorometer 
(Horiba)  in an L set up, polarisers were in place and set to 55° (magic angle). Excitation 552 
nm, emission 580 nm with slits set to 4 and 6 nm bandwidth respectively. The starting sample 
volume was 175 µl of 50 nM EEEIDVV-DOA-PRA(TMR) peptide in a 200 µl cuvette (Sub-
Micro Quartz cuvette). Protein was titrated into the cuvette from a highly concentrated stock 
solution from 175 µl up to 200 µl end volume. Titration was carried out by pipette, the sample 
agitated by pipette and allowed to equilibrate for 3 minutes after agitation prior to analysis. 




𝑏 = [𝐿𝑖𝑔𝑎𝑛𝑑]0 + [𝑃𝑟𝑜𝑡𝑒𝑖𝑛] + 𝐾𝑑 
𝑎 = (𝑏 − (𝑏2 − 4 × [𝐿𝑖𝑔𝑎𝑛𝑑]0 × [𝑃𝑟𝑜𝑡𝑒𝑖𝑛])
1






(𝑟𝑚𝑖𝑛 + ((𝑟𝑚𝑎𝑥 × 𝑄 − 𝑟𝑚𝑖𝑛) × 𝑎))/(1 − (1 − 𝑄) × 𝑎) 
Where rmax is the expected maximum anisotropy, rmin is the startpoint (ligand anisotropy), 
[Ligand]0 refers to the starting concentration of labelled ligand, [protein] refers to the protein 
concentration. Q is the quenching factor, qbound is the molecular brightness of the bound 
ligand, qfree is the molecular brightness of the free ligand. GraFit 6.0 was used to plot the 
experimental data, rmax and KD variable fitting parameters in a nonlinear least square 
regression fit. 
9.4. MorPH Peptide Examples 
Peptide synthesis and Purification 
Peptides were synthesised using Fmoc solid phase synthesis methods and labelled with TMR-
N3 as described in section 9.3. All peptides were synthesised on a 200 mg scale using Rink 
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amide functionalised Tentagel resin (Rapp Polymere) as the solid phase in 2 ml solid phase 
extraction vessels (Supelco). 
Reverse phase HPLC analysis of unlabelled peptides: Due to the short retention time of these 
peptides in reverse phase HPLC the HPLC analysis is of the Fmoc-protected forms of the 
peptides. HPLC analysis was repeated after Fmoc protecting group removal to verify the 
deprotection was complete. 
H2N-Abu-CarbPhe-E-R-CONH2: Peptide was synthesised using the standard methods 
described above on 217 mg of Tentagel resin, functionalised with Rink amide linker (loading 
of 0.23 mmol/g). (16.3 mg, 0.028 mmol, 56%), Peptide mass: 577.64. Seen: 578.55 [M+H]+ 
H2N-Abu-KER-CONH2: Peptide was synthesised using the standard methods described 
above on 242 mg of Tentagel resin, functionalised with Rink amide linker (loading of 0.23 
mmol/g).(16.0 mg, 0.031 mmol, 56%). MS (ESI) Exact mass calcd: 515.62. Seen: 516.38 [M+H]+  
H2N-AKER-CONH2: Peptide was synthesised using the standard methods described above 
on 290 mg of Tentagel resin, functionalised with Rink amide linker (loading of 0.23 mmol/g). 
(8.0mg, 0.016 mmol, 24%) MS (ESI) Exact mass calcd: 501.59. Seen: 502.57 [M+H]+  
Labelled peptides 
H2N-Abu-CarbPhe-E-R-DOA-PRA(TMR)-CONH2: Peptide was synthesised using the 
standard methods described above on Tentagel resin, functionalised with Rink amide linker. 
A sample of the resin was then removed for labelling according to the method described 
above. MS (ESI) Exact mass calcd: 1331.62. Seen:1331.21 [M+H]+ and 666.44 [M+2H]2+ 
H2N-Abu-KER-DOA-PRA(TMR)-CONH2: Peptide was synthesised using the standard 
methods described above on Tentagel resin, functionalised with Rink amide linker. A sample 
of the resin was then removed for labelling according to the method described above. MS (ESI) 
Exact mass calcd: 1268.63. Seen: 1269.26 [M+H]+ and 635.29 [M+2H]2+ 
2D-FIDA Fluorescence Anisotropy Measurement – Carried out by Nhan 
Pham. Peptides synthesised by Olivier Barbeau 
Samples were prepared in 20 mM HEPES, 100 mM NaCl, pH 7.5, 0.1 % Pluronic, 5 % DMSO 
with a ligand concentration of 2 nM. Measurements were carried out using proprietary Pick-
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o-Screen instruments with 9 measurements per concentration of protein. Measurements were 
then averaged to determine anisotropy. 
Stability analysis – Carried out by Nhan Pham 
Mouse plasma, strain BALB/C, with Li-Heparin ordered from Harlan Sera-Lab Ltd., 
Loughborough, UK.  
The 3 TMR labelled peptides were prepared in a stock of water/methanol 8:2. Each of these 
stock solutions was used to spike 3 separate 600 µl samples of plasma to a final concentration 
of 10 µM of peptide. The plasma samples were incubated at 37 °C and shaken. Time points 
were 0, 1, 2, 4, 6, 23, 30, 47, 57 and 71 hours. At each time point 40 µl of plasma was removed 
and mixed thoroughly with 120 µl of acetonitrile to precipitate the protein content. The 
mixture was centrifuged at 12000 rpm for 2 min. The supernatant was transferred to a vial 
and concentrated in a vacuum centrifuge. The residue was dissolved in water/acetonitrile 8:2 
(50 µl), sonicated and centrifuged for 1 min at 12000 rpm. 25 µl of the supernatant was 
submitted for HPLC analysis. A 4 x 4 mm Merk Lichrospher pre-column was put in place to 
ensure no proteins reached the C18 column, the solvent gradient is described as ‘plasma 
stability gradient’ in the HPLC gradient section above. Compound stability was monitored by 
detecting HPLC chromatographic peak areas of compound fluorescence emission and 
maximum absorbance of attached dye in relation to total peak area at time 0 h. 
Degradation products appeared as earlier eluting peaks, visible in both fluorescence and 
absorbance traces. 
9.5. Methionine linker and TMR Synthesis 
Synthesis of test sequence: TMR-Ala-Met 
Peptide was synthesised using the standard methods described above in section 9.2 on NH2 
functionalised Tentagel resin (Rapp polymere) with a loading of 0.30 mmol/g.  
Preparation and cleavage of single bead samples 
A needle tip of Fmoc-deprotected resin was transferred from the bulk to an insert vial. The 
insert vial was filled with methanol and the slurry agitated by pipette. Using a light 
microscope and pipette single beads in methanol were isolated from the slurry and transferred 
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to clean insert vials. These insert vials were filled with methanol and dried in a speed vac. 
Once dry the insert vials were inspected by eye to verify that a single bead was present at the 
bottom of each vial.  
Method A: 15 µl of 20 mg/ml CNBr in 0.1 M HCl, 16 hours.159   
Method B: 15 µl of 20 mg/ml CNBr in 70 % TFA, 30 % water, 16 hours.160 
Method C: 15 µl of 100 mg/ml CNBr in 70 % formic acid, 24 hours.161  
Method D: 15 µl of 30 mg/ml CNBr in propionic acid, 24 hours.28 
In all test methods cleavage solutions were prepared beforehand and carefully mixed prior to 
addition to the single beads. Insert vials were sealed with snap-cap lids and wrapped in 
parafilm. All cleavage reactions were carried out at room temperature, shaken at 180 rpm. 
Cleavage mixtures were dried in vacuo. 30 µl of acetonitrile and water (1:1) was added to each 
vial. The mixture was agitated and 25 µl of the solution was transferred to a fresh insert vial, 
with care to avoid removing the resin bead. Samples were analysed by HPLC and LCMS. 
Development of CNBr Cleavage Method 
Cleavage methods were each trialled on 20 single solid phase resin beads that held the 
methionine linker test resin as described above. 150 µl of 20 mg/ml CNBr in 70 % TFA, 30 % 
water was added to 2 insert vials containing the test resin. The vials were sealed with snap 
lids and covered in foil. The cleavage reactions were shaken on a platform shaker at 30 rpm 
before the cleavage solutions were isolated from the resin after 16 and 40 hour intervals. 
150 µl of 20 mg/ml CNBr in 70 % TFA, 30 % water was added to 3 insert vials containing the 
test resin. The cleavage solutions were agitated by pipette before the vials were sealed with 
snap lids and covered in foil. The reactions were incubated in a 40 °C water bath for 1, 2 and 
16 hours before the cleavage solutions were isolated from the resin. 
150 µl of 30, 50 and 100 mg/ml CNBr in 70 % TFA, 30 % water was added to 3 insert vials 
containing the test resin. The cleavage solutions were agitated by pipette before the vials were 
sealed with snap lids and covered in foil. The reactions were incubated in a 40 °C water bath 
for 2 hours before the cleavage solutions were isolated from the resin. 
The cleaved peptides were suspended in water and transferred to a 5 ml vial with care to 
avoid removing any resin. The volume of the peptide solution was made up to 3 ml and the 
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concentration determined by the concentration of TMR present in the solution using Equation 
7. 
TMR synthesis 
TMR methyl ester 
2-Formyl-4-methoxycarbonyl-benzoic acid (604 mg, 2.91 mmol) was stirred in propionic acid 
(15 ml) and 3-dimethylaminophenol (837 mg, 6.10 mmol) was added, followed by p-TsOH 
(113 mg, 0.58 mmol). The mixture was heated to 80 °C for 16 hours. Chloranil (714 mg, 2.91 
mmol) was added, maintaining the temperature at 80 °C and the mixture stirred for 6 hours. 
The mixture was cooled to room temperature then solvent was removed under reduced 
pressure. The crude residue was purified via chromatography. The resulting product was a 
dark purple solid (452 mg, 1.02 mmol, 35 %). Eluent for chromatography: gradient from 5% 
H2O/MeCN to 20% H2O/MeCN, Rf = 0.27 (15% H2O/MeCN).  1H NMR (500 MHz, CD3OD) δ 
8.25 (1H, dd, J = 8.2, 1.7 Hz, ArH), 8.14 (1H, d, J = 8.2 Hz, ArH), 7.85 (1H, d, J = 1.4 Hz, ArH), 
7.23 (2H, d, J = 9.5 Hz, ArH), 6.98 (2H, dd, J = 9.5, 2.5 Hz, ArH), 6.87 (2H, d, J = 2.5 Hz, ArH), 
3.90 (1H, s, OCH3), 3.25 (12H, s, 3 x NCH3); 13C NMR (125 MHz, CD3OD) δ 172.5 (C), 167.5 (C), 
161.9 (C), 159.2 (C), 158.8 (C), 146.3 (C), 133.9 (C), 132.8 (CH), 132.2 (C), 131.9 (CH), 131.6 (CH), 
131.2 (CH), 115.2 (CH), 115.1 (C), 97.5 (CH), 53.1 (CH3), 41.0 (CH3); MS (ESI) Exact mass calcd 
for C26H25N2O5 [M+H]+: 445.18, found: 445.38. 
TMR acid 
TMR-OMe (202 mg, 0.455 mmol) was dissolved in 30 ml of THF/water (1:1). NaOH (45.48 mg, 
1.137 mmol) was added to the reaction solution with stirring. The reaction vessel was covered 
in foil and stirred at room temperature overnight. Concentrated HCl was added to acidify the 
solution. The solution was stored at 4 °C, a solid precipitated over the course of 3 days. The 
solid was isolated by filtration and washed with cold water, giving the product as a purple 
crystalline solid (84 mg, 0.195 mmol, 43 %).1H NMR (500 MHz, MeOD) δ 8.48 - 8.36 (2H, m, 
ArH), 7.99 (1H, s, ArH), 7.15 (2H, d, J = 9.4 Hz, ArH), 7.10 (2H, dd, J = 9.4, 1.7 Hz, ArH), 6.97 
(2H, s, ArH), 3.33 (12H, s, 3 x CH3); 13C NMR (125 MHz, CD3OD) δ 167.7 (C), 167.5 (C), 160.2 
(C), 159.0 (C), 158.8 (C), 136.4 (C), 136.2 (C), 135.4 (C), 133.0 (CH), 132.5 (CH), 132.0 (CH), 115.6 
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(CH), 114.8 (C), 97.4 (CH), 41.0 (CH3); MS (ESI) Exact mass calcd for C25H23N2O5 [M+H]+: 
431.16, found: 431.33. 
Time course experiments 
Reverse-Phase HPLC Standards 
Stock samples of TMR-N3 and TMR-COOH were analysed by reverse phase HPLC using a 
3%/minute gradient to determine their retention times. Column information: Agilent Zorbax 
C18 Vydac C18, 4.6 mm x 150 mm, 3.5 μm particle diameter size. The retention times of the 
acid and the azide were 21 and 23 minutes respectively. 
Time Course Experiments 
Five 5 ml reactivials were prepared, each holding TMR-COOH (20 mg, 0.046 mmol) in DMF, 
with the exception of test 5 which had a 2:2:1 mixture of DMF/dioxane/water. To vial 1 DIPEA 
(16.03 µl, 0.092 mmol) was added, followed by HATU (17.49 mg, 0.046 mmol). To vial 2 DIC 
(5.81 mg, 0.046 mmol) and HOBt (6.22 mg, 0.046 mmol) were added. To vial 3 DIPEA (16.03 
µl, 0.092 mmol) was added followed by PyBOP (23.94 mg, 0.046 mmol). To vial 4 DIPEA (16.03 
µl, 0.092 mmol) was added, followed by EDC (8.82 mg, 0.046 mmol) and HOBt (6.22 mg, 0.046 
mmol). To vial 5 DIPEA (24.04 µl, 0.138 mmol) was added, followed by TSTU (18.01 mg, 0.060 
mmol). The reaction solutions were stirred at room temperature for 5 minutes in the absence 
of light. Then to each vial 3-azidopropylamine (46.40 mg, 0.46 mmol) was added, the vials 
sealed. At 1, 2, 4, 8 and 16 hour intervals a small sample of reaction solution was removed 
from each vial, the sample was diluted 1:1000 with 1:1 acetonitrile/water to significantly slow 
the reaction. Samples were submitted for analysis via reverse phase HPLC. Conversion of the 
acid to the amide was determined by percentage peak area of the peak with a retention time 
corresponding to that of the TMR-N3 in the fluorescence detector channel (Ex 555 nm, EM 575 
nm). 
TMR-N3 Synthesis 
TMR-COOH (90.0 mg, 0.209 mmol) and DIPEA (73 µl, 0.418 mmol) were dissolved in DMF 
(10ml) with stirring. HATU (79.6 mg, 0.209 mmol) was added to the reaction vessel, after a 
few minutes of stirring 3-azidopropylamine (104.737 mg, 1.046 mmol) was added to the 
reaction vessel. The vessel was sealed and the reaction mixture stirred at room temperature 
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for 2 hours. Solvent was removed in vacuo using toluene to form an azeotrope. The resulting 
solid was purified by preparative reverse-phase HPLC  yielding the product as a purple solid 
(102 mg, 0.199 mmol, 95 %). 1H NMR (500 MHz, METHANOL-d4)  8.43 - 8.45 (ArH1 dd, 1H), 
8.23 (ArH2 d, J = 6.38 Hz, 1H), 7.86 (ArH3 s, 1H), 7.19 (ArH6 d, J = 9.46 Hz, 2H), 7.09 (ArH5 dd, 
J = 2.48, 9.50 Hz, 2H), 7.02 (ArH4 d, J = 2.52 Hz, 2H), 3.47 - 3.57 (CH29 m, 2H), 3.44 (CH27 t, J = 
6.66 Hz, 2H) , 3.34 (4 x NCH38 s, 12H), 1.91 (CH210 t, J = 6.78 Hz, 2H). 13C NMR (126 MHz, 
METHANOL-d4)  168.7, 168.0, 161.3, 159.7, 159.6, 140.0, 136.2, 133.5, 132.7, 131.0, 130.6, 116.2, 
115.5, 98.1, 50.9, 41.6, 39.4, 31.3, 30.3, 24.9. MS (ESI) Exact mass calculated for C28H29N4O4 
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